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Professor Scott J. Hultgren, Chairperson 
  
Urinary tract infections (UTIs) are among the most common bacterial infections 
worldwide, costing greater than $2 billion in healthcare costs and lost wages yearly in America 
alone. The lifetime risk for a woman exceeds 50% with 25-40% of these suffering recurrent 
infections. Two of the most important risk factors for recurrent UTI are prior UTIs and sexual 
intercourse. Over 80% of UTIs are caused by uropathogenic Escherichia coli (UPEC), which 
binds and invades superficial facet cells lining the bladder surface. UPEC expresses extracellular 
fibers called type 1 pili with a terminal mannose-binding adhesin, FimH, which interacts with 
mannosylated uroplakin residues on the urothelium. UPEC replicates in the cytoplasm of bladder 
cells into biofilm-like intracellular bacterial communities (IBCs) in a protected niche. In 
C3H/HeN mice, a robust, systemic, immune response at 24 hours precedes the development of 
persistent bacteriuria and chronic cystitis, which lasts indefinitely. A less robust immune 
response results in resolution of the infection.  
I determined the population dynamics during UPEC infection with a set of 40 variants of 
a clinical isolate, UTI89, each with a unique genetic sequence detectable by multiplex PCR. I 
 xii 
identified a significant population bottleneck during the first 24 hours coinciding with the 
inflammatory response. Furthermore, I tested a panel of FimH alleles under positive selection 
and found several that impacted the ability of UPEC strains to form IBCs and promote chronic 
cystitis. These pathoadaptive alleles govern the ability of FimH to bind mannose by dynamically 
interconverting between a compact, low-affinity conformation and an elongated, high-affinity 
state. This dynamic equilibrium is crucial for virulence as alleles locked in either conformation 
are attenuated. I also developed a model of frequent inoculation of UPEC into the urinary tract to 
investigate the clinical link between frequent sexual intercourse and UTI risk. By inoculating 
mice twice during acute infection, I found a dramatic increase in the proportion of mice that 
experienced chronic cystitis. Taken together, this thesis defines bacterial and behavioral factors 
that increase the risk for chronic and recurrent UTI, providing rationale for the development of 
novel therapeutics targeting bacterial invasion to limit infection by excluding UPEC from 
intracellular niches.  
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Abstract 
 Host-pathogen interactions are often mediated by extracellular fibers known as pili. The 
best characterized Gram negative pili are assembled by the Chaperone Usher Pathway (CUP). 
CUP pili are often tipped with an adhesin that binds to receptors with stereochemical specificity 
allowing microbes to colonize and adapt to dynamically changing environments. Type 1 and P 
pili are prototype CUP pili that mediate colonization of tissues in the urinary tract during 
infection by uropathogenic Escherichia coli (UPEC). During a urinary tract infection (UTI), 
UPEC occupy and flux between multiple niches within the bladder and kidneys. In the acute 
stages of cystitis, UPEC invade superficial bladder epithelial cells, replicate within the 
cytoplasm, and form large biofilm aggregates termed intracellular bacterial communities (IBCs). 
Appropriate expression of pili and other virulence factors in the urinary tract is essential for 
pathogenesis. Type 1 pili, critical for bladder infection, are regulated by cis-encoded 
recombinases within the fim operon that reversibly invert the fim promoter, regulating 
expression. Recombinases and many other regulatory proteins serve to cross-regulate CUPs and 
fine-tune pilus expression. Understanding the structure, regulation, assembly, and function of 
these pili has lead to the development of novel anti-virulence compounds that prevent bacterial 
attachment to host tissues. 
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Introduction 
Bacterial virulence entails an ability to persist within a host and cause disease in the face 
of myriad host defense mechanisms in more than one niche or under more than one immune 
condition. The array of virulence factors that a pathogen possesses and its ability to regulate their 
expression in response to environmental signals greatly contributes to the variety and specificity 
of niches a pathogen can colonize and impacts the spectrum of diseases that occur. Colonization 
factors may confer a fitness advantage in a specific niche, being required in some environments 
and unnecessary or deleterious in others, or they may contribute globally to persistence and 
disease. Thus, coordinated gene expression is critical to ensure that appropriate genes are 
expressed in specific environments and turned off in others. For example, when a pathogen 
encounters a susceptible host, the ability to attach to a specific tissue or niche in a timely manner 
is vitally important to establishing infection in a dynamically changing local environment. A 
host-pathogen interaction is frequently the consequence of an adhesin expressed by the pathogen 
recognizing a receptor on host cells with exquisite stereochemical specificity [1, 2]. Several 
families of bacterial adhesins exist to mediate specific interactions to various hosts, tissues, 
organisms, or surfaces: outer membrane proteins, secreted soluble, extracellular proteins that 
create an adhesive matrix, type 4 pili, auto-transporters and two-partner secreted adhesins, and 
chaperone-usher pathway (CUP) assembled pili (see [1, 3] for review). Myriad gram-negative 
and gram-positive organisms utilize adhesins to attach to epithelial surfaces to persist within a 
host. Gram-negative organisms such as Porphyromonas gingivalis, Salmonella enterica, Yersinia 
enterocolitica, and Neisseria gonorrhoeae utilize surface exposed adhesins to colonize host 
mucosal surfaces (reviewed in [4]). The gram-positive organisms Enterococcus faecalis and 
Clostridium perfringens also encode pili or pilus-like adhesins that mediate attachment to surface 
4 
structures. In this chapter I will describe the virulence and regulation of CUP pili focusing on 
type 1 in uropathogenic Escherichia coli (UPEC), the most common cause of urinary tract 
infections (UTIs).  
 
Urinary Tract Infections 
E. coli are normally commensal colonizers of the gastrointestinal (GI) tract. Several 
pathotypes of E. coli exist, however, that can cause disease in a variety of organ systems in both 
immuno-competent and immuno-compromised individuals dependent on the arsenal of virulence 
factors and adhesins they express. E. coli are generally classified into 3 major groups: 
commensals, intestinal pathogens, and extra-intestinal pathogens (ExPEC) [5]. Commensal 
strains peaceably coexist with numerous other bacterial species in the GI tracts of healthy 
humans and many other animals. The majority of these strains cause no disease in healthy 
individuals, but may colonize foreign bodies if present. Additionally, these commensals lack 
many of the virulence genes that other E. coli possess. Intestinal pathotypes of E. coli are rarely 
found in the asymptomatic host, but instead are obligate pathogens of the gastrointestinal tract. 
Among the intestinal E. coli pathogens, there are several classifications based on virulence genes 
expressed: enterotoxigenic (ETEC), enteropathogenic (EPEC), Shiga toxin 
producing/enterohemmorhagic (STEC/EHEC), enteroinvasive (EIEC), and diffusely adherent 
(DAEC) (reviewed in [6]). ETEC adhere via fimbriae to the small intestine and produce one or 
both of labile toxin and stable toxin, which lead to secretory diarrhea. EPEC cause attaching-and-
effacing lesions via adherence with bundle-forming pili and export of type III secretion effectors 
resulting in loss of absorptive microvilli and diarrhea. EHEC produce shiga toxin leading to 
bloody diarrhea, hemolytic uremic syndrome, and possibly death. Attachment of EHEC to the 
5 
tissue has been speculated to occur via multiple different adhesins, and many of these may 
contribute to colonization of more than one pathotype, but no clear adherence profile exists [7]. 
EIEC invade colonocytes and secrete enterotoxins, very similar to the pathogenesis of shigellae. 
DAEC diffusely adhere to the epithelial surface and auto-aggregate, yet do not produce either of 
the toxins common to ETEC. Infection with DAEC results in edematous villi and mucoid 
diarrhea. Extraintestinal infections caused by E. coli (ExPEC) include meningitis, pneumonia, 
soft-tissue infections, and UTI. ExPEC are characterized by their lack of gastrointestinal 
pathogenesis, however they can stably colonize the GI tract [5]. In order to cause disease, these 
organisms must access the site of infection: brain, lungs, medical device, or urinary tract. ExPEC 
generally acquire stretches of chromosomal DNA called pathogenicity islands (PAI) conferring 
the virulence factors often including operons encoding adhesins necessary to colonize a 
particular niche. Uropathogenic E. coli (UPEC) are one such member of ExPEC, primarily 
responsible for UTI by virtue of the adhesins and other virulence genes they express. The array 
of virulence factors and adhesins expressed by the various E. coli pathotypes defines their 
pathogenic niche and virulence profile.   
UPEC causes >80% of community-acquired UTI and ~50% of nosocomial UTI [8, 9] and 
has evolved elaborate mechanisms that allow it to survive within and exploit multiple niches in 
the urinary tract [10, 11]. Although UTIs afflict both men and women, females are 
disproportionately affected, a trend that begins as early as 8 years old [12]. Approximately 50% 
of women will have at least one symptomatic UTI in their lifetime, with 20-40% of these 
experiencing a recurrence within six months of the first infection [13, 14]. Clinically UTIs are 
divided into categories based on symptoms. One category is infections of the bladder (cystitis), 
which are generally low mortality infections involving bacteriuria, pain or burning during 
6 
urination, urgency, and frequency. The other category includes infections of the kidneys 
(pyelonephritis), which in addition to the symptoms of cystitis include chills, fever, flank pain 
and tenderness. Antibiotics are generally successful at clearing bacteriuria and many other 
symptoms; however, many women suffer frequent recurrent infections with increased morbidity, 
necessitating long-term, daily, prophylactic antibiotics. Furthermore, studies have shown that 
frequently, the recurrent infection is caused by the same strain that caused the original, 
symptomatic UTI [15], emphasizing the presence of a bacterial reservoir within the host that 
cannot be effectively eradicated by current treatments. Additionally, certain patients experience 
asymptomatic bacteriuria or chronic cystitis marked by persistent bacteriuria with accompanying 
cystitis symptoms [16, 17].  
 
Risk factors for urinary tract infection development 
The balance between bacterial virulence factors, host genetics, and behavior dictates 
symptoms and disease state. Certain polymorphisms and reduced expression of the Toll-like 
receptor 4 (TLR4) gene are associated with less severe UTI and asymptomatic bacteriuria 
(ASB/ABU) [18, 19]. Conversely, reduced expression of the Interleukin (IL) -8 receptor, CXCR-
1, is correlated with severe pyelonephritis [19]. Other human genetic factors that impact acute, 
chronic, and recurrent UTI (rUTI) have not yet been elucidated, but studies to determine 
polymorphisms to address these common syndromes are currently being conducted. Several of 
the most important risk factors for the development of a rUTI are behavioral. For the majority of 
women, the onset of urinary tract infection coincides with becoming sexually active [20]. One of 
the most dominant risk factors is the frequency with which a woman engages in sexual 
intercourse. Having sexual intercourse greater than nine times in a month was associated with a 
7 
ten-fold increase in the likelihood of developing a rUTI compared to having intercourse zero to 
three times [20]. In combination with sexual intercourse, bacterial colonization of the 
periurethral area increases in the days preceding a UTI [21]. Thus, depending on the host factors 
and behaviors, susceptibility to a UPEC UTI differs. 
The increasingly accelerated rate of global trafficking of antibiotic resistant uropathogens 
is necessitating the development of better therapeutic strategies. In addition to the rising 
resistance to first line therapies like trimethoprim-sulfamethoxazole (TMP-SMX), UPEC are 
becoming increasingly resistant to floroquinolones, which are being used more as a result of 
TMP-SMX resistance [22-24]. Furthermore, strains of the clonal group ST131 that are resistant 
to the majority of antibiotics have globally spread, causing UTI and bloodstream infections in 
North America, Europe, Asia, and Australia [25]. The spread of these multi-drug resistant strains 
combined with the increased resistance among UPEC strains is poised to create a public health 
crisis. Thus, it is essential to thoroughly reexamine the molecular basis of UPEC infection, 
determining the role and regulation of essential virulence factors to create novel therapeutics that 
target these virulence factors while reducing the negative side-effects accompanying antibiotic 
treatment. 
 
Chaperone usher pathway overview 
UPEC and E. coli in general, heavily rely on CUP pili to mediate attachment to biotic and 
abiotic surfaces [26-29]. The chaperone-usher pathway (CUP) is a nearly ubiquitous system 
among enterobacteriaceae [30] used for the assembly of surface exposed pili (see [1] or [31] for 
thorough reviews). CUPs are genetically organized as operons encoding a pilus fiber, a 
periplasmic chaperone, and an outer membrane usher. Whole genome sequencing has revealed 
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the presence of many canonical or hypothetical CUP operons in UPEC genomes [32-34] (Table 
1). These operons are fim (type 1), pap (P), F17-like, sfa (S), yad, auf, yfc, ygi, yeh, fml, and foc 
(F1C), yde (F9), dra/afa (Dr family), fso (F7), fst, pix (reviewed in [35]) (Table 1). In fact, it was 
recently shown that UPEC possess on average twice as many fimbrial types as commensal E. 
coli [36], presumably because of the increased array of environments these organisms colonize. I 
will focus on type 1 and P pili, given that they have been the most thoroughly characterized CUP 
pilus systems via mechanistic studies that have revealed their biochemical, structural, and 
regulatory properties as well as their contribution to UPEC pathogenesis.  
Type 1 pili are encoded by the fim operon. They are composite fibers with a ~2nm wide 
fibrillar tip joined to a 0.3-1.5 µm length rod consisting of repeating subunits arranged in a 7nm 
wide right-handed helical rod [37-39]. Upon translation, pilus subunits are translocated across 
the inner membrane via the Sec translocation machinery (Fig. 1) [40]. Once in the periplasm, 
they are bound by the chaperone FimC, which is critical for subunit stability and serves to 
facilitate folding and cap interactive surfaces to prevent nonproductive aggregation [41]. Pilus 
subunits have an incomplete immunoglobulin (Ig)-like fold, missing the C-terminal 7th β-strand 
[42, 43]. The periplasmic chaperones attain a ‘boomerang’ shape with two Ig-like domains 
connected by a linker ([44, 45]. Upon binding to the chaperone, the incomplete subunit folds are 
templated to fold by a process termed donor-strand complementation (DSC), in which four 
residues from the chaperone’s G1 strand provide the steric information to complete the fold of 
the bound subunit [42, 43]. Chaperone subunit complexes are targeted to the outer membrane 
usher, the protein through which the growing pilus is extruded across the outer membrane (Fig. 
1). The outer membrane usher is a large β-barrel protein consisting of a translocation domain, a 
~120 residue N-terminal domain (NTD) and a ~170 residue C-terminal domain (CTD) that binds 
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chaperone-subunit complexes [46]. The current model suggests that incoming chaperone-subunit 
complexes are targeted to the usher NTD and transferred to the CTD where donor strand 
exchange (DSE) occurs (Fig. 1B) [46-48]. In DSE, the chaperone is displaced by a 10-20 residue 
N-terminal extension (Nte) present on the next subunit to be incorporated into the growing pilus. 
This process completes the subunit Ig fold in a canonical fashion resulting in the addition of a 
single subunit to the growing pilus rod. The order of pilus assembly corresponds to the affinity of 
the chaperone-subunit complex for the usher and the efficacy and specificity each Nte has for 
DSE [49]. Subunits are added to the base of the growing pilus, with the FimH adhesin first 
incorporated. Accordingly, the usher, FimD, has the highest affinity for FimC-FimH complexes 
[50]. After incorporation of FimH, a single subunit each of FimG and FimF are added to 
complete the tip fibrillum. FimC-FimA complexes are then added sequentially to yield a fully 
formed pilus rod containing ~1000 FimA subunits arranged in a right-handed helical cylinder 
with approximately 3.2 subunits per turn (Fig. 1) [51, 52]. The pilus is constructed from tip to 
base through targeting of chaperone-subunit complexes to the usher and DSE to complete the 
incomplete Ig-like fold of each subunit. 
DSE occurs via a concerted ‘zip-in zip-out’ mechanism at a groove of the previously 
added subunit containing five crucial residues called P1-P5 [53]. The Nte of an incoming subunit 
binds to the open P5 pocket of the previous subunit. The incoming subunit then zips in, replacing 
the hydrophobic interactions between the previous subunit and the chaperone from P5 to P1, 
displacing the chaperone. The P pilus rod is terminated by the addition of a single PapH subunit. 
PapH contains a loop partially occluding this P5 pocket, therefore the chaperone bound to PapH 
cannot be displaced and pilus rod formation is terminated [54]. How type 1 pili are terminated is 
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unclear, as no PapH equivalent has been discovered, though some studies suggest that FimI is the 
anchoring subunit [55].  
Based on sequence identity and genomic organization, it is very likely that other CUP 
systems are assembled in a manner that is similar to type 1 and P pilus biogenesis [1]. The 
presence of multiple CUP pili within E. coli genomes is thought to be required for tuning 
adhesive properties specific for different environmental niches [10, 56-59]. For example, the 
type 1 pilus adhesin, FimH, and the P pilus adhesin, PapG, bind mannosylated and digalactoside 
receptors respectively, thereby mediating UPEC colonization of bladders and kidneys [10, 58, 
60, 61]. Transcriptional profiling and genetic studies have revealed that other UPEC CUP 
systems are expressed and may contribute to virulence [26, 36, 62]. However, how expression of 
multiple CUP operons is coordinated in response to environmental signals in different niches 
during infection is essentially unknown.  
 
UPEC virulence 
The pathogenesis of community-acquired UPEC UTI is thought to begin with UPEC 
colonization of the peri-urethral area from the fecal flora. Transmission of UPEC into the bladder 
can then occur via urethral manipulation [63, 64], sexual intercourse [65], or possibly direct 
ascension, although peri-urethral presence of UPEC does not necessarily lead to infection [66]. 
Infection is likely multifactorial with colonization in nearby “staging” areas combined with 
mechanical disruption such as sexual intercourse [21]. During infection UPEC is capable of 
colonizing the urine, the bladder epithelium (both extracellularly and intracellularly), and the 
kidneys [67]. Depending on the specific niche UPEC inhabits, it encounters different elements of 
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the immune response as well as different environmental pressures, necessitating precise gene 
regulation and immune avoidance or manipulation strategies.  
Although multiple studies have correlated particular genes with virulence [68-71], to date 
there is no common virulence profile among cystitis isolates. However, the vast majority (>95%) 
encode type 1 pili, and expression of type 1 pili is highly correlated with cystitis [33, 72, 73]. 
Indeed the most consistent virulence factor expressed among cystitis isolates is type 1 pili [73]. 
UPEC isolated from women suffering rUTI expressed type 1 pili when grown in broth cultures 
[74]. Additional studies demonstrated that 75% of UPEC isolated from the urine of 41 adult 
patients had type 1 pili on their surface and were often found in association with or attached to 
exfoliated epithelial cells and leukocytes [75]. Several studies have indicated that planktonic 
cells within the urine are usually not expressing type 1 pili, implying genetic regulation that is 
niche specific [76, 77]. However, other studies have shown that expression patterns of planktonic 
UPEC in the urine are not necessarily indicative of tissue-associated bacteria [76-78]. Planktonic 
UPEC inhabiting the bladder lumen have limited ability to maintain residence in the urinary tract 
without the ability to adhere to the epithelial surface due to the flushing action of micturition 
except in conditions that lead to incomplete voiding or reflux. 
Because of the myriad outcomes that result in human UTI, it is imperative to utilize an 
interdisciplinary approach in multiple model systems to completely capture the complexities of 
UTI pathogenesis that may be differentially exhibited spatially and temporally. Several murine 
models of UPEC infection have been developed [79, 80]. Each model takes advantage of 
different available, genetically defined, inbred mouse strains that exhibit varied immunological 
responses to UPEC infection to dissect several aspects of UTI progression. Studies performed in 
C3H/HeN, C3H/HeJ and C57Bl/6J backgrounds revealed stages of acute, sub-acute and chronic 
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infection that bear striking parallels to human UTI [80-83], indicating that outcomes from these 
mouse models strongly parallel human disease. These and other models, utilizing CBA/J, 
C3H/HeOUJ, and BalB/c mouse strains provided insights into immune checkpoints that may be 
predisposing humans to chronic UTI [80, 82, 83]. Using these mouse models, significant strides 
have been made in understanding the onset and progression of UPEC through the urinary tract. 
  
Type 1 pilus-dependent bladder invasion  
The FimH adhesin located at the tip of the type 1 pilus is instrumental in mediating 
UPEC interactions with the bladder epithelium (Fig. 2). FimH has been shown to bind mannose 
and its derivatives, thereby interacting with mannosylated moieties on abiotic and biotic surfaces. 
UPEC expressing type 1 pili were shown in vitro to bind to human and mouse uroplakins (UP) Ia 
and Ib, integral membrane glycoproteins that create a hexagonal array on the surface of the 
superficial facet cells of the bladder that create an impermeable barrier to toxic compounds in 
urine [84]. UPs are highly conserved across mammals both structurally and via sequence 
homology [85]. UPIa and UPIb are members of the tetraspanin family of molecules that 
modulate immune signaling via leukocyte differentiation. Using high-resolution, freeze-fracture, 
deep-etch electron microscopy, Mulvey et al. showed that the type 1 pilus tip fibrillum interacts 
with the hexagonal array of uroplakins on the terminally differentiated superficial facet cell layer 
of C57BL6 mice (Fig. 2A) [10], validating previous in vitro data [84]. This interaction, 
combined with the high tensile strength of the pilus rod, enables UPEC to withstand the strong 
shear forces applied by urine flow and persist in the bladder [86, 87]. The crystal structure of 
FimH with α-D-mannose bound in its recognition pocket, combined with mutational analysis, 
revealed the structural details of the precise specificity of FimH for mannose [60]. Subsequently, 
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analysis of over 300 sequenced UPEC strains revealed that the FimH binding pocket is invariant, 
further demonstrating the importance of this domain for pathogenesis [88]. FimH binding to 
UPIa results in global conformational changes of the uroplakin plaques, which lead to 
cytoskeletal rearrangement and the alignment of the cytoplasmic tails of UPIa, UPIb, UPII, and 
UPIIIa, initiating second messenger signaling [89, 90]. The resultant increase in intracellular 
Ca2+ elevation mediates host cell apoptosis and Interleukin-6 (IL-6) secretion, in an effort to 
control the infection and alert the innate immune system to the bacterial presence in the urinary 
tract [90, 91]. Through the precise interaction between FimH on type 1 pili and uroplakins on the 
bladder epithelial surface, UPEC bind to the tissue, initiating downstream signaling events within 
the host cell. 
 
UPEC binding triggers host and bacterial responses 
The binding of type 1 pili to a surface enacts bacterial transcriptional changes in addition 
to host responses. Binding of UPEC to mannosylated yeast enacts transcriptional change in an E. 
coli strain (CSH50) [92]. In addition to upregulation of genes involved in general metabolism, 
several genes classified as being involved in removal of reactive oxygen species and 
hydrophobic compounds were also upregulated. These latter genes are likely involved in defense 
against antimicrobial peptides in the urine and potentially antibiotics as well as attack from 
neutrophils and other inflammatory cells.  Once bound, UPEC are capable of invading the 
superficial layer of the transitional epithelial surface in a FimH-dependent fashion (Fig. 2B) [10]. 
Interaction of UPEC with α3 and β1 integrins in cell culture leads to actin rearrangement and 
bacterial engulfment in an active process requiring Rho-family GTPases [93-95]. The invasion 
process occurs via a cholesterol- and dynamin-dependent process modulated by calcium levels 
14 
and clathrin [96]. By an unknown mechanism, UPEC escape the endocytic vesicle, where they 
replicate in the cytoplasm to form biofilm-like intracellular bacterial communities (IBCs) of 104-
105 bacteria that protrude into the luminal surface of the bladder (Fig. 2D) [29]. While type 1 
piliated UPEC binding and invasion into the superficial facet cells provides a niche for rapid 
replication, studies in C57BL/6J mice demonstrated that it also leads to a robust apoptotic 
response and exfoliation of the facet cells within a few hpi [10], jettisoning infected cells (Fig. 
2C). In addition to facet cell exfoliation, host signaling mechanisms lead to a massive influx of 
immune cells, mainly PMNs, and upregulation of other immune effectors. In spite of this robust 
response designed to thwart infection, UPEC evolved mechanisms to subvert and exploit 
elements of the innate immune response and persist within the urinary tract. UPEC utilize the 
pore-forming toxin hemolysin (HlyA) to induce the degradation of cytoskeletal scaffold protein 
paxillin, leading to host cell exfoliation [97]. Exfoliation must be properly tuned to ensure the 
appropriate balance between IBC maturation and exposure of the underlying transitional 
epithelium. The two-component signal transduction system, CpxRA, regulates the expression of 
hemolysin (Nagamatsu et al. In Preparation). Strains lacking CpxR increase hemolysin 
expression and are attenuated during infection [98]. Similarly, overexpression strains of HlyA 
are also attenuated, suggesting that hemolysin deficiency explains the deficit of the CpxR 
mutant. A hemolysin knockout does not activate the inflammasome, stimulates a lesser degree of 
host cell exfoliation, but is not attenuated, implying other pathways that induce exfoliation 
(Nagamatsu et al. In Preparation). The precise degree of exfoliation governs the eventual 
outcome of exfoliation by modulating bacterial niche-specific replication. 
Upon IBC maturation, UPEC at the outer edges of an IBC become motile and disperse 
into the extracellular compartment of the lumen. Concomitant with this fluxing event, some 
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UPEC adopt a filamentous morphology [99] (Fig. 2E), a finding that along with IBCs has been 
observed in urine from women suffering rUTI [100]. Once extracellular, the immune cell 
infiltrate attacks luminal UPEC. Filamentous UPEC are resistant to phagocyte killing, providing 
a mechanism whereby UPEC emerging from an IBC into an inflamed environment can survive 
and reinitiate the intracellular cascade [101]. Deletion of the cell division inhibitor-encoding 
gene sulA, prevented filamentation and attenuated virulence at 24 hpi and onward in C3H/HeN 
mice [102]. Thus, the ΔsulA strain formed first generation IBCs, but was incapable of 
filamentation and second generation IBCs in C3H/HeN mice. Bacterial filamentation was not 
observed during acute infection in C3H/HeJ mice that lack the ability to signal through TLR4 
[99]. Infection of C3H/HeJ mice with UTI89ΔsulA restored virulence of this bacterial strain 
[102]. Thus, filamentation and possibly second round IBC formation are dependent, in part, on 
TLR4 responses in the bladder, leading to regulatory responses by UPEC. TLR4, in addition to 
recognizing bacterial LPS to stimulate innate immune cells, may play a direct role in controlling 
UPEC access to an intracellular niche. TLR4 mediated expulsion of UPEC may play a role in 
limiting the numbers of UPEC that successfully form IBCs [103]. Thus, multiple bacterial and 
host factors regulate the ability of UPEC to mature within an IBC.  
 
Genetic regulation within IBCs 
As a result of the rapid and dramatic shift in local environment, robust transcriptional 
changes occur in UPEC inhabiting an IBC. At 6 hpi each C3H/HeN mouse bladder contains 
between 1 and 700 IBCs (Fig. 2D) [104, 105]. In the 2 hours subsequent to invasion, WT 
bacteria coalesce into loose collections 2-4 µM beneath the surface of superficial facet cells [99]. 
UPEC replicate every 30 to 35 minutes in this environment and retain bacillary morphology. 
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Invasion alone; however is not sufficient to lead to IBC formation. The commensal strain 
MG1655 invades the urothelium, but does not form IBCs, and is thus rapidly cleared [106]. 
Using a tet inducible copy of FimH, it was shown that the development of IBCs requires the 
expression of FimH and type 1 pili [105]. Additionally, deletion of the gene encoding the outer 
membrane protein OmpA or the capsule synthesis genes disrupted IBC formation despite an 
equivalent invasion efficiency relative to WT UPEC [107, 108]. Host and bacterial 
transcriptional changes that accompany intracellular replication within IBCs in C3H/HeJ mice 
have been deduced [78]. UPEC within IBCs upregulate the siderophores enterobactin and 
salmochelin to scavenge available iron. Concomitantly, host upregulation of the transferrin 
receptor and lipocalin-2 within the IBC may restrict iron availability [78]. The battle for iron 
within the host is an important battleground during the host-pathogen interaction for many 
pathogens. Indeed, in women suffering from rUTI, urinary isolates were more likely to express 
the siderophores salmochelin and yersiniabactin compared to rectal isolates from the same 
patients [109]. Thus, regulatory changes including the upregulation of siderophores and 
continued expression of type 1 pili accompany the transition from the luminal niche of the 
bladder to the intracellular niche within the bladder epithelium.   
In addition to epithelial mechanisms that restrict IBC formation, the specific allele of 
FimH also impacts the ability of UPEC to form IBCs. The mannose-binding pocket of FimH is 
comprised of invariant residues among all clinical UPEC strains [88]. Variation outside of this 
pocket occurs frequently among UPEC strains. Sokurenko et al. have used a variety of methods 
to examine the natural variation and shown that FimH is under positive selection in UPEC [110-
112]. We performed in silico analysis of FimH gene sequences from 279 diverse E. coli isolates, 
which identified several amino acid (aa) residues outside of the mannose-binding pocket under 
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positive selection [88]. Our structure/ function analyses of these positively selected residues 
indicated that although they are not part of the mannose-binding pocket, they can impact 
mannose binding, IBC formation, and virulence [88]. It was previously shown that the majority 
of E. coli isolates including the pyelonephritis isolate CFT073 and the commensal K12 strain 
MG1655 have a serine at position 62 (S62) while cystitis isolates NU14 and UTI89 have an 
alanine [88, 113]. An alanine at position 62 (A62) was associated with increased collagen and 
monomannose binding [114], and increased virulence in the cystitis isolate NU14 [113]. We 
found that an A62S fimH mutation in the chromosome of UTI89 significantly attenuated 
invasion, IBC formation and virulence and affected phase variable type 1 pilus regulation. In 
addition, we found that a double mutation of the positively selected residues at positions 27 and 
163 (UTI89 fimH::A27V/V163A) had no effect on pilus assembly or mannose binding in vitro, 
but exhibited a 10,000-fold reduction in mouse bladder colonization at 24 hpi and was unable to 
form IBCs even though it bound normally to mannosylated receptors in the urothelium [88]. 
Thus, the A27V/V163A double mutation identified a function of FimH that is required, in 
addition to mannose binding, for IBC formation and in vivo fitness, suggesting that IBC 
formation is critical for successful UTI. Thus, many factors contribute to the ability of invaded 
UPEC to form IBCs including TLR4-mediated expulsion, bladder cell exfoliation, and FimH 
allele, which may alter regulation or the ability of UPEC to aggregate intracellularly.   
 
Reservoirs form in the underlying bladder tissue 
The intracellular pathogenic cascade that UPEC undergoes has been shown to be critical 
for several of the outcomes of infection. If the immune response effectively eradicates luminal 
bacteria as evidenced by sterile urine, mice may still have bacterial CFU in the bladder [80] (Fig. 
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2G). As mentioned earlier, during the acute infection cascade, infected and uninfected cells of 
the superficial epithelium are exfoliated in a caspase-dependent manner [10, 115, 116] (Fig. 2C). 
While this defense mechanism jettisons bacteria attached to and replicating within the 
epithelium, it exposes cells of the underlying, transitional cell layer, which UPEC can invade. 
UPEC establishes reservoirs consisting of 8-12 bacteria within Lamp1+ rosettes in the bladder 
tissue called Quiescent Intracellular Reservoirs (QIRs) (Fig. 2G) [82]. The mechanism of QIR 
formation is unknown. UPEC does not actively replicate within these reservoirs, but instead 
persists in a dormant state. Bacteria in the QIR can reactivate (by an unknown mechanism) to 
release bacteria into the lumen to begin the IBC cascade anew. Reactivation of QIRs has been 
triggered pharmacologically resulting in a recurrent infection with high titers of bacteria in the 
urine of mice [81, 82]. Reservoirs can thus form in the mouse bladder that can reactivate leading 
to a rUTI.  
 
An exuberant immune response during acute infection predisposes to chronic cystitis 
 Different murine models of UTI recapitulate the range of clinical outcomes of UTI [80]. 
WT inbred C57BL/6J mice resolve bacteriuria rapidly, but are susceptible to rUTI [81], possibly 
as a result of the large amount of QIRs formed in the bladder tissue [82] (Fig. 2G). C3H/HeOUJ 
mice are exquisitely susceptible to persistent bacterial replication of an inflamed bladder 
throughout the lifetime of a mouse, a phenomenon referred to as chronic cystitis [83] (Fig. 2F). 
Elevated levels of the cytokines IL-5, IL-6, Keratinocyte Cytokine (KC), and Granulocyte 
Colony-Stimulating Factor (G-CSF) in the serum of mice at 24 hpi predict the development of 
persistent bacteriuria and chronic cystitis at 4 weeks post infection (wpi) [83]. C3H/HeN mice 
exhibited a bimodal distribution of these two outcomes with persistent bacteriuria and chronic 
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cystitis occurring in 20% when infected with 107 CFU UTI89, a prototypical virulent UPEC 
isolate. Infection of mice with a dose of 108 CFU increased the proportion of C3H/HeN mice that 
developed chronic cystitis to 50% [83]. In the bladders of mice that experienced chronic cystitis, 
the superficial facet cells become completely denuded, and IBC formation ceases to occur after 
24 - 48 hpi. Thus, during chronic cystitis, bacteria proliferate in association with the underlying 
tissue, but do not invade to an appreciable degree (Fig. 2F). Furthermore, treatment of these mice 
with an antibiotic was shown to completely sterilize the bladder [83] in contrast to the tolerance 
observed for bacteria in QIRs [81]. Thus, these outcomes are likely mutually exclusive. An 
overexuberant immune response during acute infection to invasive UPEC leads to cytokine 
secretion and rampant bacterial replication. 
 
Dissemination to the kidneys is accompanied by regulatory changes 
  The dynamics of UTI are complex, especially when bacteria seed the kidneys. The mouse 
models of UTI differ in their propensity for kidney infection [80]. C3H/HeJ mice that lack the 
ability to respond to LPS via TLR4 sustain persistent kidney infection [117]. Kidney infection in 
C3H/HeN mice generally mirrors the outcome in the bladder; however, bacterial titers in the 
kidney are generally lower than in the bladders of the same animals [83]. The ability to ascend 
from the bladder to the kidneys depends on many factors including vesicoureteral reflux (VUR) 
and bacterial motility (Fig. 2). Bacterial inoculation into the bladder leads to reflux into the 
kidneys to varying degrees depending on the volume and speed with which the inoculum is 
introduced as well as the mouse strain [118, 119]. A minor, but significant role for flagella has 
been documented contributing to ascension to the upper urinary tract. Expression of flagella 
coincided with ascension to the upper urinary tract [120], and lacking flagella decreased the 
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ability of UPEC to colonize murine kidneys [120, 121]. Expression levels of the flagella 
promoter flhDC varied within IBCs, perhaps corresponding to their maturity and likelihood of 
releasing bacteria into the bladder lumen. Robust and rapid gene expression including activation 
of motility occurs prior to a transition from a bladder niche allowing transition and colonization 
of the upper urinary tract.   
 Bacterial strains that colonize the upper urinary tract are more likely to contain the pap 
operon than those strains isolated from patients suffering lower UTI only [122]. It has been 
shown that several UPEC CUP pili can bind receptors in the human kidney [123]. Type 1 pili 
were shown to bind tissue from the proximal tubules and the vessel walls, whereas P and S 
fimbriae bound Bowman’s capsule, the glomerulus, the renal tubules, and the vessels. F1C pili 
bound to endothelial cells and the collecting duct and distal tubules. The role of P pili has been 
clearly demonstrated in cynomolgus monkeys, where the receptor specificity more closely 
matches that of humans [124]. The PapG containing strain DS17 caused significantly more 
pathology in the monkey kidneys as assessed histologically as well as resulted in a greater loss of 
renal function as compared to an isogenic knockout [125]. Furthermore, immunization against 
PapG effectively reduced renal histopathology in monkeys [126]. The role of P pili has been 
difficult to assess in mouse models because the receptor for PapG is not present in the mouse 
kidney [124, 127]. However, Pap-expressing UPEC were isolated in higher numbers from the 
kidneys of CBA/J mice, a commonly used murine UTI model strain, than those lacking P pili in 
co-infection experiments [128]. Knockout analysis of the Pap genes in CFT073 was utilized to 
determine that P pili play only a minor role in kidney colonization in the CBA/J model [129]. It 
was recently shown that Ygi fimbriae bound kidney epithelial cells in vitro [36]. Therefore, P pili 
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appear to be an essential virulence determinant in causing human UTI, however other CUP pili 
may also contribute to kidney tropism in humans and animal models.  
UPEC may also occupy disparate niches in the kidneys, as illustrated by the ability of 
different adhesins to mediate attachment to different receptors within the kidney [123]. The 
infection dynamics of UPEC infecting the kidneys was recently demonstrated utilizing intravital 
multi-photon microscopy in rats [130]. Direct microinfusion of bacteria into the nephron 
revealed a synergistic role of P and type 1 pili. Interestingly, knockouts of FimH and P pili in 
distinct UPEC strains colonized the rat renal tubule, but the kinetics and dynamics of the 
infection differed. In the absence of P pili, attachment was temporally retarded, but spatially 
indistinguishable from the WT. Inversely, a FimH knockout rapidly colonized the rat renal 
tubules, but only areas adjacent to the epithelium. Likely, in the absence of FimH, UPEC was 
incapable of coalescing into a biofilm occupying the lumen of the renal tubule [130]. FimH-
mediated bacterial aggregation may play a role in biofilm formation in the kidney and IBC 
formation in the bladder [88]. Because of the variety of niches UPEC can occupy in the bladder 
and kidneys, the dynamics of UPEC UTI are complex with genetic regulatory networks likely 
governing the appropriate confluence of virulence factor expression for each given niche.  
 
Regulation of type 1 pili 
The most well associated virulence factor with UPEC strains causing cystitis is type 1 
pili, present in greater than 95% of cystitis isolates [73, 122]. Type 1 piliated UPEC are more 
effective at colonizing the mouse bladder than non-piliated UPEC [131-133]. Although type 1 
pili are essential for bladder colonization, their expression is dispensable and perhaps 
disadvantageous in other niches such as the kidneys, colon, or environment. In fact, loss of type 
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1 piliation does not decrease intestinal colonization of individual animals [134]; however, it does 
significantly reduce communicability [135], further supporting the argument that E. coli 
expressing type 1 pili is better suited for life in the urinary tract compared to the GI tract [88]. 
However, reports to the contrary have shown that type 1 pili are essential for GI tract 
colonization [136]. Interestingly, clinical data may be shifting this paradigm of a source-sink 
relationship in this complex disease. In a study of women experiencing multiple rUTIs, it was 
shown that at the time of infection, the dominant E. coli strain in the bladder and the GI tract was 
the same [137]. The role of type 1 pili in the gut niche has not been fully characterized. It has 
been demonstrated; however, that in transitioning niches out of the bladder, gene expression 
changes regulate pilus expression. Accordingly, type 1 pilus expression is reduced in kidney 
infections of mice [118]. Within the bladder niche where type 1 pilus expression governs 
pathogenesis, the fim genes are more likely to be expressed. Bacteria attached to epithelial cells 
sloughed in mouse urine were significantly more likely to express type 1 pili than planktonic 
bacteria in the same urine sample [138]. This niche specific difference in type 1 pilus expression 
provides strong evidence for the spatial and temporal regulation of this CUP operon and its 
necessity in causing cystitis. Accordingly, a vaccine against FimH was shown to dramatically 
decrease infection in both infected mice and monkeys [139, 140].  
Type 1 pili are phase variable, transcriptionally regulated by the inversion of the 314bp 
fim promoter, fimS, that is located between flanking invertible repeats which are recognized by 
the recombinases, FimB and FimE (Fig. 3A). FimB and FimE, which are 48% identical are 
encoded by two regulatory genes, fimB and fimE, 5’ of the fimS region [141-143]. FimB 
recombines the invertible repeats showing no preference in promoter orientation, while FimE 
inverts the promoter to the OFF orientation only [142, 144]. FimB appears to show no bias in 
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turning the switch ON or OFF; however, the rate with which FimE turns the switch OFF is an 
order of magnitude greater than FimB [145]. Thus, the abundance and activity of FimE and 
FimB appear to be the determining factors of the orientation of the phase switch.  
A number of factors have been identified that in turn control expression or activation of 
FimB and FimE, thus contributing to modulation of type 1 pili expression in response to 
environmental changes. For example, in broth cultures at 37oC, FimB is produced in excess 
leading to the population distribution skewed to more piliated bacteria [146, 147]. Recently, in 
silico analysis has demonstrated stringent control of the type 1 fimbriation switch, such that at 
temperatures lower than body temperature, FimE dominates, inverting the promoter to the OFF 
orientation [145]. At physiological or elevated host temperatures, during febrile episodes for 
example, the ON-to-OFF switching rates are lowered dramatically via increasing activity of 
FimB, locking UPEC into the more fimbriate state. Additionally, mutation of one of the 
invertible repeats of the fim promoter such that the promoter was irreversibly “locked” in the 
OFF orientation, resulted in significantly fewer CFUs retrieved from urine and bladders at 24hpi, 
compared to the WT strain, CFT073 [148]. As expected, when the promoter was locked in the 
ON orientation, the resulting strain slightly out-competed WT CFT073 in the bladder at 4 and 24 
hpi. In a recently conducted study with globally spreading, multi-drug resistant UPEC strains of 
the clonal group ST131, Totsika et al. found that growth in static conditions, known to enrich for 
fim expression [149], increased bladder colonization without affecting urine titers at 18 hpi 
[133]. In contrast strains from the same collection that lacked the ability to turn fim ON were 
unable to colonize the bladder [133]. Affecting the orientation of the promoter via genetic 
manipulation or through natural environmental changes alters the degree of piliation and fitness 
in the bladder. 
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Multiple studies have demonstrated that UPEC lacking both FimB and FimE rapidly 
inverted the fim promoter to the ON orientation when inoculated into mice [150, 151]. These 
experiments revealed that additional recombinase enzymes influence phase variation. Genome 
analysis of the pyelonephritis isolate CFT073 revealed 3 such recombinases ipuA, ipuB, and ibpA 
with 65-70% sequence similarity to FimE and FimB (Fig. 3A) [151]. ipuA and ibpA were able to 
invert the fim switch in the absence of FimE and FimB in vitro and when inoculated into the 
urinary tract of mice. Further analysis revealed that IpuA acts similarly to FimB, inverting the 
switch bidirectionally, whereas IpbA can only invert the promoter from OFF to ON. The cystitis 
isolate UTI89 contains FimX, an IpbA homolog, with 49.1% amino acid similarity to FimB 
[150] but does not contain IpuA or IpuB. A phase OFF triple fimBEX deletion mutant was 
completely deficient in bladder colonization at 6 hpi, whereas a phase OFF fimBE mutant 
colonized at WT levels, indicating that fim phase inversion was due to the activity of FimX. 
Indeed, complementation of the fimBEX mutant with fimX alone was sufficient to restore wild 
type levels of bladder colonization at 6 hpi, suggesting that UPEC has several functionally 
redundant recombinases that enable colonization of the bladder by mediating fim promoter 
inversion to the ON orientation [150]. In addition, these functionally redundant recombinases 
may serve to fine-tune the phase status of the population in certain niches or they may represent 
redundant regulators in the event of a fimB or fimE mutation, which occurs in certain UPEC 
strains, such as the multi-drug resistant clones of the ST131 lineage [133]. The majority (59 to 
71%) of strains from this clonal group were shown to have an insertional mutation in fimB, yet 
87% of tested isolates were still able to express type 1 pili as assessed by yeast agglutination, and 
adherence to and invasion into bladder epithelial cells [133]. One representative member of this 
group, EC958 contained ipbA, which may account for the observed fim promoter recombination. 
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By virtue of its importance in bladder colonization, type 1 pili are regulated by many 
functionally redundant recombinases. 
DNA binding proteins that impact structure of the chromosome and global regulators also 
influence the directionality of the fim promoter. Integration host factor (IHF) plays a dual role in 
governing phase status of UPEC [152]. Mutations in IHF locked the phase switch in the OFF or 
ON orientation, thereby preventing inversion of the promoter [153]. Additionally, when the fim 
switch was locked in the ON orientation, mutation of IHF led to a sevenfold reduction in LacZ 
expression of a FimA-LacZ fusion [152]. Mutations in the histone-like protein H-NS were shown 
to dramatically increase the rate of fim promoter inversion [154]. Conversely, mutations in the 
master regulator Leucine-responsive regulatory protein (Lrp) decreased the rate of fim promoter 
inversion. Lrp increased the transcription of fimB and decreased fimE expression [155]. 
Additionally, Lrp binds directly to the fim invertible repeat region, thereby sterically hindering 
FimB/FimE binding or RNA polymerase complex recruitment [156]. Binding of the catabolite 
repression system through cAMP-CRP (cAMP receptor protein or Catabolite Activator Protein, 
CAP) also influenced the fim promoter (Fig. 3A) [157]. Deletion of the crp gene led to higher 
expression of fimA transcript while decreasing P pili and flagella. The effects of cAMP-CRP on 
the fim promoter are complex likely because this regulator imparts pleiotropic effects in response 
to the nutritional status of the cell and growth phase. Additionally in log phase of growth, CRP-
cAMP repressed fimbriation whereas in stationary phase, it appeared to have little effect. The 
contribution of multiple regulatory networks and proteins like the ones we discussed here are 
likely to be critical in ensuring appropriate expression of type 1 pili during transitions between 
niches with varying temperatures and nutritional availability. 
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FimH allele regulates type 1 pili 
 In addition to the aforementioned external regulators of type 1 pili, the allele of fimH can 
also regulate type 1 pilus expression. A mutation of the FimH binding pocket from a glutamine 
to a lysine at position 133 resulted in 50% of the bacterial population to turn type 1 pili off 
relative to 90% in WT UTI89 [88]. Similarly an A62S mutation had the same effect. This 
regulation may be due in part to the structural conformations that FimH adopts during its 
translocation. The pilus initiation complex for type 1 pili has recently been crystallized, 
demonstrating that FimH adopts an elongated conformation when being assembled [158]. 
Immediately therafter, FimH adopts a bent, compressed conformation when it is extruded out of 
the FimD usher [159]. These conformational differences are similar to those observed when 
FimH is bound by the chaperone FimC versus when it is assembled into a tip [160]. When FimH 
binds mannose or when it is bound by its chaperone, it adopts an elongated, high affinity 
conformation [43, 161]. When mannose is absent, FimH is in a low affinity, compressed state 
[160]. FimH allelic differences may govern both mannose binding as well as the regulation of the 
expression of this virulence factor.    
 
Differential methylation regulates P pili 
Unlike the DNA-inversion based phase variation of type 1 pili, phase variation of the pap 
operon is mediated by differential methylation of two DNA adenine methyltransferase (DAM) 
sites in the promoter (Fig. 3B) [162], while additional regulation is accomplished by the cis-
encoded regulators PapB [163] and PapI [164] as well as several DNA binding proteins 
including H-NS, Lrp, and CRP-cAMP. PapB and PapI, are encoded upstream of the pap operon. 
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PapI is transcribed from its own promoter in the opposite direction to the papBA transcript [164]. 
Two GATC methylation regions are present upstream of the papBA promoter [162]. Methylation 
of GATC1130 (GATCprox) results in phase ON cells that can be actively transcribed, whereas 
methylation of GATC1028 (GATCdist) results in phase OFF bacteria (Fig. 3B). Because 
methylation is the main mechanism for P pilus phase variation, P piliation is linked to cell 
division during which these epigenetic changes can be enacted [165]. Furthermore, pap genes 
were not expressed when Dam was present in too high or too low quantities within the bacterial 
cell, implying that appropriate methylation is essential for proper regulation. The regulator PapI 
binds to DNA upstream of the papBA promoter at distal sites. With Dam absent, the proper 
methylation of GATC1130 does not occur, and transcription is abrogated. Conversely, 
overexpression of Dam prevented phase OFF bacteria from turning ON, presumably as a result 
of aberrant methylation of GATC sites [162]. As for type 1 pili, Lrp also affects P piliation. 
Methylation of GATC1028 (distal) and cooperative Lrp binding at proximal sites prevented RNA 
polymerase from transcription at the papBA promoter [165].   
Autoregulation of the pap operon by PapB is exquisitely tuned to the amount of the 
regulator present. PapB binds to three locations within the operon: 200 bp upstream of the papI 
promoter adjacent to the binding site of CRP, adjacent to the -10 area of the papBA promoter, 
and within the PapB coding sequence (Fig. 3B) [166, 167]. PapB binds upstream and activates 
the transcription of papI, perpetuating a positive feedback loop, maintaining bacteria in the P 
piliated state [168]. However, overexpression of PapB led to repression of P piliation, by 
blocking the binding of RNA polymerase at the -10 region of the papBA promoter [167, 168]. 
CRP-cAMP is essential for the transcription of the pap operon [169]. Binding of CRP-cAMP 
215 bp upstream of the papBA promoter led to increased levels of transcript. Binding of Lrp 140 
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bp upstream of the promoter was essential for CRP-mediated papBA transcription [170]. 
Addition of PapI in trans dramatically increased OFF to ON switching rates and subsequent 
papBA transcription. The precise control of P pilus regulation by metabolite binding proteins and 
cis-encoded regulators serves to assess local environmental conditions and respond accordingly 
with the timely expression of the appropriate pilus system.  
 
Pilus cross-regulation 
 In order to accomplish accurate and rapid exchange of expressed CUPs, regulators of the 
P, type 1, and S pilus systems interact with other operons, regulating their expression (Fig. 3C). 
These regulatory networks are likely responsible for ensuring UPEC expresses the appropriate 
pili in a timely manner to colonize a specific niche. Most E. coli only express one pilus type at a 
time [171] with cross-regulatory networks likely responsible for switching between expressed 
pilus systems [172].  
 Deletion of a pathogenicity operon encoding P-related fimbriae in the UPEC strain 536 
diminished expression of S pili encoded by the sfa operon [173, 174]. The regulators PrfB and 
PrfI encoded by the P-related fimbriae operon are 76% and 87% homologous to the S pili 
regulators, SfaB and SfaI, respectively. PrfB and PrfI act in trans on S fimbriae promoting their 
expression and complemented sfaB and sfaI knockouts [174]. Coordinate expression of these two 
pilus operons and other interactions not yet known may serve to enhance the probability of 
attaching to a host surface. It is possible that attachment feedback through master regulators 
selects for the expression of appropriate adhesin systems for that environment. This theory is 
consistent with data suggesting that attachment altered complex genetic regulatory networks [92, 
175, 176]. Further, negative cross-regulatory interactions between pili may serve to divert 
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resources to the conditions for most effective persistence or transit throughout hosts. 
Transcription of both the P and S pilus operons repressed type 1 pili expression (Fig. 3C) [177, 
178]. PapB binds to several regions of the fim operon and enhances the expression of fimE and 
also prevents the ability of FimB to invert fimS [178] (Fig. 3). SfaB represses FimB-mediated 
recombination without affecting FimE [177] (Fig. 3C). When expressed from its native promoter 
in E. coli K12 and CFT073, PapB was shown to inhibit type 1 pili. Furthermore, the expression 
of P pili in clinical isolates from patients with varying clinical UTI syndromes repressed type 1 
pili [179]. These data present a model of coordinate regulation of virulence factors in which 
during cystitis, type 1 pilus expression is dominant whereas other CUPs such as P or S pilus 
expression are expressed in the kidneys during pyelonephritis, repressing type 1 pilus expression.  
 Altering the balance of the two-component regulatory system QseBC that is present in 
many pathogenic bacteria [180], affects many UPEC virulence factors, CUP systems chief 
among them [62, 181]. Aberrant and uncontrolled phosphorylation of QseB via deletion of the 
sensor kinase QseC in UTI89 lead to decreased type 1 pilus expression, decreased flagella 
expression, and increased expression of the sfa operon encoding S pili, the F-17 operon, and the 
fml operon. The expression of the CUP operons yqi, yeh, and auf were decreased. The alteration 
of conserved metabolic processes likely accounts in part for these pleiotropic effects [62]. It is at 
present unclear whether these changes are direct effects of QseB phosphorylation or whether the 
decrease in fim expression leads to the concomitant changes in other CUP expression.     
  
Anti-virulence compounds to treat UTI 
 UPEC colonization of the diverse urinary tract niches largely depends on its ability to 
adhere to different receptors that are niche-specific. Therefore, inhibiting the adhesive organelles 
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that mediate attachment poses an attractive strategy for treating or preventing UTIs. The 
mannose-binding pocket of FimH is invariant among sequenced UPEC, and a mutation in this 
region rendered FimH defective in mannose binding, as well as bladder cell invasion and IBC 
formation [60, 88]. FimH is known to bind human uroplakins that coat the luminal surface of the 
bladder [84]. Recently small molecular weight orally available compounds called mannosides 
that bind the FimH binding pocket with low nanomolar affinities were developed using rational 
structure-directed design [182-185]. The addition of mannosides to an oral regimen of the 
antibiotics trimethoprim-sulfamethoxazole (TMP-SMX) was additive in reducing bacterial 
burden by the sensitive strain UTI89 [185]. By utilizing a strain resistant to TMP-SMX, PBC-1, 
it was shown that mannoside addition potentiated the effects of this antibiotic combination. 
Mannoside prevented PBC-1 from accessing the intracellular niche of the bladder, thus 
partitioning organisms to the urine and bladder lumen, where antibiotic levels were above the 
minimum inhibitory concentration for the clinically resistant PBC-1 strain. Mannoside was also 
effective at reducing bacterial titers by greater than 4 logs in as little as 6 hours after its oral 
administration to mice experiencing chronic cystitis at 2 wpi [185]. Because mannosides do not 
need to access the bacterial cytosol, they are not subject to efflux pumps, degradation, or changes 
in outer membrane permeability, implying that resistance development is unlikely.  
While type 1 pilus inhibition would likely be effective for preventing and treating cystitis, 
a more general approach targeting multiple CUPs could incapacitate multiple pilus systems 
limiting colonization of multiple niches. Accordingly, compounds have been designed to block 
pilus biogenesis by taking advantage of the structural similarity between CUPs [27]. These 
bicyclic 2-pyridinones known as pilicides reduced type 1 and P pilus based hemaggluttination 
and biofilm formation. Structural analysis revealed that these compounds bind to the surface of 
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the chaperone that interacts with the usher [27]. Therefore, pilicides function by entering the 
bacterial periplasm and binding to the chaperone to prevent pilus assembly through the usher. 
Anti-virulence compounds such as pilicides and mannosides represent novel strategies to 
translate basic knowledge from the investigation of pilus structure and function into new 
therapeutics that may have efficacy in treating UTIs by affecting CUP expression and function. 
 
Conclusions and Perspectives 
 Surface expressed organelles with terminal adhesins mediate the first interaction between 
host and pathogen. In colonizing a host or the environment, bacteria encounter many niches with 
disparate surfaces on which to attach. Accordingly, many pathogens have the capacity to express 
different adhesins assembled into different surface organelles to mediate attachment to the 
various niches and surfaces they encounter.  Understanding the regulatory interplay between 
pilus function and regulation and the cross-talk between operons has led to the development of 
novel anti-virulence therapeutics such as mannosides and pilicides, which target the FimH 
adhesin expressed at the distal tip of type 1 pili or multiple chaperone usher pili, respectively [27, 
182, 185, 186]. Furthermore, understanding the complex population dynamics, niche occupation, 
and bacterial fluxing between urinary tract niches in time and space is crucial to dissecting the 
importance of virulence factors. Virulence gene expression is precisely regulated over time and 
space by the local environmental conditions including the receptors for attachment, 
immunological response, and other bacterial populations nearby.  
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Overview 
 This thesis describes the ability of UPEC to occupy intracellular and extracellular bladder 
niches throughout infection in multiple models. I hypothesized that occupation of an intracellular 
niche would precede and lead to the development of chronic cystitis. To this end, I determined 
the population dynamics and niche distribution throughout infection using a panel of isogenic, 
signature-tagged, UPEC strains. This work revealed a dramatic population bottleneck that 
accompanies acute infection. UPEC transit this bottleneck by occupying intracellular niches in 
the form of IBCs. I also determined the role of several residues of FimH that are evolving under 
positive selection. UTI89 and CFT073 harboring FimH::A62/V163 were more fit throughout 
infection, especially in the ability to cause and persist during chronic cystitis. Thus, these 
positively selected alleles conferred a colonization advantage to both intracellular and 
extracellular niches. By conducting biolayer interferometry, I determined that these residues 
impacted the ability of FimH to bind mannose. Finally, I developed a model of repeat infection 
to mimic the clinical situation of frequent sexual intercourse. I found that this process induced 
higher rates of chronic cystitis in susceptible and resistant mouse strains. This increase in chronic 
cystitis depended on invasion, IBC formation, and regulation of host cell exfoliation. The 
information herein will help to identify certain factors, both bacterial and behavioral, that might 
portend worse prognosis for women suffering an acute UTI, necessitating more aggressive and 
novel treatments. 
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Figures 
Table 1. Distribution of chaperone usher pathway pili in sequenced uropathogenic E. coli 
genomes. 
K12 UPEC CUP 
Operons MG1655 UTI89 CFT073 536 
fim + + + + 
pap - + +* + 
F17-like - + - + 
sfa - + - + 
yad + + + + 
auf - ± + + 
yfc + + + + 
ygi + + + - 
yeh + + + + 
fml ± ± + - 
foc - - + - 
yde + - + - 
Dr family1 - - - - 
fso1 - - - - 
fst1 - - - - 
pix - - - + 
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(+) indicates presence, (-) indicates absence, and (±) indicates that an operon is present, but 
likely nonfunctional due to mutation or deletion of genes. 
(*) indicates that two copies of the operon are present. 
1 indicates that these operons are not present in these UPEC, but are present in many clinical 
isolates. 
Figure is modified with permission from Chen et al. (2006). Copyright (2006) National 
Academy of Sciences, U.S.A. 
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Figure 1. Model of type 1 pilus biogenesis.  
A) Subunits are secreted across the Sec apparatus and immediately bound by the cognate 
periplasmic chaperone, the absence of which results in subunit misfolding and degradation. The 
chaperone donates its G1 beta strand to the subunit to complete its incomplete Ig-like fold in 
donor strand complementation. B) The chaperone then delivers the subunit to the NTD of the 
membrane usher, FimD. The subunit is then transferred to the CTD, where donor strand 
47 
exchange occurs with the previously added subunit. P pilus biogenesis occurs in a similar 
fashion. (A) modified with permission from John Wiley and Sons. Henderson et al. 2011. 
Molecular Microbiology. 
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Figure 2. Pathogenesis of UPEC UTI.  
A) A population of UPEC from the GI tract is introduced into the bladder where the bacteria 
attach to the epithelial surface with the FimH adhesin at the tip of type 1 pili. B) UPEC invades 
49 
the superficial facet cells of the bladder within the first hour of infection. C) UPEC replicates 
within the facet cells in a type 1 pili-dependent manner unless they are expelled via a TLR4-
dependent process or infected epithelial cells are jettisoned by an apoptotic, exfoliation 
mechanism. D) UPEC form intracellular bacterial communities (IBCs) within the cytoplasm of 
superficial facet cells of the bladder. E) Between 16-24 hpi, UPEC flux out of the IBC with some 
bacteria becoming filamentous to become the dominant population of the bladder. Additional 
UPEC clones may descend from the infected kidneys. F) chronic cystitis is marked by bacterial 
replication in the lumen of the bladder and adherence to the tissue via type 1 pili. If the infection 
resolves, the formation of Quiescent Intracellular Reservoirs (QIRs) may result, as shown in (G). 
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Figure 3. Type 1, P, and S pilus regulation.  
A) Type 1 pili are transcriptionally regulated by recombinases that invert the promoter, fimS. 
FimE binds the inverted repeats, turning the promoter OFF. FimB can invert the promoter 
bidirectionally; however, its major function is turning the promoter ON. The functionally 
redundant recombinases FimX/IpbA can also turn the promoter ON, whereas ipuA functions 
similarly to FimB. Lrp and CAP inhibit FimB-mediated OFF-to-ON inversion. B) The pap 
operon is regulated via differential Dam methylation. In the ON orientation, PapI-Lrp complexes 
bind the distal methylation sites, allowing RNA polymerase to transcribe the pap genes. Binding 
of Lrp to proximal GATC sites prevents Dam methylation and RNA polymerase binding, 
shutting down P pilus transcription. C) The cross-regulation between pilus operons serves to 
ensure appropriate adhesin expression for in vivo niche. PapI binds the sfa operon and enhances 
its transcription. PapB and SfaB inhibit FimB-mediated OFF-to-ON inversion of the fim 
promoter, preventing type 1 pilus transcription. 
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Abstract  
 Urinary tract infections (UTIs) have complex dynamics with uropathogenic E. coli 
(UPEC), the major causative agent, capable of colonization from the urethra to the kidneys in 
both extracellular and intracellular niches while also producing chronic persistent infections and 
frequent recurrent disease. In mouse and human bladders, UPEC invades the superficial 
epithelium, and some enter the cytoplasm to rapidly replicate into intracellular bacterial 
communities (IBCs) comprised of ~104 bacteria each. Through IBC formation, UPEC expands in 
numbers while subverting aspects of the innate immune response. Within 12 hr of murine 
bladder infection, half of the bacteria are intracellular, with 3-700 IBCs formed. Using mixed 
infections with GFP and WT UPEC, we discovered that each IBC is clonally derived from a 
single bacterium. Genetically tagged UPEC and a multiplex PCR assay were employed to 
investigate the distribution of UPEC throughout urinary tract niches over time. In the first 24 hpi, 
the fraction of tags dramatically decreased in the bladder and kidney while CFUs increased. The 
percentage of tags detected at 6 hpi correlated to the number of IBCs produced, which closely 
matched a calculated multinomial distribution based on IBC clonality. The fraction of tags 
remaining thereafter depended on UTI outcome, which ranged from resolution of infection with 
or without quiescent intracellular reservoirs (QIR) to the development of chronic cystitis as 
defined by persistent bacteriuria. Significantly more tags remained in mice that developed 
chronic cystitis arguing that a higher number of IBCs formed during the acute stages of infection 
precedes chronic cystitis, while fewer precede QIR formation.  
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Introduction  
Population bottlenecks exist for many infections and are particularly well-documented 
during transmission between hosts for RNA viruses and parasites [1-6]. Localizing bottlenecks in 
time and space during an infection can identify steps in pathogenesis where an organism 
encounters the strongest barriers to establishing a foothold within a host. Bottlenecks may also 
represent important steps in host colonization and pathogenesis to target with therapeutics. 
Similar studies have been undertaken to identify genes important for tissue colonization and 
transit between tissues for bacterial pathogens ([7-9]. Several potential bottlenecks limiting the 
progression of uropathogenic E. coli (UPEC) to later stages of infection exist in the pathogenic 
cascade of UTI: i) invasion of the superficial bladder epithelium, ii) avoidance  of Toll-like 
receptor 4 (TLR4)-mediated expulsion [10], iii) persistence in the face of superficial facet cell 
exfoliation, iv) the maturation process of IBCs, v) ascension from bladder to the kidneys, and vi) 
possible descent from kidneys to the bladder. These population dynamics all occur in the face of 
clearance mechanisms, including micturition and the innate immune system [11]. Understanding 
these bottlenecks in the setting of mucosal infection of the urinary tract will provide insight into 
the pathogenesis of this complex infection with the goal to develop better treatments.   
UTIs are painful, expensive to the individual and society, and will affect 50% of women 
during their lifetime [12]. The vast majority of community-acquired UTIs are caused by UPEC. 
The clinical diagnosis of UTI hinges upon the ability to culture bacteria from clean-catch urine 
samples. When the uropathogen is sensitive to the chosen agent, oral antibiotics typically 
produce a rapid improvement in symptoms and sterilization of the urine [13, 14]. Despite 
appropriate treatment of a primary UTI, 25-40% of adult women will have at least one 
recurrence (rUTI) within 6 months of her initial infection [15, 16]. Additionally, up to 20% of 
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women may experience the symptoms of cystitis, or infection of the bladder, with accompanying 
urine cultures from clean catch specimens below the diagnostic cutoff of 105 CFU/mL [17]. This 
implies that bacterial occupation of urinary tract niches even in the absence of clinical diagnosis 
can contribute to symptoms of UTI. The exact location of bacteria within the urinary tract in 
these syndromes is, at present, unknown. The high prevalence of UTI, frequent repeated 
antibiotic therapy for rUTI, and the failure to use stringent diagnoses of UTI may drive rising 
antibiotic resistance [13, 14, 18]. Through a thorough examination of the molecular basis for 
rUTI and the identification of the major persistent reservoirs for UPEC within the urinary tract, 
new therapeutic strategies may be designed to eliminate UPEC from the urinary tract and thus, 
better guide appropriate antibiotic usage. 
 Current knowledge of the pathogenesis of UPEC UTI is incomplete, but accumulated 
molecular studies demonstrate tremendous complexity in the pathogenesis of the disease. In most 
primary UTIs, UPEC is thought to ascend the urethra from the perineum to colonize the bladder 
lumen. Additionally, UPEC can ascend the ureters and colonize the kidneys. Increased 
vesicoureteral reflux (VUR) enhances the likelihood of bacterial ascension into the kidneys and 
subsequent renal scarring in children and individuals with neurogenic bladder [19]. Through 
studies in a murine model of UTI, several novel intracellular pathways within the bladder 
important for UPEC pathogenesis have been elucidated. After experimental transurethral 
inoculation of UPEC into the urinary tract, UPEC invades the superficial facet cells of the 
bladder in a type 1-pilus dependent manner [11, 20, 21]. In order to evade expulsion from these 
cells via a TLR4-dependent mechanism [10], UPEC must escape into the cell cytoplasm, where 
they rapidly replicate and aggregate into cytosolic clusters of bacteria called intracellular 
bacterial communities (IBCs), a process that occurs independent of specific host genotypes [22, 
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23]. After full maturation of the IBCs, UPEC become filamentous and flux out of the superficial 
facet cell in response to a TLR4-dependent host signal [24]. The luminal bacteria may then 
invade other superficial facet cells, renewing the invasion and intracellular replication cascade 
[24, 25]. Thus, UPEC undergo at least two rounds of IBC formation over the first 24 hours post 
infection (hpi). Occupation of an intracellular niche by UPEC is not unique to the mouse model, 
as IBCs and filamentous bacteria have been frequently identified in urine from women with 
acute cystitis [26]. Replication within epithelial cells may protect UPEC from being cleared by 
neutrophils, antimicrobial peptides, micturition, and antibiotic administration [24, 27]. In the 
C3H/HeN mouse model of UTI, the IBC stage is most active during the first 24 hpi [25]. Thus, 
during UTI many niches within the urinary tract are colonized including the bladder lumen, 
within cells of the bladder epithelium, and the kidneys. 
IBCs are not typically observed in C3H/HeN mice after 48 hpi. However, outcomes of 
the infection are dependent on the immune response to acute events [28]. The C3H/HeN mouse 
model of UTI recapitulates several of the outcomes present in humans. The outcome of bladder 
infection in these mice is bimodal with twenty to forty percent of infected C3H/HeN mice 
developing persistent bacteriuria and chronic cystitis [28]. Placebo-controlled trials have 
demonstrated persistent bacteriuria in women with or without resolution of symptoms in the 
absence of antibiotic treatment [15, 29]. High levels of interleukin (IL) -5, IL-6, keratinocyte 
cytokine (KC), and granulocyte colony-stimulating factor (G-CSF) in the serum of C3H/HeN 
mice at 24 hpi are nearly 100% predictive of ensuing chronic cystitis [28]. The remaining mice 
have low levels of these cytokines and resolve the acute infection, evidenced by sterile urine. 
However, even upon resolution of bacteriuria, UPEC may occupy niches in the underlying 
epithelium in quiescent intracellular reservoirs (QIRs) [30]. Thus, UTI pathogenesis has 
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complexity in both space (tissue niche) and time. During the acute stages of pathogenesis, IBC 
formation facilitates the expansion of bacterial numbers in the face of innate defenses. A 
multitude of consequences to the acute events exist ranging from resolution of infection with or 
without accompanying QIRs, or ensuing chronic cystitis or pyelonephritis. The relationship 
between IBC formation during acute infection and the subsequent outcome of infection is not 
known. The dynamics of acute infection and the subsequent outcomes may also be altered if the 
kidneys are infected concurrently with the bladder. Underlying conditions such as vesicoureteral 
reflux (VUR) increase the likelihood of co-infection of the kidneys and bladders. These 
complicated population dynamics may be modeled in specific mouse strains such as C3H/HEN. 
These mice are also susceptible to kidney infection due to a high rate of VUR [31-33]. 
With all of the transitions UPEC makes between anatomic and cellular spaces, it is likely 
that only a fraction of the total bacterial population transitions from one niche to another, in 
which case, population bottlenecks likely occur. Based on the complexity of UTI and the various 
niches UPEC inhabits during infection, we sought to determine transit between relevant niches 
and barriers within the urinary tract over time and whether the penetration of infection barriers 
resulted in an expansion of those descendents. A prior study indicated that intracellular UPEC 
make up a significant proportion of bacteria in the bladder during the first 48 hours post infection 
(hpi), as determined by ex vivo gentamicin protection assays [11]. Early in infection, micturition 
and neutrophil influx may disproportionately reduce or eliminate luminal bacteria, while 
intracellular UPEC are largely protected from these clearance mechanisms.  
 We addressed the role of bottlenecks in UPEC population dynamics during UTI using a 
panel of 40 unique genetically-tagged isogenic UPEC that were tracked using a multiplex PCR 
assay. We modeled the dynamics of population flux using a calculated multinomial distribution 
58 
and compared theoretical values to a complicated model of infection using the C3H/HEN mouse, 
which is susceptible to VUR, thus resulting in UPEC being distributed during acute infection in 
the bladder and kidneys. In the bladder, we demonstrated that each IBC arises from replication of 
a single invasive bacterium and that the number of IBCs present at 6 hpi strongly correlates with 
the number of unique tags present. In mice that would likely resolve bacteriuria and/or develop 
QIRs, the fraction of uniquely tagged UPEC decreased to 10-20% of the tags present in the 
initial inoculum during the first 24 hpi in whole bladder specimens. In contrast, in mice with 
persistent bacteriuria, a hallmark of chronic cystitis, nearly 60% of unique tags remained. Thus, a 
high number of IBCs formed at 6 hpi and/or an inability to clear bacteria from the bladder lumen 
precedes chronic cystitis. Utilizing ex vivo gentamicin protection assays to separate intracellular 
and extracellular bladder populations, we found that during acute UTI the majority of remaining 
clones occupied all niches within the urinary tract while later in infection disparate clonal 
populations existed independently in the bladders or kidneys. 
Results 
IBCs arise from a single invasive bacterium. 
 UPEC invade the superficial facet cells of the bladder 15 minutes – 1 hour post 
inoculation into the urinary tract as determined by ex vivo gentamicin protection assays [34]. 
Over the next 8-12 hours, IBC formation ensues for bacteria that have successfully invaded and 
escaped into the cytosol of the superficial facet cells [25]. To address whether IBCs contain a 
clonal population expanded from a single bacterium or an aggregate of multiple distinct 
founders, we performed co-infections of mice with 1:1 and 50:1 ratios of unlabeled and GFP-
marked isogenic UPEC [35]. Six hours post infection, mice were euthanized, and the bladders 
were splayed, fixed, and stained with TOPRO-3 and examined by confocal microscopy. As a 
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result the unlabeled UPEC appeared red and the GFP-marked UPEC appeared yellow-green. Of 
the approximately 500 IBCs examined, each was exclusively red or yellow-green, regardless of 
the inoculation ratio (Figure 1). When superficial facet cells contained more than one IBC 
derived from a different inoculating strain, a clear demarcation existed such that no bacterial 
mixing occurred (Figure 1 C-D), indicating that IBCs are clonal formations arising from a single 
invasive bacterium. 
 
Formation of IBCs strongly correlates to tag diversity. 
 Given that each IBC is derived from a single bacterial founder and IBC formation is rare, 
with only 0.01-0.001% of the initial inoculum successfully undergoing IBC formation, we 
anticipated that various bottlenecks restricting invasion and subsequent IBC formation may 
result in a significant founder effect in later stages of infection. At 6 hpi following an initial 
inoculation of 1-5 X 107 CFU UPEC, each mouse bladder contained between 3 and 700 IBCs 
(Figure 2; median 49.5; geometric mean 40), consistent with previously reported data for 
C3H/HeN mice [36-38]. Combining prior knowledge that the bacterial population is primarily 
intracellular at 12 hpi [11, 39] with the finding that IBCs are clonal, we hypothesized that the 
invasion and IBC formation cycle acts as a strong population bottleneck that restricts overall 
bacterial diversity and may subsequently contribute a significant proportion of bacteria 
populating later stages of infection. In order to test this hypothesis, we designed 40 isogenic 
strains of UTI89 each with a unique 100-300 bp genetic sequence inserted into the λ phage 
region of the genome (See Materials and Methods). Bacteria containing these unique tags were 
identified using 8 multiplex PCR reactions. We reasoned that the small number of clonal IBCs 
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relative to the total inoculum, which was at primarily intracellular by 12 hpi [11], may contribute 
to a founder effect in the number of unique genotypes arising from this early bottleneck event.  
We infected mice with a pool of the tagged strains in equal proportions. At 6 hpi, the 
mice were sacrificed and the infected bladders were splayed and stained with X-gal to detect 
bacterial beta-galactosidase and thus localize UPEC in mature IBC formations, which stained 
punctate purple. Following enumeration of IBCs, the bladders were homogenized, and genomic 
DNA was extracted from the bacteria present in the bladder. We found a broad range of unique 
bacterial signatures corresponding to the range of IBCs formed per bladder at 6 hpi (Figure 2, 
black squares). Based on the hypothesis that the bacteria contained in IBCs account for the 
majority of bacteria in the bladder at 6 hpi, we calculated the fraction of tags that most likely 
would be remaining relative to the number of IBCs present using a multinomial distribution 
(Figure 2, line). Superimposition of the theoretical multinomial distribution onto the 
experimental data revealed a close fit (see Discussion and Supplemental Material). The five data 
points marked with asterisks represent bladders that contained more tags than IBCs. The 
increased fraction of tags in these bladders likely represented invasion events of bacteria that had 
not yet replicated into a mature IBC and thus not yet discerned in the X-Gal-stained bladders but 
were detected by the more sensitive multiplex PCR assay. For mice whose bladders contained 
>100 IBCs at 6 hr, all 40 tags were present. These data suggest that early in infection, the clonal 
IBC populations, arising from a small number of bacterial founders, may contribute the majority 
of bacterial diversity to later stages of infection. 
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Bacterial diversity decreased dramatically in the bladders and kidneys over time. 
 During the most acute stages of isolated cystitis, the formation of IBCs each from a single 
invasive bacterium, coincident with luminal clearance of bacteria, would be anticipated to 
constitute a stringent bottleneck, limiting the genetic diversity of organisms progressing to later 
stages of infection. We first determined the overall dynamics of infection using our set of 40 
uniquely tagged UPEC as a proxy for bacterial diversity to understand the occupation of the 
urinary tract over time. We infected C3H/HeN mice with 1-5 X 107 total CFU (2.5 X 105 – 1.25 
X 106 CFU/unique strain) and tracked them over the course of 4 wks. At the designated times 
after infection, the bladders and kidneys were homogenized, and 6% of the sample was plated to 
enumerate CFU (Figure 3 A-B). Through this approach, rare abundance tags are likely amplified 
to above the limit of detection in the multiplex PCR assay. A tag comprising <20 CFU in the 
sample could potentially be lost with this method, but such rare abundance tags are not likely to 
persist within the urinary tract for an extended period of time. 
Total bacterial diversity in the bladder decreased significantly over the first 24 hpi (p = 
0.003, 1 hpi vs. 24 hpi) to a median plateau of 25-40% of initial tags remaining (Figure 3C) 
while CFUs increased over this same time period to 105 CFU (Figure 3A). The simultaneous 
reduction in tag diversity with an increase in CFUs occurred during the time in which IBCs 
formed, suggesting a relationship between the IBC bottleneck and a founder effect in populating 
the bladder. Bacterial diversity in the kidneys also decreased over this same timespan (p = 0.003, 
1 hpi vs. 24 hpi) with approximately the same fraction of tags present in the bladders and kidneys 
by 1 week post infection (Figure 3D).  
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IBC formation correlates with outcome of infection. 
 In C3H/HeN mice, the fate of disease is determined within the first 24 hours of infection 
[28]. The two disease outcomes of resolution of bacteriuria concomitant with the establishment 
of QIRs and the development of persistent bacteriuria indicative of chronic cystitis, result in a 
bimodal distribution of bacterial CFU within the bladder that occurs after 1 week [40]. Thus, we 
investigated the relationship between the number of IBCs formed early in infection and the 
impact on the fraction of tags remaining later in infection and disease outcome [28, 30]. 
We infected 20 mice with equal proportions of the 40 unique, tagged UTI89 and 
determined the bacterial CFU and the number of unique tags that remained by 2 weeks post 
infection (wpi). Mice were stratified based on their urine titers over time and their 2 wpi bladder 
titer. Chronic cystitis was categorized by persistent bacteriuria of >104 CFU/mL at 1,3, 7,10, and 
14 days post infection (dpi) and a 2 wpi bladder titer of >104 CFU [28]. The remaining mice 
were classified based on bladder titers <104 CFU and at least one urine collection over the 2 
week infection that contained <104 CFU/mL UPEC (Figure 4 A, B). Mice that developed 
persistent bacteriuria and chronic cystitis had significantly more unique UPEC signatures present 
in the bladder by 2 wpi than mice that resolved infection (Figure 4C). Based on the founder 
effect theory, this would argue that development of chronic cystitis is correlated with increased 
IBC formation during the acute stage of infection, which is consistent with the strong correlation 
between IBC formation and the fraction of tags present throughout the bladder during the IBC 
cycle (Figure 2). Conversely, decreased IBC formation is more likely correlated with resolution 
of bacteriuria with reservoir bladder titers <104 CFU.  
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Population dynamics in acute vs. chronic infection. 
UTI is a dynamic infection sometimes entailing concomitant kidney infection. 
Populations of UPEC within the bladder and kidneys of C3H/HeN mice may thus be shaped by 
different independent environmental forces, including unique bottlenecks.  These physically 
separated populations may subsequently intermix to generate some intermediate, combined 
population. Abundant influx of neutrophils and immune mediators into the bladder occurs very 
early during UTI in both mice and humans [31, 41, 42]. Invasion of the bladder epithelium may 
represent a mechanism for UPEC to increase its population during UTI while remaining 
separated from much of the innate immune response. Gentamicin protection assays on ex vivo 
infected bladders support this concept, demonstrating that by 12 hpi in murine UTI, the majority 
of UPEC are intracellular [11]. On the basis of these prior studies, we sought to determine the 
location of UPEC within urinary tract niches throughout infection. In order to obtain a more 
complete understanding of how bacterial subpopulations are distributed within the urinary tract 
at a given time, sampling of different niches within the urinary tract was performed using mice 
infected with equal numbers of each of the 40 genetically tagged UTI89 strains at different times 
post infection. We obtained clean-catch urine from mice by gentle suprapubic pressure and 
plated it to enumerate CFU (Figure 5A). Afterwards, the mice were sacrificed, and the bladder 
was bisected twice and washed with sterile PBS to liberate loosely bound and planktonic UPEC, 
heretofore referred as “luminal” or “extracellular” fraction (Figure 5B). The intact, quadrisected 
bladder was incubated with the antibiotic gentamicin, which does not penetrate the bladder 
epithelium, thus selectively eliminating extracellular organisms. After the gentamicin was 
washed away, the bladder tissue was homogenized to liberate the intracellular bacteria, 
designated as the “gentamicin-protected bladder” population (Figure 5C). During the first 24 hpi, 
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this fraction represented bacteria that invaded superficial facet cells and were, in some cases, 
within IBCs. After 48 hpi when IBC formation no longer occurs, the gentamicin-protected 
fraction consisted of bacteria within QIRs or another niche protected from gentamicin. Kidneys 
were also homogenized and plated to enumerate CFU (Figure 5D). 
All of the 40 uniquely tagged UPEC strains were present in both the extracellular and 
intracellular populations at 1 hpi (Figure 5F-G). This amount of tag diversity was not statistically 
different than that observed in the whole bladder at 1 hpi (Figure 3C; p> 0.05, Wilcoxon signed 
rank, hypothetical median = 1.0). At 6 hpi, the proportion of genetic tags approached 1 in the 
kidneys, likely due to VUR of the inoculum in the C3H/HEN mice at the initiation of the 
infection.  However, the proportion of genetic tags was decreased in the urine and all 
compartments of the bladder (Figure 5F-G) during the time when host innate defenses have been 
shown to be induced and engaged [42].  The data re-confirmed that only 0.1-1% of invasive 
events lead to the formation of an IBC, perhaps as a result of TLR4 mediated bacterial expulsion 
[10]. Furthermore, the wide range of unique tags present in the intracellular compartment at 6 hpi 
(Figure 5G) corresponded with the natural variation in IBC number between mice, correlating 
with our earlier results (Figure 2).  
  Between 6 and 24 hpi, the bacterial tags detected in the kidneys decreased (Figure 5H).  
However, the tags detected in the bladder lumen and intracellular bladder fractions increased 
(Figure 5F-G), suggesting that the overall bacterial diversity of the bladder was increasing due to 
shedding of bacteria carrying independent, unique tags from the kidney. In order to understand 
the overlap of bacteria in different niches, the identities of each tag were determined in each 
niche at each time point. We then determined on a per-mouse basis the fraction of unique and 
shared tags present within and between the following niches: urine, bladder lumen, within the 
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bladder epithelium, and kidneys. For each time point, we determined the fraction and identity of 
each tagged strain present in each of the 15 possible overlapping and distinct niche combinations 
out of the total number of tags present within the urinary tract (Figure 5I-M). At 6 hpi, the 
kidneys and urine contained 34% of bacterial diversity not present in a bladder niche, likely 
reflecting the population that gained access to the kidney earlier in the infection as a result of 
VUR. At 24 hpi, 38% of the total tagged strains still present within the urinary tract were shared 
between all of the compartments (Figure 5J). These data show that at 24 hpi the majority of 
individual clones of bacteria are populating every niche within the urinary tract likely as a result 
of emergence from IBCs earlier in infection and descent from the kidneys to seed other niches of 
the urinary tract.   
By 48hpi, the CFU in the bladder stratified into a bimodal distribution reflecting the 
development of persistent bacteriuria and bladder titer of >104 CFU or resolution of bacteriuria 
and establishment of QIR with UPEC titer of <104 CFU [28, 30]. The bimodal distribution was 
evident in the bladder lumen and gentamicin-protected fractions at 1 wpi (Figure 5C). At 2 wpi 
in this experimental set, bacteria were no longer present in the lumen and urine in 4/5 of the 
mice, and instead exclusively occupied gentamicin-protected reservoirs within the bladder 
epithelium or kidney (Figure 5L). Among the mice 1 wpi with high bladder bacterial counts 
indicative of chronic cystitis, 21% of the tags were shared in all niches. In contrast, 15% of the 
tags remaining in mice that resolved bacteriuria and formed QIRs, were located exclusively in a 
gentamicin-protected niche, which increased to 28% of all urinary tract diversity by 4 wpi 
(Figure 5K,M). The majority of tags at 4 weeks post infection (60%) were present only in the 
urine without a bladder or kidney niche colonized, potentially suggesting that these bacteria 
colonized the ureter, urethra or peri-urethral area, explaining why they were not found in another 
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niche (Figure 5M). The lumen in these mice was not colonized with bacteria, while the 
gentamicin-protected fraction had 103 CFU, suggesting that these mice were resolved with QIR 
formation. Thus at different times during the infection, the urine fraction contains bacteria shed 
from the kidneys, planktonic bacteria from the bladder lumen, bacteria strongly adhered to or 
within exfoliated epithelial cells, or bacteria otherwise lost from bladder and kidney niches 
(Figure 5I-M). 
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Discussion 
We created 40 isogenic uniquely tagged UPEC strains and assessed the presence of these 
bacteria in niches within the urinary tract over time with a multiplex PCR assay. This approach 
allowed us to provide an accurate accounting of the strains distributed throughout different 
compartments in the urinary tract over the course of UTI. By recovering bacteria from the 
samples on agar overnight to amplify even rare genetic tags, our approach resulted in a highly 
sensitive assay that provided a conservative estimate of the strains present in each compartment 
and their distribution throughout the urinary tract at the time of sampling. Using this molecular 
approach to better understand the obstacles in UPEC pathogenesis, we have revealed a series of 
population bottlenecks and interactions between distinct populations of the bladder and kidneys 
that impact on the dynamics of the UPEC population during infection as a whole.  
When C3H/HeN mice are inoculated with 107 CFU UTI89, 103-104 CFU invade the 
bladder epithelium at 1 hpi, and all of bacterial tags can be accounted for in the bladder 
intracellular population (Figure 5G). Subsequently, 3-700 IBCs are formed per bladder by 6 hpi, 
and as demonstrated herein, each IBC is derived from a single bacterium that enters into the 
cytoplasm of a superficial facet cell (Figure 1, 2). Together, 0.1% of the inoculum invades the 
epithelium, and <2% of the invasive bacteria successfully form IBCs. The most stringent 
population bottleneck observed is between 1 and 24 hpi corresponding to the time frame when a 
limited number of invasive bacteria have entered into the IBC cycle while innate immunity is 
engaged to clear luminal organisms. These dynamics produce a founder effect. The variance of 
the fraction of tags present within the bladder epithelium at 6 hpi and in the whole bladder at 24 
hpi (Figures 2, 3C, 5G) reflects the large bladder to bladder variance in IBC number and begins 
to reflect the bimodal distribution in infection outcome. The cause of the variance in IBC number 
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is unknown, but presumably reflects factors necessary to penetrate the various bottlenecks 
described here. 
Our experimental data demonstrating the clonality of IBCs suggest that IBC formation 
with a concurrent reduction of the luminal UPEC population places a significant constraint on 
the number of organisms progressing through to later stages of infection. Indeed, modeling 
clonal IBC formation as the only pathway by which organisms can persist in the urinary tract fits 
the observed data very well and supports this hypothesis (Supplemental Figure 1). Given that 
IBCs are clonal, a single IBC can only contribute to the detection of a single tag.  So long as a 
tag is detected in our PCR assay, we cannot distinguish whether it was present in one or many 
IBCs.  Therefore, assuming that tags are equivalent and detection by PCR is efficient, this is akin 
to an experiment where for every IBC, a die with 40 different numbers (each corresponding to a 
tag) is cast, and we count how many different numbers were thrown as a result of all casts of the 
die. With these assumptions, the probability distribution of the number of tags detected (different 
numbers of the die) given a number of IBCs formed (number of casts of the die) can be 
calculated exactly using a multinomial distribution (Supplemental Figure 1).  If there are other 
pathways to persistence that do not involve IBC formation (such as persistence exclusively in the 
lumen of the bladder), the number of tags detected can be modeled as additional throws of the 
die, 1 per each additional extracellular clone (Supplemental Figure 1A). Given the close fit 
between the multinomial expectation (based solely on IBC number) and the observed number of 
tags (Figure 2), if there is another pathway to persistence, its contributions in terms of diversity 
are very small and effectively not measurable in our data. Small exclusively luminal populations 
(not necessarily clonally derived from a single founder) would be predicted to drastically 
increase the expected fraction of tags persisting when low numbers of IBCs are present, though 
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this is not experimentally observed (see Fig. S1A in the supplemental material and Fig. 2). 
Although it is formally possible that clonal, extracellular populations contribute to bacterial 
diversity within the bladder at 6 hpi, the most likely interpretation of our data is that by 24 hpi, 
the extracellular population is largely a subset of bacteria arising from bacterial subpopulations 
that have emerged from other niches with IBCs being a major source (Figure 5I, J).  
The outcomes of acute infection are: 1) resolution of bacteriuria which can be 
accompanied by formation of a QIR, which can lead to recurrent infection or 2) chronic active 
cystitis marked by persistent bacteriuria for >7 months, which presumably reflects extracellular 
replication of bacteria [28, 30]. Our data described above indicate that the strongest population 
bottlenecks exist within the first 24 hpi. Prior studies of UPEC mutants with defects in IBC 
development suggest that the first generation IBCs are important for the establishment of acute 
cystitis [24, 34].  
The studies presented herein have several key implications. First, in species such as 
humans, where isolated cystitis is common, the bottlenecks due to invasion and the IBC cycle 
may be even more stringent than observed in our studies in C3H/HeN mice because there may be 
no mixing of bacteria being shed from the kidneys into the bladder. Inhibitors at the point of the 
major bottlenecks within the first 24 hours of infection may significantly attenuate infection, 
both acute and chronic. For instance, inhibition of the IBC pathway, either by blocking IBC 
formation, development, or dispersal, may alter outcomes by reducing the QIR and limiting 
chronic active cystitis. Combined with a FimH vaccine, invasion inhibitors may be particularly 
potent in preventing and treating UTI [43]. A recent study showed that in a urological cohort of 
women, UPEC isolated from urine from 6/8 patients were not actively expressing type 1 pili 
[44]. Our results from figure 5M showing that 60% of strains detected were present only in the 
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urine argue that these UPEC may indeed reflect strains lost from the bladder as they were not 
detectable in any other urinary tract niche. Thus, although it is possible that these strains are not 
expressing type 1 pili as suggested by the results of Hagan et al 2010 [44], their existence 
presumably depended on earlier colonization events involving type 1 pili and other virulence 
factors. Finally, the development and maintenance of genomic changes by UPEC during UTI 
may be contingent on the timing of acquisition of mutations, rearrangements, or deletions in the 
genome due to the bottleneck constraints present in the system. For instance, a mutant 
subpopulation obtaining antimicrobial resistance to trimethoprim through a mutation in 
dihydrofolate reductase (DHFR) may be extinguished by a stringent stochastic bottleneck even 
under circumstances when the antibiotic is being administered and an antibiotic resistance 
mutation provides a selective advantage. This would be expected to occur if the proportion of the 
population with that advantage is sufficiently too small to overcome the inherent stochastic 
barriers that eliminate the vast majority of the population and produce a founder effect, likely in 
this case to arise from majority members that do not have the advantageous mutation. 
Alternatively, hosts in which bacteria more effectively penetrate the early bottlenecks such as 
those developing chronic cystitis where diversity is maintained, may provide productive 
environments for the selection and perpetuation of adaptive mutations. Thus, diversity and 
selective evolution may be constrained by these stochastic mechanisms during cystitis and/or 
dramatically favor mutations that facilitate invasion and IBC formation. Indeed, several genes 
important for invasion, IBC formation and living within host cells were shown to be under 
positive selection in UPEC [37, 45].  
The findings herein present the hypothesis that an increased number of IBCs activates a 
host immune response that predisposes to persistent bacteriuria and chronic cystitis. In C3H/HeN 
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mice, increasing the inoculum to 108 CFU/mL increases the average number of IBCs formed and 
increases the percentage of mice experiencing persistent bacteriuria [28]. Currently, it is not 
possible to evaluate these metrics of infection within the same mouse. Longitudinal monitoring 
of bacterial populations in vivo using techniques in development such as intravital multi-photon 
microscopy to enumerate acute IBC formation at 6 hpi and determine bacteriuria and tissue titers 
at 2 wpi will provide further resolution to the consequences of early infection events on subacute 
and chronic outcomes. Our findings are especially relevant for mucosal pathogens that have to 
transit through potential population bottlenecks similar to those described in this work [5, 6, 46]. 
Finally, the methodology described herein would be ideal to analyze population bottlenecks, 
niche occupation, and clonality by other bacterial pathogens of mucosal sites. 
 
Materials and Methods 
Construction of 40 isogenic tagged UPEC strains. 
Unique tags were inserted into the chromosome following the ybhC gene in the region of 
the lambda phage attachment site into the clinical isolate UTI89 [39]. This site was chosen since 
prior insertions in this region (gfp reporter fusions) did not adversely affect pathogenesis [35]. 
The tags were designed using unique sequences as reported by Lehoux et al [47, 48]. Primer 
sequences are shown in Supplemental Table 1. For the construction of the genomic insertion 
cassettes, the chloramphenicol or kanamycin cassette from pKD3 or pKD4 [49] was amplified 
using primers BP-1 in combinations with BP-2A, BP-2B, BP-2C. The respective products were 
digested with EcoRI and column purified (Qiagen). Each of the BP-00F primers was 
phosphorylated in a reaction that included 1 x T4 ligase buffer (NEB), 10 mM dATP (Promega) 
and 1 U of T4 polynucleotide kinase (Invitrogen) for 30 min at 37oC. The appropriate BP 00F 
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and BP 00R primers were annealed by mixing an equal molar ratio in dH2O, heating to 95oC for 
5 min, and cooling slowly to RT. In a similar method, primers BP-5 and BP-6 were annealed to 
each other. A tripartite ligation was performed using the BP-1/BP-2 digested PCR products with 
the annealed products of BP-00F/R and BP-5/BP-6 in 1 x T4 ligase buffer and 10 U of T4 ligase 
for 1 hr at RT. To a PCR reaction containing 1 x Pfx buffer (Invitrogen), 2 mM MgSO4, 0.2 mM 
dNTP, 2.5 U of Pfx polymerase (Invitrogen), and 200 pmol each of primers BP-1 and BP-6, 0.5 
µl of each ligation was added. The reactions were cycled at 94 oC for 3 min followed by 30 
cycles of 94 oC for 15 sec, 55 oC for 45 sec, and 68 oC for 1.5 min. A final extension at 68 oC for 
7 min was performed. The ~1.6 kb products were verified by gel electrophoresis and column 
purified (Qiagen). Chromosomal insertion of the tag constructs was performed using the Red 
Recombinase method [49]. The tags were verified by colony PCR in a reaction mixture 
containing 1 x PCR buffer (Invitrogen) with 0.2 mM dNTP, 2.5 mM MgCl2, 2.5 U of Taq 
polymerase (Invitrogen) and 200 pmol each of the appropriate primers pairs BP-8K (kanamycin 
template) or BP-8C (chloramphenicol template) and BP-00F. Growth curves of each individual 
strain were performed to ensure no gross growth defects in broth culture (data not shown).  
Evaluation of isogenic UPEC strains in a murine cystitis model.   
In preparation for inoculation into mice, each of the 40 isogenic UTI89 derivatives was 
grown individually in LB statically at 37oC overnight and then sub-cultured 1:1000 into 2 ml of 
fresh LB with static growth at 37oC for 18-24 hr. Cell density was measured using an OD600 
value, and each clone was added in approximately equal cell numbers to a central pool. The 
pooled bacteria were centrifuged for 10 min at 6,500 x g at 4oC. The pellet was resuspended in 
20-25 ml of sterile PBS to yield a final cell suspension where 50 µl contained ~1-2 x 107 CFU. 
Fifty µL was introduced over 10 seconds into 7-8 week old C3H/HeN mice under 2.5% 
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isofluorane inhalation via a transurethral route. The infections were allowed to proceed for 1 hr 
up to 4 wks at which time the mice were sacrificed under anesthesia, and the bladders and 
kidneys were removed and homogenized in 1 mL or 0.800 mL sterile PBS, respectively. 
Homogenates were serially diluted and plated to enumerate the bacteria in the tissues. Genomic 
DNA was obtained from the bacterial lawns by the addition of two milliliters of sterile water in 
each Petri dish and scraped using a bacterial cell scraper (BD Falcon). The bacteria were pelleted 
by centrifugation and washed with PBS. The final pellet was processed using the Promega 
Genomic DNA Isolation Kit per the manufacturer’s instructions. Genomic DNA was also 
prepared from a bacterial pellet of the pooled input inoculum. 
BAR-PATH multiplex PCR was performed using 50 ng of genomic DNA in a PCR 
reaction mix including 1 x Taq buffer (Invitrogen), 2.5 mM MgCl2, 0.2 mM dNTP, 100 pmol 
each of BP-8C and BP-8K, and 2.5 U Taq DNA polymerase (Invitrogen). The BP 00F primers 
(see Table S1 in the supplemental material) were mixed in sets of 3 primers for inclusion in PCR 
reactions: [BP 01F, BP 02F, BP 03F], [BP 04F, BP 05F, BP 06F], etc. and added to the reaction 
mixture at final concentrations of ~66.6 pmol/primer. Reactions were cycled with a hot start then 
94 C x 3 min followed by touchdown PCR with 10 cycles of 94 oC for 30 sec, 62 oC for 30 sec 
with a 1 degree decrease per cycle, and 72oC for 30 sec.  Next, 30 cycles were performed at 94oC 
for 15 sec, 55oC for 15 sec, 72oC for 30 sec. A final 7 min extension at 72oC was performed.  
Ten microliters of the 25 µl reaction was run a 2.5 % TBE-agarose gel. Presence or absence of 
an individual strain present in the multiplex PCR was determined by eye in comparison to the 
intensity of its cognate band in the inoculum. If a strain was not detected in the inoculum pool, it 
was not included in the analysis for that experiment. Thirty-seven of the forty tags were routinely 
detected in the inoculum. Three tags were statistically underrepresented in the PCR of the 
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inoculum pool and were thus excluded in the subsequent analyses of the endpoint samples. 
Ambiguous bands were analyzed in an independent multiplex PCR replicate. All mouse infection 
studies were approved by the Animal Studies Committee of Washington University in St. Louis. 
IBC enumeration.  
To quantify the number of IBCs per bladder, bladders were bisected and splayed onto 
sterile silica plates and fixed with 3% paraformaldehyde (Sigma). The bladders were washed 3X 
with 2mM MgCl2 (Sigma), 0.01% Na deoxycholate (Sigma), 0.02% Nonidet-P40 (Roche) in 
sterile PBS, pH 7.4. Bladders were then stained in 0.4 mL 25 mg/mL X-gal (Sigma) and a 
solution containing 1 mM potassium ferrocyanide and 1mM potassium ferricyanide (Sigma). 
After incubating at 30oC for 16 hours, bladders were visualized under a dissecting microscope 
where IBCs appeared as bright blue punctate circles. 
Confocal scanning laser microscopy. 
 Female 6-7 week old C3H/HeN mice were infected with a 1:1 or 1:50 mixture of UTI89 
and UTI89::HKGFP and sacrificed at 6 or 12 hpi [35]. Bladders were extracted, splayed, and 
counterstained with Topro-3 and imaged with a Zeiss LSM410 confocal scanning laser 
microscope. 
Ex vivo gentamicin protection assay.  
At the indicated times post-infection, bladders were removed aseptically and bisected 
twice. The bladders were washed three times with 500 µL sterile PBS. The washes were pooled, 
spun at 500 rpm for 5 min and dilution plated as described earlier. This wash was termed 
“luminal” or “extracellular.” The bladders were then incubated for 90 min. with 100 µg/mL 
gentamicin to kill adherent extracellular bacteria. After this incubation, the bladders were washed 
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twice with 1 mL sterile PBS. The bladder was then homogenized in 1 mL sterile PBS and 
dilution plated to enumerate intracellular CFU. Bacterial pellets were obtained and processed as 
described earlier. 
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Figures  
 
 
Figure 1.  IBCs are clonal, derived from single invasive bacteria.  
C3H/HeN mice were co-infected with UTI89 and UTI89::HKGFP and sacrificed at 6 hpi 
and 12 hpi. Bladders were aseptically removed and splayed and imaged with confocal 
microscopy. (A-B): IBCs in whole mount at 6 hpi, counterstained with TOPRO-3. Each image 
shows the merged red and green channel data. (C-D): Co-resident IBCs inside a single 
superficial facet cell at 12 hpi. Representative images of over 500 independent IBC are shown. 
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Figure 2. IBC number correlates with number of tags present.  
C3H/HeN mice were infected as described and processed to enumerate IBCs and extract 
bacterial genomic DNA (see methods). Black squares represent the number of IBCs and the 
number of tagged strains present per mouse bladder. The line is the median number of tags 
expected based on a multinomial distribution of IBC number (see Discussion and Supplemental 
Material). Data represent 3 independent experiments with 5-10 mice per experiment. * represent 
bladders with a greater number of tags than IBCs. 
 
 
 
 
 
 
 
81 
 
Figure 3. Bacterial diversity decreased dramatically during first 24 hpi.  
At the indicated times post infection, C3H/HeN mice were sacrificed, and the bladder and 
kidneys were removed aseptically, homogenized in PBS, and 6% of the homogenate was plated 
to enumerate CFU in the bladders (A) and kidney pair (B). Genomic DNA was isolated from a 
lawn of UPEC isolated from the tissue homogenates, and multiplex PCR was conducted to 
determine the fraction of the 40 unique tags present in each bladder (C) and kidney pair (D).  
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CFU data are presented as CFU/whole organ. Bars are median values. N = 1-2 experiments with 
5-8 mice each. P values were calculated using a two-tailed Mann Whitney non-parametric 
comparison. An Initial experiment conducted with 43 tags is also included in this analysis. 
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Figure 4. Higher fraction of unique bacterial signatures remain in mice experiencing chronic 
cystitis.  
A) 2 weeks post infection, C3H/HeN mice were sacrificed, and the bladders were 
removed aseptically, homogenized, and plated to enumerate CFU. B) Urines were obtained by 
gentle suprapubic pressure and plated to enumerate CFU. The dashed line at 104 CFU represents 
the limit for assessing the presence of UTI in clean catch urine samples (40). Urine titers above 
this point are considered bacteriuria indicative of a UTI, while bladder titers greater than this 
cutoff indicate chronic cystitis. C) Genomic DNA was then obtained from the bacteria from each 
bladder sample and multiplex PCR was conducted. Bars are median values. P values were 
calculated using a two-tailed Mann Whitney non-parametric comparison. 
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Figure 5. Niche specific diversity over time demonstrates population dynamics throughout UTI.  
At the indicated times post infection, urine was obtained via gentle suprapubic pressure and 
plated to enumerate CFU (A) and fraction of tags remaining (E). A gentamicin protection assay 
was performed to enumerate luminal CFU (B) and fraction of tags remaining (F) and gentamicin 
protected CFU (C) and tags remaining (G). Kidneys were also plated to enumerate CFU (D) and 
85 
tags remaining (H). The niche occupation of specific tags was determined and is represented as 
average fraction of tags present in distinct and overlapping niches (15 total permutations) and 
displayed as a 4-set Venn diagram at 6 hpi (I), 24 hpi (J), 1 wpi (K), 2 wpi (L), and 4 wpi (M). 
Each percentage listed displays the fraction of tags present in that unique or shared niche out of 
the total number of tags in each murine urinary tract. Data for (A-H) represent 1-3 experiments 
with 5 mice per timepoint. Data for (I-M) represents experiments where kidney information was 
available: 2 experiments with 4-5 mice for panel I and 1 experiment with 5 mice each for panels 
J to M. * signifies the niche combination with the greatest unique diversity present. Bars are 
median values. P values were calculated using a two-tailed Mann Whitney non-parametric 
comparison. 
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Supplemental Information 1 
Table 1S: Primers Used for Polymerase Chain Reaction (PCR). 2 
Primer Name  Sequence (5’3’) Target 
kps Reg1 
KO#1 
GTTACAACCCATTGATTTAGCATAAATAAATTATAGTGGGTTCGGGTTTGT
TGTGTAGGCTGGAGCTGCTTC 
kps Region I, 5’ / pKD4  
kps Reg1 
KO#2 
TGGAAATGATTTTTTGGCTACTTAAAATTCAAAAGATATTGACTTGAAATAT
GGGAATTAGCCATGGTCC 
kps Region I, 3’ / pKD4 
kps Reg1 #1 ATGTTCCCGGTGGTCAACATGCTTCCAGCACTCCTT kps Region I, 5’ 
kps Reg1 #2 CCTCTTTGCACGATAAAAGGATTTTCTTG kps Region I, 3’ 
BP 1F GTACCGCGCTTAAACGTTCAG BAR-PATH 
BP 1R AATTctgaacgtttaagcgcggtacAGC BAR-PATH 
BP 2F GTACCGCGCTTAAATAGCCTG BAR-PATH 
BP 2R AATTcaggctatttaagcgcggtacAGC BAR-PATH 
BP 3F GTACCGCGCTTAAAAGTCTCG BAR-PATH 
BP 3R AATTcgagacttttaagcgcggtacAGC BAR-PATH 
 
 
BP 4F GTACCGCGCTTAATAACGTGG BAR-PATH 
BP 4R AATTccacgttattaagcgcggtacAGC BAR-PATH 
BP 5F GTACCGCGCTTAAACTGGTAG BAR-PATH 
BP 5R AATTctaccagtttaagcgcggtacAGC BAR-PATH 
BP 6F GTACCGCGCTTAAGCATGTTG BAR-PATH 
BP 6R AATTcaacatgcttaagcgcggtacAGC BAR-PATH 
BP 7F GTACCGCGCTTAATGTAACCG BAR-PATH 
BP 7R AATTcggttacattaagcgcggtacAGC BAR-PATH 
BP 8F GTACCGCGCTTAAAATCTCGG BAR-PATH 
BP 8R AATTccgagattttaagcgcggtacAGC BAR-PATH 
BP 9F GTACCGCGCTTAATAGGCAAG BAR-PATH 
BP 9R AATTcttgcctattaagcgcggtacAGC BAR-PATH 
BP 10F GTACCGCGCTTAACAATCGTG BAR-PATH 
BP 10R AATTcacgattgttaagcgcggtacAGC BAR-PATH 
BP 11F GTACCGCGCTTAATCAAGACG BAR-PATH 
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BP 11R AATTcgtcttgattaagcgcggtacAGC BAR-PATH 
BP 12F GTACCGCGCTTAACTAGTAGG BAR-PATH 
BP 12R AATTcctactagttaagcgcggtacAGC BAR-PATH 
BP 13F CTTGCGGCGTATTACGTTCAG BAR-PATH 
BP 13R AATTctgaacgtaatacgccgcaagAGC BAR-PATH 
BP 14F CTTGCGGCGTATTATAGCCTG BAR-PATH 
BP 14R AATTcaggctataatacgccgcaagAGC BAR-PATH 
BP 15F CTTGCGGCGTATTAAGTCTCG BAR-PATH 
BP 15R AATTcgagacttaatacgccgcaagAGC BAR-PATH 
BP 16F CTTGCGGCGTATTTAACGTGG BAR-PATH 
BP 16R AATTccacgttaaatacgccgcaagAGC BAR-PATH 
BP 17F CTTGCGGCGTATTACTGGTAG BAR-PATH 
BP 17R AATTCTACCAGTAATACGCCGCAAGAGC BAR-PATH 
BP 18F CTTGCGGCGTATTGCATGTTG BAR-PATH 
BP 18R AATTCAACATGCAATACGCCGCAAGAGC BAR-PATH 
 
 
BP 19F CTTGCGGCGTATTTGTAACCG BAR-PATH 
BP 19R AATTCGGTTACAAATACGCCGCAAGAGC BAR-PATH 
BP 20F CTTGCGGCGTATTAATCTCGG BAR-PATH 
BP 20R AATTCCGAGATTAATACGCCGCAAGAGC BAR-PATH 
BP 21F CTTGCGGCGTATTTAGGCAAG BAR-PATH 
BP 21R AATTCTTGCGGCGTATTTAGGCAAGAGC BAR-PATH 
BP 22F CTTGCGGCGTATTCAATCGTG BAR-PATH 
BP 22R AATTCACGATTGAATACGCCGCAAGAGC BAR-PATH 
BP 23F CTTGCGGCGTATTTCAAGACG BAR-PATH 
BP 23R AATTCGTCTTGAAATACGCCGCAAGAGC BAR-PATH 
BP 24F CTTGCGGCGTATTCTAGTAGG BAR-PATH 
BP 24R AATTCCTACTAGAATACGCCGCAAGAGC BAR-PATH 
BP-2A Tgattaagatgaattcatgggaattagccatggtcc BAR-PATH 
BP-2B Tgattaagatgaattcgtgacacaggaacacttaacggctgac BAR-PATH 
BP-2C tgattaagatgaattccgcactgagaagcccttagagcctc BAR-PATH 
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BP-8K gcttcaaaagcgctctgaagttcctatac BAR-PATH 
BP-8C Cgtgccgatcaacgtctcattttcg BAR-PATH 
BP-1 gaaccgtaggccggataaggcgtttacgccgcatccggcacatagttaacagctcgtgtaggctggagctgc
ttc 
BAR-PATH 
BP-5 /5Phos/ctacttcttcgcctctgcaaccactttgctacccacgccgcggttattgtattcc BAR-PATH 
BP-6 ggaatacaataaccgcggcgtgggtagcaaagtggttgcagaggcgaagaagtaggct BAR-PATH 
 3 
 4 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Mathematical model of tag diversity subsequent to a population bottleneck
As discussed in the main text, IBC formation is clonal and hypothesized to be the main contribution to
bacterial persistence in the bladder. Assuming that bacteria carrying different tags are equivalent both in
terms of IBC formation and in detection efficiency, the number of tags expected to be detected due solely
to IBCs can be modeled as a multinomial distribution. Because tag detection does not differentiate between
whether one or multiple IBCs contained that tag, we are interested simply in the number of different tags
(multinomial outcomes) detected at all, and not in their relative abundance. In short, the problem of how many
tags remain following a population bottleneck is identical to asking how many distinct bar codes are chosen
when they are randomly sampled with replacement, the number of samples taken representing the population
bottleneck. From the point of view of tags detected, we can calculate other populations from other bacterial
niches by including additional samplings (multinomial trials), with one additional sample per bacterial clone.
This problem has been previously examined in (Ma, 2001), where formulas for the number of ”live” terms
in a complete multinomial expansion were presented - this corresponds precisely to our problem of calcu-
lating how many tags are expected to be detected in a given experiment. In the notation of (Ma, 2001),
n is the number tags, representing mutually exclusive categories that result from a sampling (i.e. multino-
mial choices); k is the number of bacterial clones (either IBCs or clones included in other niches), or the
number of multinomial trials; m is the number of tags detected, or those that have been sampled at least
once in an experiment (live terms). A closed formula for the complete multinomial distribution is well known:
ai1,i2,...,ink,p = n!/k!(n  k1)!(n  k2)!...ik11 ik22 ...iknn However, as noted by (Ma, 2001), this is computationally in-
tractable for values of n and k that we are interested in. (Ma, 2001) developed a closed formula for calculating
individual terms of the multinomial expansion, but use of this requires iterating over all combinations of live
terms, which is equivalent to finding all combinations of a set of k integers that sum to n. To translate from this
into the distribution of total number of live terms is also computationally intractable for reasonable n.
Therefore, we have extended the reasoning used by (Ma, 2001) to directly calculate the number of multi-
nomial samplings that have a given number of live terms. Our calculation has polynomial complexity because
it does not explicitly calculate each term of the multinomial; instead, it calculates sums of distinct sets of the
multinomial expansion, which are precisely the values that we are interested in.
We do a direct calculation of the number of ways that k samples from a multinomial with n possibilities,
all with equal probability, results in exactly m outcomes occuring at least once. We let Tm be the number
of possibilities that have exactly m live terms. For m = 1, this is trivial; for every sample, there is only 1
possibility, and thus there is 1k = 1 combination. However, there are n choices for which outcome is the only
successful one; thus, there are n ⇥ 1 = n total ways that exactly one outcome is successful in all k samples:
T1 = (n1 )1
k = n.
For m = 2, each of the k samples has two possibilities, resulting in 2k total combinations. However, 2k
counts all the possibilities of no more than 2 successful outcomes; this includes outcomes where only one of
the two is successful (all k choices result in the same outcome) and thus these must be subtracted. There are
(21) = 2 possibilities for the single successful outcome, thus we have 2k   (21)1k total outcomes where exactly
two possibilities are successful. There are (n2 ) ways to pick which two outcomes are successful, giving us a
total of T2 = (n2 )[2k   (21)1k] ways to have exactly two successful outcomes after k trials.
A similar reasoning is used for m = 3. Given the 3 outcomes, there are 3k possibilities that have no more
than those 3 outcomes; we must now subtract the possibilities that only 2 or 1 of the 3 desired outcomes is
successful. When subtracting the possibilities that only 2 of the desired 3 outcomes is successful, we must only
count those outcomes where exactly 2 of the outcomes is successful and not include the subset where only 1
of the 2 outcomes is successful. As above, the possibilities for exactly 2 successful outcomes is 2k (21)1k, and
there are (32) combinations of two outcomes, giving (32)[2k   (21)1k]. The correction for outcomes with only one
successful outcome is (31)[1k]. Again, there are (n3 ) ways of choosing a subset of three successful outcomes,
giving a total of T3 = (n3 )[3k   (32)[2k   (21)1k]  (31)[1k]].
We now introduce a recursive definition for the term cm,k = mk  ⌃m 1i=1 (mi )ci,k form > 1, and c1,k = 1k = 1.
The term cm,k represents the number of ways to get exactly m successful outcomes in k trials. Note that cm,k
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does not depend on the total number of possible outcomes. Then we can simplify the above expressions to:
T1 = (n1 )c1,k
T2 = (n2 )c2,k
T3 = (n3 )c3,k
In general, we have
Tm = (nm)cm,k
which is now, as expected, dependent on the total number of possible outcomes.
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Supplementary Figure 1 
 
 
 
 
 
 
 
Figure 1. Predictive stochastic selection models of tag diversity 
in relationship to clonal intra- and extra-cellular communities. 
(A): Median number of tags (total = 40) expected based on a multinomial expan-
sion with increasing contributions of tags from theoretical, clonal extracellular 
populations (see supplemental material). (B): The probability distributions for the 
likelihood of detecting a specific number of tags based on the amount of IBCs 
formed.
A
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Chapter 3: Positively selected FimH residues enhance virulence during urinary tract 
infection by altering FimH conformation. 
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ABSTRACT 
Chaperone-usher pathway (CUP) pili are a widespread family of extracellular, Gram-
negative bacterial fibers with important roles in bacterial pathogenesis. Type 1 pili are important 
virulence factors in uropathogenic Escherichia coli (UPEC), which cause the majority of urinary 
tract infections (UTI). FimH, the type 1 adhesin, binds mannosylated glycoproteins on the 
surface of human and murine bladder cells, facilitating bacterial colonization, invasion, and 
formation of biofilm-like intracellular bacterial communities (IBCs). The mannose-binding 
pocket of FimH is invariant among UPEC. We discovered that pathoadaptive alleles of FimH 
with variant residues outside the binding pocket affect FimH-mediated acute and chronic 
pathogenesis of two commonly studied UPEC strains, UTI89 and CFT073. In vitro binding 
studies revealed that while all pathoadaptive variants tested displayed the same high affinity for 
mannose when bound by the chaperone FimC, affinities varied when FimH was incorporated 
into pilus tip-like, FimCGH, complexes. Structural studies have shown that FimH adopts an 
elongated conformation when complexed with FimC, but when incorporated into the pilus tip, 
FimH can adopt a compact conformation. We hypothesize that the propensity of FimH to adopt 
the elongated conformation in the tip corresponds to its mannose binding affinity. Interestingly, 
FimH variants, which maintain a high-affinity conformation in the FimCGH tip-like structure 
were attenuated during chronic bladder infection arguing that FimH’s ability to switch between 
conformations is important in pathogenesis. Our studies argue that positively-selected residues 
modulate fitness during UTI by affecting FimH conformation and function, providing an 
example of evolutionary tuning of structural dynamics impacting in vivo survival. 
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Significance 
 Evolution of multidrug-resistance in pathogenic bacteria, including uropathogenic E. coli 
(UPEC) that cause most urinary tract infections (UTIs), is becoming a worldwide crisis. UPEC 
utilize a variety of virulence factors and adhesins, including the mannose-binding FimH adhesin, 
to colonize and invade bladder tissue, often forming intracellular biofilms and quiescent 
reservoirs that can contribute to recurrent infections recalcitrant to treatment. Using two 
prototypical UPEC strains, we discovered that positively-selected residues outside of the FimH 
mannose-binding pocket, affect transitions between low and high-affinity FimH conformations 
which extraordinarily impacts FimH function during pathogenesis. Thus, this work elucidates 
mechanistic and functional insights into pathoadaptation and evolutionary fine-tuning of critical 
virulence interactions. 
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Introduction 
 Urinary tract infections (UTI) are common infections causing serious morbidity and 
significant expenditures in healthcare dollars and lost wages. Women are disproportionately 
affected, with over half of women experiencing at least one UTI during their lifetime [1]. In the 
absence of treatment, 50-80% of women will resolve a UTI within 2 months, but up to 60% of 
women may remain bacteriuric with or without symptoms for at least 5-7 weeks after the initial 
infection [2]. Furthermore, even when effective therapy is given and bacteriuria and symptoms 
of the acute UTI resolve, 25-40% of women experience a recurrent UTI (rUTI) [2, 3]. rUTI can 
occur by recolonization of the urinary tract from the gastrointestinal (GI) tract or from another 
environmental source by the same or different strain or may be due to reactivation of the original 
UTI strain from a bladder reservoir [4-6]. Uropathogenic Escherichia coli (UPEC) cause 80-90% 
of community acquired UTI and 50% of nosocomial UTI [7]. The increasing prevalence of 
multidrug-resistant organisms can prolong the infection [8]. Thus, chronic and recurrent UTI 
represents a major health concern worldwide, necessitating molecular understanding of disease 
pathogenesis and investigations into novel diagnostics and therapies. 
UTI is a highly complex disease involving colonization of multiple niches, each of which 
presents a unique set of evolutionary pressures shaping host-microbe and microbe-microbe 
interactions involving a multitude of virulence factors that determine disease onset, progression, 
and outcome. Adhesive pili assembled by the chaperone-usher pathway (CUP), such as type 1 
pili, are well-characterized UPEC UTI virulence determinants. Type 1 pili, like other CUP pili, 
contain an adhesin (FimH) at their tip that plays an important role in host-pathogen interactions 
and biofilm formation. Type 1 pili are nearly ubiquitous among clinical UPEC isolates [9, 10] as 
well as commensal E. coli and other Enterobacteriaceae. Expression of type 1 pili is essential for 
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colonization of the murine urinary tract [11]; however, expressing type 1 pili is not sufficient for 
long-term colonization, as commensal E. coli are rapidly cleared [12]. 
Upon UPEC entrance into the bladder, FimH binds mannosylated glycoproteins, 
including uroplakins expressed throughout human and murine bladders [13]. Subsequent to 
attachment, UPEC invade superficial facet cells in a FimH-dependent manner [12, 14] and 
replicate in the cytoplasm, forming large biofilm-like structures called intracellular bacterial 
communities (IBCs) [15]. The formation of IBCs has been observed for numerous clinical UPEC 
isolates in multiple mouse models and in exfoliated uroepithelial cells in urines of patients with 
acute UTI, but not from healthy controls [16, 17]. The process of invasion and IBC formation 
provides UPEC an ability to survive stringent bottlenecks during pathogenesis in the urinary tract 
[18, 19]. Outcomes of infection range from resolution with or without accompanying quiescent 
intracellular reservoirs (QIRs) in the bladder tissue [4] to persistent bacteriuria and chronic 
cystitis [20]. In C3H/HeN mice, the formation of a high number of IBCs at 6 hours post infection 
(hpi) and an exuberant systemic innate immune response at 24 hpi, measurable in both urine and 
serum, correlate with the development of chronic cystitis marked by persistent urine and bladder 
titers >104 CFU/mL and severe bladder immunopathology [18, 20]. In addition to colonizing the 
bladder, UPEC can ascend the ureters and infect the kidneys, leading to pyelonephritis. The 
connection between acute and chronic UTI is just now beginning to be characterized [21-23]. 
Type 1 pili and the tip adhesin, FimH, are encoded by the fim operon [24, 25]. Mature FimH is a 
279 amino acid (aa) two-domain protein containing a mannose-binding lectin domain (residues 1 
– 150) and a pilin domain (residues 159 to 279) with an 8 amino acid (aa) linker connecting the 
domains (Fig. 1) [26-28]. The mannose-binding pocket of FimH is invariant among sequenced 
UPEC [29, 30]; however, several residues outside the mannose-binding pocket (positions 27, 62, 
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66 and 163) were found to be evolving under positive selection in clinical UPEC isolates 
compared to fecal strains (Fig. 1) [29, 31, 32]. Among four fully sequenced UPEC isolates 
(UTI89, CFT073, 536, and J96), differences exist in positively selected residues 27, 62, and 163 
(Table 1). Clinical isolates expressing different fimH alleles have observable differences in the 
degree of pathogenicity as measured by IBC formation [16] and the development of chronic 
cystitis [20]. We found that UTI89, a cystitis isolate, formed more IBCs and had higher bladder 
titers at 6 hpi than CFT073, a pyelonephritis isolate, in single and co-infections. Because of the 
demonstrated importance of type 1 pilus function in pathogenesis, we conducted fimH allele 
swap experiments to determine whether the differences in fimH between UPEC strains were 
responsible for the phenotypic differences. We generated CFT073 and UTI89 strains containing 
different fimH alleles inserted into the normal chromosomal position. We found that presence of 
a fimH sequence encoding FimH from UTI89 (denoted FimH::A62/V163) resulted in significant 
increases in IBC development and the propensity to cause chronic cystitis compared to 
expression of CFT073 FimH (FimH::S62/A163). In co-infections, strains expressing 
FimH::A62/V163 significantly outcompeted otherwise isogenic strains harboring 
FimH::S62/A163 in both CFT073 and UTI89. FimH complexed with its chaperone FimC adopts 
an elongated conformation (Fig. 1A), which binds mannose with high affinity [26, 33]. When 
complexed with the FimG adaptor, FimH can adopt a compact conformation which binds 
mannose with low affinity (Fig. 1B) [33]. The identity of residues at positively selected positions 
outside the binding pocket dramatically impacts the mannose binding affinity of FimH when in 
the FimCGH tip-like complex but not in the FimCH complex. Thus, we argue that the 
combination of residues at positively selected positions affects the propensity of FimH to adopt 
an elongated conformation in the tip and thus its relative mannose binding affinity. FimH alleles 
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that retained the high affinity binding conformation in the tip were significantly attenuated in a 
mouse model of UTI suggesting that equilibrium between FimH conformations, which is 
modulated by positively-selected residues, is critical in pathogenesis. 
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Results 
Prevalence of positively selected FimH alleles in humans  
Comparing UPEC-infected urine isolates to fecal E. coli from healthy humans and 
animals has previously identified genes and residues within genes under positive selection in 
UPEC [29, 34, 35]. We analyzed a collection of fimH sequences obtained from 33 fecal E. coli 
from healthy, uninfected humans as well as 232 urine and periurethral isolates from women 
suffering acute or rUTI, asymptomatic bacteriuria, or pyelonephritis [16, 17, 29, 36-39]. We 
were particularly interested in cataloguing naturally occurring residue combinations at positions 
27, 62, and 163, since in previous studies these residues showed evidence of positive selection, 
and mutations in these residues impacted fitness of the cystitis isolate UTI89 [29]. In sequences 
of fecal and E. coli from infected urine, we found one of two residues at each of these positions. 
An alanine occurred at position 27 in 85% of fecal isolates and 81% of urine isolates, while a 
valine occurred at position 27 in the other sequenced isolates. A serine occurred at position 62 in 
all of the fecal isolates and in 93% of urine isolates, while an alanine occurred in 7% of urine 
isolates. At position 163, a valine occurred in all fecal isolates and in 93% of urine isolates, with 
alanine occurring in the other 7% of urine isolates. Of the eight possible combinations of these 
three residues, we found only the four combinations shown in Table 1. Most E. coli isolates 
encode FimH::A27/S62/V163, with this allele being present in a higher percentage of fecal 
strains than urine strains. The prototypical UPEC isolates, UTI89 and CFT073 encode two 
different pathoadaptive FimH variants, A27/A62/V163 and A27/S62/A163, respectively. Neither 
fimH allele was observed in healthy feces (Table 1). All other residues in the mature FimH of 
UTI89 and CFT073 are identical. UTI89 was isolated from the urine of a patient experiencing an 
uncomplicated acute UTI [12]. CFT073 was isolated from the blood and urine of a woman 
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suffering acute pyelonephritis and sepsis [40]. Because of these differences in occurrence of 
different fimH alleles in different types of clinical samples, we examined their impact on 
pathogenesis in the urinary tract. 
 
FimH sequence modulates IBC number 
 We first performed a systematic analysis of the differences in infection between UTI89 
and CFT073. We transurethrally inoculated female C3H/HeN mice with 107 or 108 CFU of 
UTI89 or CFT073 in 50 µL of PBS (Fig. 2). The median number of IBCs formed at 6 hpi was 
significantly higher for UTI89 than the number of IBCs formed by CFT073 at both inoculum 
concentrations (Fig. 2A). Similar, statistically significant results were observed at 6 hpi in whole 
bladder titers (Fig. 2B). Bacterial titers at 6 hpi in the kidneys (Fig. 2C) did not significantly 
differ between strains, and we observed only a slight increase in kidney titers with an increased 
UTI89 inoculum.   
To assess the impact of different fimH alleles in isogenic UTI89 and CFT073 
backgrounds, we conducted fimH allele swaps. Hereafter, we will refer to these FimH alleles by 
the residue expressed at the relevant, positively selected position. We examined the effect on 
pathogenesis of three fimH alleles in each background: A62/V163, S62/V163 and S62/A163. 
Except for the previously published in vitro defects of FimH::S62/V163 [29], we saw no effect 
of FimH variants on growth in LB media in single and co-culture (Fig. S1A, Fig. S2), status of 
the fim promoter (Fig. S1B), total surface piliation (Fig. S1C), or 1 hpi invasion into 5637 
cultured bladder cells (Fig. S1D) in either the UTI89 or CFT073 backgrounds. We found a 
moderate, but statistically significant, 2-fold increase in guinea pig red blood cell 
hemagglutination (HA) for FimH::A62/V163 in both strain backgrounds (Fig. S1E) and 48 hr 
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biofilm formation in LB in PVC plates in CFT073 (Fig. S1F). A reproducible HA titer difference 
of 2-fold has previously been shown to affect IBC formation [29]. Accordingly we saw that 
CFT073 encoding FimH::A62/V163 (UTI89 FimH) resulted in a greater number of IBCs (Fig. 
3A) than WT CFT073 in an independent challenge experiment. No statistically significant 
difference in 6 hpi IBC number was obtained between UTI89 FimH::A62/V163 and UTI89 
FimH::S62/A163, suggesting possible strain-dependent effects. Additionally, it is possible that 
subtle fim regulation defects exist in vivo even though we observed no differences in vitro with 
these strains. 
 
FimH sequence modifies ability to persist during chronic cystitis  
We then assessed the effect of FimH variation on development of chronic cystitis. Sixty-
eight percent of mice developed persistent bacteriuria and chronic cystitis with bladder titers 
greater than 104 CFU at sacrifice 4 weeks post infection (wpi) when infected with 107 CFU 
UTI89 expressing its cognate FimH::A62/V163 compared to 40% of mice infected with UTI89 
expressing the CFT073 cognate allele, FimH::S62/A163 (p<0.05; Fig. 3B). CFT073, expressing 
its cognate FimH::S62/A163 caused chronic cystitis in only 23% of mice, statistically 
significantly different from both UTI89 FimH::A62/V163 (68%) (p<0.0005) and CFT073 
FimH::A62/V163 (47%) (p<0.05; Fig. 3B). Kidney titers were also increased for both UTI89 
and CFT073 strains expressing FimH::A62/V163 (Fig. 3C), which likely reflects the higher 
bladder titers and the noted vesicoureteral reflux and/or ability of UPEC to ascend the ureters in 
this model [18, 41].   
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Strains expressing FimH::A62/V163 displace strains expressing FimH::S62/A163 during chronic 
co-infection 
  We found that in both backgrounds, strains expressing FimH::A62/V163 had subtle, yet 
significant, increases in tissue occupation versus strains expressing FimH::S62/A163 after co-
infections (Fig. S3). At three hpi, 1.7-1.8-fold more bacteria encoding FimH::A62/V163 were 
found in the gentamicin-protected fraction in both strain backgrounds (Fig. S3).  At 6 hpi, 2.2-
fold more CFU of CFT073 FimH::A62/V163 was obtained (Fig. S3B). In addition to this acute 
advantage, strains expressing FimH::A62/V163 outcompeted strains expressing 
FimH::S62/A163 in the bladders and kidneys of mice experiencing chronic cystitis at four wpi 
based on log10 competitive index in both strain backgrounds (Fig. 4; p<0.005, Wilcoxon Signed 
Rank). With the average chronic cystitis bladder containing 107 CFU at 4 weeks, a log10CI of > 5 
indicates that strains with FimH::S62/A163 are near the limit of detection (20 CFU). The median 
log10 CI for co-infecting UTI89 FimH::A62/V163 SpectR and UTI89 FimH::S62/A163 KanR was 
also significantly higher than a control competition between UTI89 KanR and UTI89 SpectR with 
the same fimH, confirming that the difference in antibiotic resistance marker could not account 
for the infection phenotypes (Fig. S4). Thus, in co-infections, independent of strain background, 
expressing FimH::A62/V163 was advantageous over expressing FimH::S62/A163 in the urine as 
well as in chronic organs at four wpi (Fig. 4). 
 
UTI89 outcompetes CFT073 in co-infection experiments even when expressing the same FimH 
To further clarify the relative contribution of FimH differences versus other factors in 
UTI89 and CFT073 for different pathogenic phenotypes, we conducted additional co-infection 
experiments. We first, co-inoculated CFT073 and UTI89 each expressing their natural fimH 
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allele. UTI89 had higher titers than CFT073 in the bladder lumen as well as the intracellular 
compartment (Fig. S5A – B, D). We observed no difference between UTI89 and CFT073 in the 
kidneys (Fig. S5C). We then co-inoculated UTI89 and CFT073, both of which were expressing 
FimH::A62/V163 and found that UTI89 outcompeted CFT073 during chronic cystitis even when 
both expressed the same fimH allele (Fig. 4C), suggesting UTI89 expresses other factors, which 
in addition to its fimH allele contribute to chronic cystitis.  
 
Positively selected FimH residues impact affinity, but only when FimH is incorporated into a tip-
like complex 
We hypothesized that the fitness advantage of expressing FimH::A62/V163 over 
FimH::S62/A163 throughout infection was due to differences in the ability to bind mannosylated 
epitopes on the bladder surface. Therefore, we used BioLayer Interferometry to assess mannose 
binding of different FimH variants. FimH is known to adopt two different conformations, which 
vary in their affinity for mannose [33]: an elongated conformation with high mannose affinity 
and a compressed conformation with low mannose affinity (Fig. 1). In the first set of binding 
experiments, FimCH complexes were used in which FimC traps FimH in the elongated, high 
mannose binding conformation [33, 42]. We immobilized biotinylated BSA-mannose on 
SuperStreptavidin pins and tested for binding of FimCH complexes in solution. For these assays 
we utilized FimH with variations at positions 62 and 163 as seen in UTI89 and CFT073. We also 
varied position 27 since this position was previously found to be under positive selection [29]; 
this residue is variable in both uropathogens and fecal strains (Table 1). All FimCH complexes 
had very similar affinity to BSA-mannose regardless of the variant with the exception of 
FimH::Q133K, which has a mutation within the mannose binding pocket resulting in an inability 
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to bind to mannose (Fig. 5A) [26]. The FimCH fit curves had very high R2 values and KD values 
between 1.5 and 4.2 µM (Table 2), consistent with previously reported affinity calculations for 
the isolated FimH lectin domain [42].  
Each variant was then reconstituted into a tip-like FimChisGH complex in vitro by 
combining FimChisG and FimCH (Fig. 5B). In addition to FimChisGH complexes, small 
quantities of higher order structures such as FimChisGGH and FimChisGGGH were detected, but 
the distributions of these complexes were equal among FimH alleles. FimH within the 
FimChisGH complex is able to adopt the compact conformation seen in tip structures, as the 
lectin domain is no longer restrained from bending by FimC [33, 43, 44]. In the tip-like 
FimChisGH complexes, different FimH alleles elicited dramatic differences in BSA-mannose 
binding affinity (Fig. 5C), with three general affinity patterns: high, intermediate, and low. 
FimChisGH::V27/A62/A163 and FimChisGH::A27/A62/A163 maintained the same high affinity 
as their FimCH counterparts (Table 2, Fig. 5), suggesting that these variants may not adopt the 
compressed, low-affinity conformation in the pilus or that their propensity to transition to the 
elongated state is increased accounting for higher relative affinities. The UTI89 natural variant 
(FimH::A27/A62/V163) and CFT073 natural variant (FimH::A27/S62/A163) both showed 
intermediate-affinity when in the FimChisGH complexes. However, FimChisGH::A27/A62/V163 
had a significant (p = 0.0087, Mann-Whitney U Test), two-fold higher affinity than 
FimChisGH::A27/S62/A163 (1.2 vs. 2.5 x 10-4 M; Table 2). A two-fold difference in FimH KD 
would likely translate to a very large difference in adherence in piliated UPEC containing 20-200 
pili per bacterium (Fig. S1C). FimChisGH::A27/S62/V163 and FimChisGH::Q133K both had low 
affinity with KD values in the 3 mM range (Table 2). This suggests that FimH::A27/S62/V163 
may not be able to adopt the elongated high-affinity conformation as efficiently.  
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To assess whether higher binding correlated with increased in vivo infection, we tested 
virulence at 4 wpi mice were co-infected with UTI89 expressing either of the high affinity FimH 
variants, FimH::A27/A62/A163 or FimH::V27/A62/A163 and WT UTI89 (Fig. 5D). Both 
FimH::A27/A62/A163 and FimH::V27/A62/A163, but not the WT control were attenuated in the 
bladders of mice 4 wpi compared to WT UTI89 (Table 2). This result suggests that mannose-
binding affinity does not directly correlate with pathogenicity. Instead, an intermediate binding 
affinity is the best predictor of virulence, implying that FimH may dynamically interconvert 
between conformations depending on the local environment.  
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Discussion 
The looming worldwide crisis of globally spreading, multi-drug resistant microorganisms 
[45], the growing body of work delineating the important benefits of the host’s normal 
microbiota [46], and the deleterious effects of broad-spectrum anti-microbial treatments on these 
symbiotic/commensal relationships [47], argue that we need to develop new approaches to treat 
and prevent common infectious diseases such as UTI. With the delineation of Koch’s postulates 
and Falkow’s molecular postulates [48, 49], infectious disease experts have learned to associate a 
particular disease with the presence or absence of a particular pathogen or “virulence factor”, 
respectively, in a diseased host.  In considering UTI pathogenesis, a critical factor is that 
virulence is not simply dichotomous (presence/absence of a microorganism in the host or 
virulence factor within a bacterium). Outcomes of infectious disease in general, and UTIs 
specifically, are determined by a complex, yet seemingly subtle, interplay between differing host 
genetics and immune states [50, 51], host experiences/exposures [52, 53], bacterial gene carriage 
[9, 10, 16], co-infecting species [54], and many other factors. In this study, we detail an instance 
that goes beyond presence or absence of virulence factors, showing that possession of particular 
allelic variants of a critical adhesin of UPEC modulates the pathogenic process. We have 
combined an evolutionary analysis of fimH, multiple clinical UPEC isolates, representative in 
vivo models of infection, and biochemical structure-function correlation to explain how the 
identity of individual amino acid residues, far from the ligand binding “active site” (Fig. 1), alter 
FimH binding affinity likely through modulation of conformational dynamics, governing 
virulence of two pathogenic UPEC strains.  
Adhesive pili assembled by the chaperone-usher pathway (CUP), such as P and type 1 
pili, contain adhesins at their tips that play important roles in host-pathogen interactions. Each 
107 
sequenced UPEC strain has been found to encode numerous CUP operons [55]. Some CUP 
adhesins are known to recognize specific receptors with stereochemical specificity, such as 
FimH for mannosylated glycoproteins. Type 1 pili, like other CUP pili, are encoded in a gene 
cluster comprised of regulatory genes (FimB, FimE), a major pilin subunit (FimA), a periplasmic 
chaperone (FimC), an outer membrane usher (FimD), minor tip pilins (FimF, FimG) and the 
adhesin (FimH). Type 1 pili, like P pili and others, are composite structures, consisting of long, 
rigid, helical rods made up of FimA, joined at the distal end to a short, linear fiber consisting of 
FimF, FimG and the FimH adhesin [56, 57]. Tip adhesins consist of two domains: a lectin 
domain and a pilin domain (Fig. 1). Pilin domains and subunits are incomplete immunoglobulin 
(Ig)-like folds, encoding just six of the needed seven strands and thus pilin subunits require the 
action of dedicated periplasmic chaperones for folding and stability. We discovered that the 
molecular basis of chaperone-assisted folding was a reaction that we named donor-strand 
complementation (DSC) [58-60] in which the chaperone transiently completes the Ig-like fold of 
each subunit, providing the missing 7th beta strand needed for pilin subunit folding [61]. The 
DSC subunit-chaperone complex holds the subunit in a primed high-energy state with connecting 
loops disordered and the subunit hydrophobic core incompletely collapsed [60-62]. These 
complexes are then differentially targeted to the outer membrane usher [63, 64] (Fig. 6A), which 
is a five domain gated channel that catalyzes pilus assembly by driving subunit polymerization in 
a reaction we termed donor strand exchange (DSE). Each of the non-adhesin subunits contains a 
short N-terminal extension (Nte). DSE occurs in a zip-in-zip-out mechanism where an incoming 
subunit’s Nte zips into the chaperone-bound groove of a nascently incorporated subunit at the 
growing terminus of the pilus resulting in chaperone dissociation [65]. This allows the final 
folding of the subunit with the collapse of the hydrophobic core and the ordering of loop regions, 
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such that every subunit in the pilus completes the Ig fold of its neighbor. The usher converts 
subunit binding and folding energy into work, acting by sequential allosteric interactions, 
promoting sequential DSE and incorporation of subunits into the growing pilus while stably 
maintaining contact with the growing pilus and ensuring the integrity of the outer membrane 
barrier in the absence of ATP [66, 67].  
FimH has a distal mannose binding lectin domain (FimHL) and a proximal pilin domain 
(FimHp). The FimG pilin adapts FimH to the tip of the pilus (Fig. 1). Le Trong et al recently 
compared FimHL and Fim tip crystal structures, and found that FimH adopts at least two 
conformations with FimHL elongated or compact (Fig. 1, 6A) [33, 68]. Functional biochemical 
assays indicated that mannose binds tightly to the elongated FimHL but weakly, if at all, to the 
compact FimHL [33, 42]. Recent structural “snapshots” of pilus assembly captured these same 
FimH conformations during its assembly across the usher: elongated while still bound to FimC 
prior to DSE and compact after DSE with FimG, which incorporates FimH into the pilus tip and 
its extrusion through the usher pore (Fig. 6A insets) [43, 67].  
The advent of high-throughput sequencing has allowed the examination of hundreds of 
FimH alleles, providing insight into the evolutionary process of this virulence factor [29, 35]. 
FimH is highly conserved both in clinical and commensal E. coli isolates, with all alleles 
encoding identical amino acids at 90% of the positions [29]. The mannose-binding pocket of 
FimH is invariant among sequenced UPEC, but residues 27, 62, and 163 outside of this binding 
pocket showed evidence of positive selection (Fig. 1), suggesting the identity of residues at these 
positions can confer increased fitness in the urinary tract [29, 35]. All of the positively selected 
residues in FimH are in locations previously identified to displace significantly between 
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elongated and compressed conformations, suggesting that residues may impart steric clashes in 
one conformation or the other (Fig. 1) [33, 44, 69].  
The FimH of the two prototypical UPEC isolates, UTI89 (a cystitis isolate) and CFT073 
(a pyelonephritic/sepsis isolate) are identical at residues 27 (both having A), but differ at 62 and 
163; UTI89 expresses A62/V163 and CFT073 expresses S62/A163 and are otherwise identical. 
Here, we demonstrate that both of these alleles show high affinity for mannose when complexed 
with FimC and an intermediate affinity when complexed with FimG in a tip-like FimChisGH 
complex. Strains harboring a FimH sequence coding for A27/A62/V163, present in the cystitis 
isolates NU14 and UTI89, demonstrated increased fitness in the bladder compared to strains 
expressing A27/S62/A163, present in UPEC 536 and CFT073, as determined in single and co-
infections at 4 weeks post infection (Table 2; Fig. 6B). Because strains with 
FimH::A27/S62/A163 were essentially absent in 4 week bladders (Fig. 4, 6B), it is likely that 
bottlenecks enforced by innate defenses were more easily transcended by strains harboring 
FimH::A27/A62/V163 likely because of differences in binding and invasion efficiencies (Fig. 
6B) leading to higher IBC numbers during early infection [18]. In addition, the UTI89 fimH 
allele demonstrated enhanced fitness relative to all of the other tested wild type and mutant 
variations of these alleles during chronic cystitis (Table 2), when the superficial facet cells are 
completely denuded [20] suggesting continued selection based on fimH allele during chronic 
infection.  
All of the FimH alleles tested, except Q133K, exhibited high affinity for mannose when 
complexed with FimC and held in the elongated conformation, and all naturally occurring FimH 
alleles exhibited a low or intermediate affinity for mannose when incorporated into the tip 
structure. Interestingly, while UTI89 FimH functions with an A62 and CFT073 functions with an 
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A163, in a survey of FimH sequences from naturally occurring E. coli strains the combination of 
A62/A163 has never been observed. We show that A62/A163 variants (both 
FimH::V27/A62/A163 and FimH::A27/A62/A163) retain their high affinity for mannose even 
when incorporated into tip-like complexes suggesting that FimH::A62/A163 does not adopt the 
low-affinity compact conformation when in the pilus tip or that it’s transition to the high affinity 
elongated form is greatly enhanced in the presence of mannose. Despite their increased relative 
affinity for mannose, strains harboring these fimH alleles were severely attenuated, and it was 
previously shown that FimH::V27/A62/A163 does not form IBCs at 6 hpi [29]. This may reflect 
a critical role in pathogenesis for the compact state in pathogenesis and/or for the ability to 
convert between the compact and elongated conformation states. The elongated conformation 
may prevent detachment from the uroplakin receptor, making UPEC more vulnerable to TLR4-
mediated expulsion from the urothelium [70]. Alternatively, the compact or low-affinity state 
may be needed within the IBC or to resist shear stress in the urinary tract. Sokurenko et. al. 
discovered that FimH binds via a “catch-bond” mechanism in which shear force can influence 
the strength of binding [71, 72]. We posit that a dynamic equilibrium of FimH between the two 
conformations may allow UPEC to resist shear forces within host niches and that residues at 
positions 27, 62 and 163 may impact the transitioning between the two conformations.  It is 
possible that FimH::A62/A163 has dramatically higher mannose binding affinity in its compact 
state thus potentiating transitioning to the elongated state, but the binding pocket of the compact 
state of FimH is partially occluded, and would have to adapt to accommodate mannose to an 
appreciable degree [33].  
 Possession of an alanine at position 62 (instead of serine) has been associated 
with increased virulence, mannose binding, and an increased ability to bind to collagen [29, 73, 
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74]. Further, it was previously determined that mutation of position 62 from a serine to a leucine 
or glutamic acid enhanced bacterial binding to surface mannose [69], consistent with our 
findings. Our work would suggest that mutation of this residue from alanine to serine, in the 
context of V163 (FimH::A27/S62/V163) may decrease the ability of FimH to transition from the 
compressed, low-affinity conformation seen in the tip in the absence of mannose to the high 
affinity, elongated conformation. Thus, the combination of amino acids present at positions 62 
and 163 modulate FimH function. We propose that evolutionary pressure on UPEC isolates has 
led to the selection of FimH residue combinations, which alter the stability or affinity of one 
conformation or the other, affecting the equilibrium between the different conformations and 
thus mannose affinity and pathogenesis. The FimH alleles with intermediate binding affinity, 
A27/A62/V163 and A27/S62/A163, expressed by UTI89 and CFT073, respectively, may be able 
to dynamically switch between conformations allowing them to bind to and invade superficial 
facet cells, and then detach and enter the cytoplasm to replicate into IBCs (Fig. 5, 6B).   
We have recently characterized the population dynamics between gastrointestinal (GI) 
and bladder niches in women suffering UTI (Fig. 6C). At the time of UTI in four patients, we 
found that the UPEC strain that occupied the urinary tract was the same as the dominant E. coli 
found in the GI tract [6]. Interestingly, in one patient from this study, when a recurrent UTI was 
caused by a different strain of UPEC, this new strain also replaced the previous strain in the GI 
tract, implying that increased fitness in the urinary tract was not accompanied by a decrease in 
fitness in the gut, which was corroborated by a fitness analysis in both niches in animal models 
(Fig. 6C) [6]. The most common combination of positively-selected residues we found in both 
healthy human feces as well as the urinary tracts of women suffering UTI was A27/S62/V163, 
perhaps suggesting a generalist FimH, capable of colonizing both niches. The low affinity for 
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mannose of a UTI89 FimH mutated to carry this combination of residues suggests that this FimH 
allele likely is very poor in adopting an elongated conformation perhaps signifying that the 
compact conformation is of greater importance throughout infection. Additionally, residues 
elsewhere in FimH may further modulate the conformation equilibrium of this particular 
combination of positively-selected residues. The two combinations we found only in diseased 
urine but not in healthy feces (FimH::A27/A62/V163 and FimH::A27/S62/A163) suggests that 
these alleles may have increased virulence in the urinary tract. It is possible that E. coli 
expressing this allele may invariably lead to UTI, which may accelerate the decision to seek 
treatment. Selection for fimH is likely quite different in the urinary and GI tracts due to 
differences in shear stress, which has been shown to influence FimH binding, due to urine flow 
and peristalsis [71, 72, 75]. Thus, it will be interesting to assess the effect of FimH variants in the 
GI tract. These types of studies and investigations similar to those performed by Chen et al in 
which multiple niches are sampled longitudinally may further help refine the source-sink 
hypothesis of virulence and pathoadaptation of UPEC in multiple niches [6, 76].  
Increasing rates of antibiotic resistance in bacteria, including uropathogens [77], the 
spread of multi-drug resistant strains [45], and the dearth of new antibiotic candidates in 
pharmaceutical development pipelines make a compelling argument and opportunity for novel 
virulence-based therapeutics (Fig. 6D-E) [78]. Multiple groups are investigating methods to 
inhibit the ability of UPEC to bind and invade bladder tissue as well as to block catheter 
colonization via anti-adhesive small molecule inhibitors and vaccines (Fig. 6D-E) [79-82]. High 
affinity mannosides that bind in the FimH binding pocket have been shown to block invasion and 
IBC formation as well as biofilm formation on abiotic surfaces [79, 80]. Additionally, 
mannosides delivered orally were shown to dramatically reduce bacterial burden during chronic 
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cystitis (Fig. 6D) [80]. Pilicides have been designed aimed at disrupting assembly of multiple 
CUP pili in order to incapacitate bacterial adhesion in various tissue niches and body habitats 
(Fig. 6E) [83]. These molecules work, in part, by blocking the interaction of the usher with 
chaperone-subunit complexes, thus blocking pilus assembly [83]. These anti-virulence 
therapeutics hold promise for targeting recalcitrant UPEC infections.  
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Conclusion 
Our current understanding of the pathogenic lifestyles of UPEC is in part an extension of 
the molecular and structural characterization of type 1 pili. This has led to a new understanding 
of clinical UTIs and its complicating factors. Combining this with genomic and pathoadaption 
studies, we have elucidated a connection between evolutionary pressures, protein structural 
dynamics, and in vivo disease pathogenesis. UTIs are one of the greatest contributors to 
antibiotic consumption and thus likely an important driver of the development of antibiotic 
resistance. Our analysis here would argue that, in addition to the therapeutic strategies addressed 
above, therapeutics that block the interconversion of the FimH adhesin between conformations; 
locking it in either conformation would impede UPEC pathogenesis [69, 84]. Analyses of other 
pathogens and virulence genes by combining positive selection analyses, in vivo models of 
pathogenesis, and biochemical and structural characterization could lead to identification of 
similar targets for the development of novel therapeutics that will be needed to fend off the 
looming crisis of multi-drug resistant bacterial pathogens. 
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Materials and Methods 
Bacterial Strains.  
UTI89 strains with chromosomally integrated fimH variants were generated using the λ Red 
recombinase system [85] and are the same as previously published [29]. The same method was 
used to create similar fimH variants in CFT073. Creation of HK marked antibiotic resistant 
strains was conducted similarly. 
Mouse infections.  
Infections, LacZ staining of bladders, and ex vivo gentamicin protection assays were conducted 
as previously described [18, 41, 86]. All mouse infection studies were approved by the Animal 
Studies Committee of Washington University in St. Louis, MO.  
Protein Purification.  
See Supplemental Materials for purification details. 
Biolayer Interferometry (BLI).  
OCTET was used to attain BLI progress curves, which allowed us to extract kinetic parameters 
(kon, kdis, and KD). See Supplemental Materials for more details. Analysis was conducted on 
ForteBio Data Analysis 6.4. Processed data was fit globally for each variant at 3 concentrations 
between 1.25 and 12 µM for FimCH and 1.8 to 200 µM for FimChisGH per experiment in a 1:1 
kinetic binding model.  
Statistical analysis.  
Statistical analysis was performed in GraphPad Prism 5.0. CFU values of zero were set to the 
limit of detection of the assay. Competitive Index (CI) = (CFUoutput strain A/ CFUoutput strain 
B)/(CFUinput strain A/ CFUinput strain B). Wilcoxon Signed Rank was used on log transformed CI 
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to determine if the median value was different than 0. Statistical analysis to compare median 
values between groups was determined by Mann-Whitney U test. To compare proportions of 
mice experiencing persistent bacteriuria and chronic cystitis, we used Fisher’s Exact Test. p 
<0.05 was considered significant.    
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Figures and Tables 
 
Figure 1. FimH positively selected residues  
FimH is a two-domain adhesin comprised of a lectin domain of residues 1-150 (green) and a 
pilin domain with residues 159-279 (blue), and a linker loop (yellow) connecting them. 
Positively selected residues are mapped onto the structures of FimH as red spheres. A) In the 
elongated FimH (V27/S62/V163) structure, mannose is observed at the distal binding pocket in 
white sticks (J96 FimH; PDB:1KLF; FimC removed for clarity). B) In the compressed FimH 
(A27/S62/A163) structure in the absence of mannose, position 133 of the binding pocket is 
colored white (F18 FimH; PDB:3JWN). Note the distance of these positively selected residues 
from the mannose binding pocket. 
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Figure 2  
CFT073 and UTI89 acutely infect mouse urinary tracts. A) IBCs per bladder were enumerated 
with LacZ stain. B) Total bladder bacterial counts were determined after homogenization. C) 
Total bacteria present in both kidneys was enumerated. N = 2 experiments with 5 mice per 
group. Panel C includes kidney titers of mice from panels A and B. 
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Figure 3  
FimH allele modulates acute and chronic pathogenesis. Mice were infected with 107 CFU (range 
3.4 x 106 – 1.8 x 107; median 1.02 x 107) of the indicated strains. A) IBCs were enumerated after 
LacZ staining. B) Urine was collected at days 1, 7, 14, and 21, and the number of bacteria 
present in bladders was determined at 4 wpi. Data points above 104 CFU reflect mice that had 
persistent bacteriuria and are considered to have chronic cystitis. Red symbols denote mice that 
resolved bacteriuria and either had a recurrence or high levels of reservoir titers, and were thus 
included in the resolved category because they did not experience persistent bacteriuria and 
chronic cystitis. The percentage of mice per group experiencing chronic cystitis is displayed at 
the top of each column. C) Kidney titers of the mice from panel B. A) N = 2 – 11 experiments 
with 2 – 8 mice per group. B-C) N = 2 – 8 experiments with 5 – 10 mice each.    
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Figure 4 
FimH::A62/V163 displaces FimH::S62/A163 during chronic co-infection. Co-infections were 
conducted A) between UTI89 with FimH::A62/V163 and FimH::S62/A163, B) between CFT073 
with FimH::A62/V163 and FimH::S62/A163, and C) between UTI89 FimH::A62/V163 and 
CFT073 FimH::A62/V163. Urine was collected at days 1, 3, 7, 14, and 21 days post infection 
(dpi), and bladder and kidney titers were determined at 28 dpi. Log10 of competitive indices of 
the mice experiencing chronic cystitis is plotted as determined via plating on selective 
antibiotics. N = 2-3 experiments with 5-10 total mice per group. Wilcoxon signed rank test was 
conducted to evaluate whether the median value was significantly different from 0; **, p<0.01, 
***, p<0.005.    
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Figure 5 
Effect of FimH on mannose binding and chronic fitness. A) Representative curves showing 
FimCH association to and dissociation from immobilized BSA-mannose at indicated 
concentrations. Two biological replicates conducted. B) Representative 14% SDS-PAGE gel 
indicating select variants in FimCHisGH samples. “B” marks the boiled lanes. C) Representative 
curves showing FimCHisGH association to and dissociation from immobilized BSA-mannose at 
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the indicated concentrations. Representative of three biological replicates with two technical 
replicates each with combined KD data shown in Table 2. D) Four week bladder titer is shown 
for mice experiencing chronic cystitis with co-infections of the listed strains. N = 1-3 
experiments with 5-10 mice each. 
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Figure 6 
Structure-function-treatment model of UPEC pathogenesis. A) Model of pilus biogenesis 
including delivery of chaperone-subunit complexes to the NTD (blue) of the usher (orange) with 
transfer to the CTDs (yellow and pink). The next subunit reacts with the previous by DSE 
polymerizing the pilus rod. Insets represent recent crystal structures demonstrating the 
orientation of FimH as it binds to and exits the usher [43, 67] (PDB: 3RFZ and PDB: 4J30). B) 
UPEC pathogenic cascade showing type 1 piliated UPEC attaching to superficial cells of the 
bladder, invasion into these cells, and replication in the cytoplasm to form IBCs. Mice can then 
either resolve the infection with potential recurrences thereafter or develop persistent bacteriuria 
and chronic cystitis. C) The dynamics of transmission from the gut to the bladder and vice versa 
is an intriguing concept that is just now beginning to be studied [6]. D) Mannoside treatment can 
detach bacteria from the bladder epithelium during chronic cystitis leading to clearance. E) 
Pilicides block the ability of the pilus to polymerize. 
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Table 1. Prevalence of positively selected FimH residues. 
Residuea Frequency 
in healthy 
fecesb (%) 
Frequency in 
urine/ 
periurethrab 
(%)  
Sequenced 
Analogc 
V27/S62/V163 5/33 (15) 49/254 (19) MG1655/J96 
A27/A62/V163 0 19/254 (7) UTI89/NU14 
A27/S62/A163 0 17/254 (7) CFT073/536 
A27/S62/V163 28/33 (85) 169/254 (67) None 
a All other possibilities not observed. 
b 287 strains utilized from human ECOR and clinical E. coli isolates with 33 fecal samples from 
uninfected women and 254 infected urine/periurethral isolates.   
c Published strain for which fimH sequence is available [34, 73, 87-90]. No fully sequenced analog of 
A27/S62/V163 is published.   
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Table 2. Affinity values and fits for Fim allele complexes 
Pathogenesisb FimH allelea FimCH 
Mean KD 
(µM) 
Mean 
Fit 
(R2) 
FimChisGH 
Mean KD 
(µM) 
Mean 
Fit 
(R2) 
Acute Chronic 
Q133K 0 0.46 7193 ± 2957  0.94 - -- 
A27/S62/V163 3.6 ± 0.2 0.99 3198 ± 1917  0.99 + - 
A27/S62/A163 
(CFT073) 
1.5 ± 0.8 0.99 252 ± 110 0.98 + + 
A27/A62/V163 
(UTI89) 
4.2 ± 0.6 0.99 119 ± 33   0.98 ++ ++ 
V27/A62/A163 3.0 ± 0.0 0.99 2.4 ± 0.2 0.98 - -- 
A27/A62/A163 1.7 ± 0.0 0.99 7.0 ± 0.6 0.98 ? -- 
aRelative to UTI89 FimH, where applicable 
bfrom figures 2, 3, 5D, or inferred based on data from Chen et al 2009. 
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Supplementary Material  
Supplemental Methods 
In vitro bacterial assays.  
Guinea pig hemagglutination assays (HA) were conducted as previously described [91] with 
minor modifications. Bacteria were grown 2 x 24 hours in 10 mL LB at 37oC statically. Bacteria 
were centrifuged 6500 RPM for 10 min. and resuspended in PBS to an OD600 of 1.0. Guinea pig 
serum (Colorado Serum) was washed with PBS and diluted to OD640 of 1.9-2.0. Twenty-five µL 
of guinea pig blood was added to each well. The HA titer reported is the well containing the last 
amount of visible RBC agglutination. Invasion assays were similar to those previously described 
[92, 93]. Bladder 5637 cells were grown to confluence and split such that 1 – 5 x 105 cells were 
in each well in RPMI. UPEC was added to each well at a multiplicity of infection (m.o.i.) of 10. 
After centrifugation, we aspirated the media and replaced it with RPMI supplemented with 120 
µg/mL gentamicin (Sigma) and incubated for 60 min at 37 oC. Bacteria were serially diluted and 
plated to LB-agar plates with the appropriate antibiotics after eukaryotic lysis with 1% Triton X-
100. Biofilm assays were conducted in LB in PVC plates and quantified by Crystal Violet at 600 
nm as described previously [83, 94]. 
 
Protein Purification 
FimCH complexes were expressed in E. coli C600 with a pBAD33 plasmid containing the 
appropriate fimH allele and pTRC99a plasmid containing UTI89 fimC. The protein sequence of 
FimC is identical for UTI89 and CFT073 [34, 95]. Periplasm was prepared as previously 
described [96]. The supernatant was purified over columns as previously described [97] and 
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cleaned on an additional Source 15S column in 15mM 2-(N-morpholino)ethanesulfonic acid 
(MES) pH 5.8 in the absence of mannose. His-tagged FimC was co-expressed on pETS1000 with 
FimG expressed on pETS2A and FimChisG purified essentially as previously described [64]. 
Periplasm was dialyzed with PBS and 250 mM NaCl overnight. A Talon column (Clontech) was 
run with a gradient of PBS with 300 mM imidazole. Pooled fractions were dialyzed against 15 
mM MES at pH 5.8 overnight. A 2nd Source column (15S GE) was run with a gradient of 15 mM 
MES pH 5.8 with and without 400 mM NaCl. For generation of FimChisGH variant complexes, 
FimCH variant complexes were mixed with FimChisG complexes in equimolar ratios and 
incubated at 4 oC for 18-20 hrs.  
 
Biolayer Interferometry 
For BLI experiments, SuperStreptavidin (SSA) pins were first dipped in a baseline in HEPES-
Buffered Saline (HBS) pH 7.5 for 120 seconds, followed by loading of 10 µg/ml biotinylated 
BSA-mannose (DEXTRA) in HBS for 240-300 seconds, quenching by 10 µg/ml biocytin in HBS 
for 180 seconds, and another baseline step in HBS for 120 seconds. Thereafter, pins were dipped 
in HBS + 1% BSA + 0.05% TWEEN-20 to block non-specific interactions for 300 seconds, 
transferred to protein samples (either FimCH or FimChisGH variants) for association for 300-600 
seconds, and moved to HBS for dissociation for 300 seconds. KD values for pilot FimChisGH 
experiments were not included for FimH::A27/A62/V163, FimH::A27/S62/A163, 
FimH::A27/S62/V163, and FimH::Q133K because determined KD values were greater than 10-
fold above the highest tested concentration, below the limit of detection of the instrument. R2 
values greater than 0.98 and 0.90 were included in the analysis for FimCH and FimChisGH 
complexes, respectively. 
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Supplementary Figures 
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Supplementary figure 1: in vitro effects of fimH allele  
A) Growth was determined for 16 hrs in LB in 96 well plates. B) PCR was conducted on 1 µL of 
bacteria grown 2 x 24 hrs in static culture at 37 oC and graphed as the fraction of the bacterial 
population with the fim promoter in the ON orientation. C) Degree of piliation was assessed by 
TEM for each strain. Fraction of cells expressing no (bald), 1-20 (low), 20-100 (moderate) or 
>100 (abundant) pili per cell. Represents 2 pooled experiments. D) Titers of bacterial strains 
after 1 hr invasion into cultured 5637 cells is shown. Data are pooled from 3 biological replicates 
with 3 technical replicates each. E) Guinea pig RBC HA in the absence of mannose was 
conducted for the strains indicated. Titer is listed as the last well showing visible agglutination. 
Pooled data from 2-9 biological replicates with 2 technical replicates each. F) Strains were 
grown in LB statically at room temperature in a 96-well PVC plate for 42-45 hrs to evaluate 
biofilm formation. Percent of biofilm relative to UTI89 is displayed. 3 biological replicates with 
6-8 technical replicates each are pooled.  
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Supplementary Figure 2: in vitro LB co-infections 
One µL of a 2 x 24 LB culture was inoculuated after dilution into 10 mL LB and allowed to 
grow statically for 24 hrs. Two hundred microliters was taken 2, 4, 7.5, 12, and 24 hrs after 
inoculation and plated to selective media. A) All Log10 CIs are graphed for a sample co-
inoculated with UTI89 FimH::S62/A163 Kanr and UTI89 FimH::A62/V163 Spectr in magenta. 
Orange is a co-inoculation of CFT073 FimH::A62/V163 Kanr and CFT073 FimH::S62/A163 
Chlorr. B) All Log10 CIs are graphed for a sample co-inoculated with UTI89 FimH::S62/A163 
Kanr and CFT073 FimH::S62/A163 chlorr (blue). Black squares represent all timepoint Log10CIs 
of a co-inoculation of CFT073 FimH::A62/V163 Kanr and UTI89 FimH::A62/V163 Spectr. C-D) 
Log10CI for each strain comparison over time for panels A and B, respectively. 
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Supplementary Figure 3: FimH allele modulates acute niche occupation  
Ex vivo gentamicin protection assay was conducted on bladders extracted at 3 and 6 hpi. Log10CI 
of FimH::A62/V163 relative to FimH::S62/A163 is shown for 3 (A) and 6 (B) hpi for 
competitions in CFT073 and UTI89 backgrounds. Wilcoxon Signed Rank, *, p<0.05; **, p< 
0.01; ***, p<0.005. 
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Supplementary Figure 4.  
Log10CI of chronic bladder titers graphed for a co-infection between isogenic strains differing by 
antibiotic marker.  Data in the left column reproduced from Figure 3A representing the effect of 
FimH on chronic fitness. Data in the right column is a control co-infection of isogenic strains 
differing only by antibiotic resistant marker. 
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Supplementary Figure 5: UTI89 outcompetes CFT073 during acute infection  
7-8 week old female C3H/HeN were infected with a 50 µL inoculum containing CFT073 and 
UTI89 totaling 2 x 107 CFU (range 1.46 x 107 – 2.2 x 107). At 6 hpi, mice were sacrificed, and an 
ex vivo gentamicin protection assay was conducted on the bladder. A) Bacterial titers present in 
the lumen were enumerated by plating onto antibiotic selective agar plates. B) Intracellular 
UPEC were enumerated after gentamicin treatment. C) Kidney pairs were homogenized and 
plated. D) Log10 CI were computed for UTI89 titers relative to CFT073 to control for varying 
inoculum concentrations. Data is pooled from 2 experiments with 2 competitions of 5 mice each 
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where UTI89 KanR and CFT073 chlorR were co-infected as well as UTI89 chlorR and CFT073 
KanR. A-C) statistical analysis was conducted using Mann-Whitney U-test. D) Wilcoxon Signed 
rank relative to zero was determined. **, p<0.01. 
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Chapter 4: Uropathogenic Escherichia coli Superinfection Enhances the Severity of 
Mouse Bladder Infection  
 
D. J. Schwartz, M. S. Conover, T. J. Hannan, and S. J. Hultgren 
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Abstract  
Urinary tract infections (UTIs) afflict over 9 million women in America every year, often 
necessitating long-term prophylactic antibiotics. One risk factor for UTI is frequent sexual 
intercourse, which dramatically increases the risk of UTI. The mechanism behind this increased 
risk is unknown; however, bacteriuria increases immediately after sexual intercourse episodes, 
suggesting that physical manipulation introduces periurethral flora into the urinary tract. In this 
paper, we investigated whether superinfection (repeat introduction of bacteria) resulted in 
increased risk of severe UTI, manifesting as persistent bacteriuria, high titer bladder bacterial 
burdens and chronic inflammation, an outcome referred to as chronic cystitis. Chronic cystitis 
represents unchecked luminal bacterial replication and is defined histologically by urothelial 
hyperplasia and submucosal lymphoid aggregates, a histological pattern similar to that seen in 
humans suffering chronic UTI. C57BL/6J mice are resistant to chronic cystitis after a single 
infection; however, they developed persistent bacteriuria and chronic cystitis when superinfected 
24 hours apart. Elevated levels of interleukin-6 (IL-6), keratinocyte cytokine (KC/CXCL1), and 
granulocyte colony-stimulating factor (G-CSF) in the serum of C57BL/6J mice prior to the 
second infection predicted the development of chronic cystitis. These same cytokines have been 
found to precede chronic cystitis in singly infected C3H/HeN mice. Furthermore, inoculating 
C3H/HeN mice twice within a six-hour period doubled the proportion of mice that developed 
chronic cystitis. Intracellular bacterial replication, regulated hemolysin (HlyA) expression, and 
caspase 1/11 activation were essential for this increase. Microarrays conducted at four weeks 
post inoculation in both mouse strains revealed upregulation of IL-1 and antimicrobial peptides 
during chronic cystitis. These data suggest a mechanism by which caspase-1/11 activation and 
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IL-1 secretion could predispose certain women to recurrent UTI after frequent intercourse, a 
predisposition predictable by several serum biomarkers in two murine models.   
 
Author Summary 
 Urinary tract infections (UTIs) affect millions of women each year resulting in substantial 
morbidity and lost wages. Approximately 1.5 million women are referred to urology clinics 
suffering from chronic recurrent UTI on a yearly basis necessitating the use of prophylactic 
antibiotics. Frequent and recent sexual intercourse correlates with the development of UTI, a 
phenomenon referred to clinically as “honeymoon cystitis.” Here, using superinfection mouse 
models, we identified bacterial and host factors that influence the likelihood of developing 
chronic UTI. We discovered that superinfection leads to a higher rate of chronic UTI, which 
depended on bacterial replication within bladder cells combined with an immune response 
including inflammasome activation and cytokine release. These data suggest that bacterial 
inoculation into an acutely inflamed urinary tract is more likely to lead to severe UTI than 
bacterial presence in the absence of inflammation. Modification of these risk factors could lead 
to new therapeutics that prevent the development of recurrent UTI. 
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Introduction 
 Nearly nine million people present each year to primary care physicians with a urinary 
tract infection (UTI), costing nearly $2 billion yearly [1, 2]. Women suffer the majority of these 
infections, with the lifetime risk approaching 50% [3]. Furthermore, 25-40% of these women 
will suffer recurrent UTI (rUTI), with 1.5 million women referred to urology clinics and often 
requiring prophylactic antibiotics to prevent recurrence [4-6]. Uropathogenic E. coli (UPEC) are 
responsible for >80% of community acquired UTI and 50% of nosocomial UTI [7, 8]. In the 
absence of antibiotic therapy, up to 60% of women experience symptoms and/or bacteriuria 
lasting months after initial infection [9-12], implying that cystitis is not always self-limiting. 
Furthermore, if the infection persists without adequate treatment, the organisms have the 
capacity to ascend the ureters, causing pyelonephritis and sepsis [13]. Antibiotic resistant 
organisms further complicate infection and threaten to increase the likelihood of chronic UTI, 
pyelonephritis and potentially bacteremia [14, 15]. UTIs are increasingly being treated with 
fluoroquinolones, which in turn has led to a rise in resistance and the spread of multi-drug 
resistant microorganisms globally, which is a looming worldwide crisis [16, 17]. It is therefore 
imperative to understand the molecular mechanisms that underlie this problematic disease in 
order to develop novel therapies. 
 Sexual intercourse is one of the most significant risk factors predisposing otherwise 
healthy women to UTI. Early studies demonstrated that sexual intercourse led to a 10-fold 
increase in bacteria/ml of urine and a subsequently increased predisposition to developing a UTI 
within 24 hours thereafter [5, 18-21]. More recent studies have shown that the frequency with 
which a woman has sexual intercourse dramatically impacts the likelihood of developing both 
acute and rUTI [4, 22, 23]. Scholes et. al found a direct association between the number of 
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episodes of sexual intercourse in a given month and the risk of developing rUTI. However the 
significance of the timing between these episodes of sexual intercourse is unknown. Are evenly 
spaced episodes associated with an equal risk or, instead, does an episode prime the bladder for 
rUTI if another insult follows within a sensitive period? To address this question, we developed a 
model of sequential infection in mice to explore the hypothesis that a sensitive period exists after 
an initial bacterial insult to the bladder in which the likelihood of developing severe, chronic 
infection is dramatically increased. 
Murine models of UTI have been used to decipher complexities of this disease in naïve 
individuals. UPEC are capable of colonizing multiple body habitats and niches, including both 
intracellular and extracellular locations within the bladder, as well as in the gastrointestinal (GI) 
tract and the kidneys. Selective pressure and bacterial population bottlenecks during colonization 
impact the ultimate fate of disease [24-27]. Adhesive pili assembled by the chaperone/usher 
pathway (CUP), such as type 1 pili, contain adhesins at their tips that function in adherence and 
invasion of host tissues and in biofilm formation on medical devices. Upon introduction of 
UPEC into the bladder, bacteria bind to either mannosylated uroplakin plaques or b1-a3 integrin 
receptors on the epithelial surface of the bladder via the type 1 pilus FimH adhesin [28-30]. 
Upon internalization, UPEC can be exocytosed as part of a TLR4 dependent innate defense 
process [31]. In addition to expulsion of individual bacteria, the host can exfoliate superficial 
facet cells to shed attached and invaded bacteria into the urine for clearance [29]. A small 
fraction of invaded bacteria escape into the host cell cytoplasm, where they are able to subvert 
expulsion and innate defenses by replicating into biofilm-like intracellular bacterial communities 
(IBCs) [24, 32]. UPEC eventually flux out of these communities with a substantial proportion 
existing as neutrophil resistant filaments [33, 34]. Importantly, evidence of IBCs and bacterial 
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filaments have been observed in women suffering acute UTI, one to two days post self-reported 
sexual intercourse, but not in healthy controls or infections caused by Gram-positive organisms, 
which do not form IBCs [21]. IBCs have also been observed in urine from children with an acute 
UTI [35]. Additionally, IBC formation and the innate immune response of cytokine secretion and 
exfoliation have been observed in all tested mouse strains, but the long-term outcome of 
infection differs [36-38].  
There are two main, mutually exclusive, outcomes to acute infection in C3H/HeN mice: 
either chronic bacterial cystitis (chronic cystitis), which is characterized by persistent high titer 
bacteriuria (>104 CFU/ml) and high titer bacterial bladder burdens (>104 CFU) two or more 
weeks after inoculation, accompanied by chronic inflammation [37, 39], or resolution of 
bacteriuria [37]. Mice that resolve infection may harbor small populations of dormant UPEC 
called Quiescent Intracellular Reservoirs (QIRs) [40]. Other mouse strains exhibit varied 
proportions of these two outcomes. C57BL/6J mice resolve bacteriuria within days and thus are 
resistant to chronic cystitis, but are susceptible to QIR formation [40, 41]. In contrast, other 
TLR4-responsive C3H background sub-strains and closely related CBA/J and DBA/2J mice 
experience persistent high-titer bacteriuria and bladder colonization by UPEC in the presence of 
chronic inflammation lasting at least four weeks post-infection (wpi). During chronic cystitis, 
persistent lymphoid aggregates and urothelial hyperplasia with lack of superficial facet cell 
terminal differentiation accompany luminal bacterial replication [37]. These same histological 
findings of submucosal lymphoid aggregates and urothelial hyperplasia have been observed in 
humans suffering persistent bacteriuria and chronic cystitis [42]. Since murine chronic cystitis 
predisposes to recurrent chronic UTI after antibiotic-mediated bacterial clearance, this is also a 
relevant model to interrogate the mechanism of recurrent cystitis [37]. In mouse models of UTI, 
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mice initially experience urinary frequency and dysuria as determined by reaction to noxious 
stimuli and nerve responses during acute infection [43, 44]; however, during chronic cystitis 
bacterial replication may exist in an asymptomatic carrier state as studies have not been 
conducted to determine whether dysuria persists. Interestingly, higher serum levels of 
interleukins (IL) 5 and 6, keratinocyte cytokine (KC/CXCL1), and granulocyte colony-
stimulating factor (G-CSF) in C3H/HeN mice at 24 hours post infection (hpi) predicted the 
development of persistent bacteriuria and chronic cystitis thereafter, suggestive of a host-
pathogen checkpoint during acute infection that predicts long term outcome [26, 37]. In women 
with an acute UTI, increased amounts of serum CXCL1, M-CSF, and IL-8 correlated with 
subsequent rUTI, suggesting a similar checkpoint [45].  
 In this manuscript, we developed a superinfection model to mimic the clinical scenario of 
frequent sexual intercourse whereby sequential inocula are introduced within a brief period of 
time. C57BL/6J mice are resistant to chronic cystitis when singly infected; however, 30% of 
C57BL/6J mice developed chronic cystitis when superinfected 24 hours after the initial infection. 
Serum elevations of IL-6, KC, and G-CSF prior to superinfection predicted the development of 
persistent bacteriuria in C57BL/6J mice similar to singly infected C3H/HeN mice. 
Superinfecting C3H/HeN mice 1-6 hours after the initial inoculation increased the proportion of 
mice experiencing chronic cystitis. In order for this elevation to occur, we found that the initial 
UPEC inoculum (the “priming” inoculation) must be alive, invasive, capable of intracellular 
replication, and able to regulate hemolysin expression. Inhibition of the caspase 1/11 
inflammasome prior to priming reduced bacterial CFU at four wpi relative to DMSO-treated 
mice. Microarray analysis of mouse bladders four wpi revealed that both C57BL/6J and 
C3H/HeN mice secreted antimicrobial peptides and IL-1 during chronic infection.  In contrast to 
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C3H/HeN mice, immunoglobulin expression was upregulated in C57BL/6J mice experiencing 
chronic cystitis. This immunoglobulin expression was absent in C57BL/6J mice that resolved 
infection and in C3H/HeN mice. Our data suggest mechanisms whereby certain women may be 
susceptible to rUTI after frequent sexual intercourse dependent on intracellular bacterial 
replication and the host immune response.  
 
Results  
Time-sensitive enhancement of infection 
 Studies suggest that a host-pathogen checkpoint within the first 24 hpi determines UTI 
outcome in C3H/HeN mice [26, 37]. In addition, the chronic inflammation observed in mice 
experiencing chronic cystitis was found to predispose to rUTI after re-infection [37]. Thus, we 
hypothesized that superinfecting mice during this period of acute inflammation would increase 
the proportion of mice experiencing chronic cystitis. We transurethrally infected 7-8 week old 
female C3H/HeN mice with 107 CFU UTI89 or PBS as the priming inoculation and 
superinfected them 1-2, 6, or 24 hours thereafter. Enumeration of bacterial CFU at one wpi as an 
initial screen revealed a dramatic increase in the proportion of mice experiencing chronic cystitis 
in mice superinfected 1-6 hours after priming compared to singly infected or PBS treated mice 
(Fig. 1A). We used a cutoff of 106 CFU to demarcate mice experiencing high-titer bacterial 
infection at one week. Importantly, we did not observe a significant increase in CFU when a 
single inoculum was doubled (2 x 107 CFU). Superinfection at 24 hpi had no effect on bacterial 
titers at one week, suggesting that the factors predisposing to increased susceptibility to chronic 
cystitis upon superinfection wane over time [26]. However, inoculation with PBS followed by 
UTI89 24 hpi did lead to high titers in 60% of mice. While this result is perplexing, it possibly 
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reflects that sacrifice six days post infection was not sufficient to delineate the typical bimodal 
distribution of outcomes [37]. The process of catheterization also induces inflammation, which 
may not have resolved by 6 dpi [46]. We conducted all subsequent C3H/HeN superinfections 
one hour after priming. 
Since early severe inflammatory responses predispose to chronic cystitis [37], we hypothesized 
that the initial inoculum primed the bladder by initiating an innate immune response to 
intracellular bacteria that predisposed to a higher proportion of mice experiencing chronic 
cystitis upon superinfection. We utilized a panel of UTI89 mutants in fimH, ompA, and kps that 
have been shown to differ in their ability to: i) invade and form IBCs and ii) persist during 
chronic cystitis in co-infection experiments [47, 48]. Mature IBCs caused by WT bacteria are 
clonally derived from a single invasive event [24]. The mannose-binding pocket of FimH is 
invariant among sequenced UPEC [47], and the binding pocket mutant, FimH::Q133K, is 
defective in mannose-binding and can neither invade the bladder epithelium nor form IBCs. 
FimH undergoes compact and elongated conformational changes wherein the receptor binding 
domain bends approximately 37° with respect to the pilin domain. The mannose-binding pocket 
is deformed in the compact conformation whereas the elongated conformation is mannose 
binding proficient [49, 50]. Several residues outside the mannose-binding pocket (positions 27, 
62, 66 and 163) are under positive selection in clinical UPEC isolates compared to fecal strains 
[47] and have been shown to function in modulating the conformational changes between the 
elongated and compact states [48]. FimH::A27V/V163A predominantly adopts a high-mannose 
binding, elongated conformation. Its expression results in: i) a 10-fold reduction in intracellular 
CFU one hpi and ii) a defect in the ability to form IBCs at six hpi. FimH::A62S shifts the 
equilibrium towards the compact conformation. Expression of this allele results in: i) a 10-fold 
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reduction in intracellular CFU one hpi and ii) a 10-fold reduction in IBC formation compared to 
WT UTI89 [47, 48]. UTI89ΔompA forms half the number of IBCs as UTI89 [51], and 
UTI89Δkps is defective in IBC formation. UTI89Δkps can replicate intracellularly and the IBC 
defect can be rescued by co-inoculation with WT UTI89, which results in mixed strain, non-
clonal, IBCs [52].  
We primed mice with these strains and superinfected one hpi with WT UTI89 and assessed 
bacteriuria at days 1, 7, 14, and 21 and enumerated bladder titers at 28 dpi. Mice were designated 
as having chronic cystitis if they had urine bacterial titers greater than 104 CFU/ml at each time 
point and bladder titers greater than 104 CFU at sacrifice [37]. We found that the 
FimH::A27V/V163A allele was incapable of priming the bladder for the development of chronic 
cystitis (p<0.05 relative to WT superinfection). In contrast, FimH::A62S did not significantly 
differ from PBS or WT superinfection; therefore, it may be capable of priming, though to a lesser 
degree. UTI89ΔompA and UTI89Δkps were both able to prime the bladder for enhanced chronic 
cystitis relative to PBS when superinfected one hpi with WT UTI89 (p<0.05 and p<0.01 
respectively; Fig. 1C). We also primed with heat-killed UTI89 and found that live, but not heat 
killed, UTI89 were capable of priming the bladder indicating that bacterial products such as LPS 
were insufficient (Fig. 1B). These data indicate that live and invasive UTI89 capable of at least 
some degree of intracellular replication are required for the priming to enhance the incidence of 
chronic cystitis upon superinfection of UTI89. Taken together these data suggest that priming 
begins during invasion and early IBC formation. 
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UPEC Hemolysin and Caspase 1/11 activation are essential 
 One of the most potent host defenses to eliminate adherent and invaded UPEC is 
superficial facet cell exfoliation [29]. The process of exfoliation is activated in part by the 
bacterial expression of hemolysin (HlyA) [53](Nagamatsu et al. in review). UTI89ΔcpxR 
overexpresses HlyA, leading to exfoliation and attenuation in our murine model of cystitis 
(Nagamatsu et al. in review). The UTI89ΔcpxRΔhlyA double mutant was not attenuated, 
suggesting that the in vivo defect was due to increased hemolysin expression (Nagamatsu et al. in 
review). The ability of UPEC to rapidly build up in numbers in the form of IBCs and then 
disperse to neighboring cells may be part of a mechanism to subvert an exfoliation response. 
Thus, fine-tuning the expression of HlyA during acute bladder infection may serve to maximize 
UPEC persistence and give UPEC a fitness edge against the host innate inflammatory response. 
Interestingly, in C3H/HeN mice, UTI89 ΔhlyA is not attenuated throughout infection and causes 
chronic cystitis comparable to UTI89; however, other reports suggest deletion of HlyA in UPEC 
CFT073 decreases virulence [54]. We investigated the role of hemolysin in priming the bladder 
for chronic cystitis upon superinfection by utilizing UTI89ΔhlyA or UTI89ΔcpxR as the initial 
inoculation followed by WT UTI89 one hpi. Both of these strains were statistically significantly 
different when compared to WT UTI89 as the priming inoculum. Therefore, we conclude that 
neither was capable of priming the bladder for enhanced chronic cystitis (Fig. 1D). Thus, too 
high or low expression of hemolysin abolished the ability of UTI89 to prime for enhanced 
chronic cystitis implying that an optimal level of hemolysin expression is critical for priming the 
bladder for enhanced chronic cystitis.  
HlyA-mediated exfoliation is in part due to its ability to trigger degradation of paxillin, a 
scaffold protein that modulates the dynamics of cytoskeletal rearrangements [55]. HlyA can also 
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trigger cell death in human bladder epithelial cells and release of IL-1α via caspase-4 (the 
murine ortholog is caspase-11) activation and caspase-1-dependent IL-1β secretion via activation 
of the NLRP3 inflammasome pathway, which orchestrates additional cell death (Nagamatsu et 
al. in review). We hypothesized that inflammasome and caspase 1/11 activation were essential 
for superinfection. Thus, mice were treated intravesically with a dose of caspase 1/11 inhibitor or 
DMSO one hour prior to priming and a second dose with the priming inoculum to test this 
hypothesis (Fig. 2A). Providing two doses of the inhibitor was previously shown to be effective 
in dampening in vivo inflammatory responses. In vitro, the inhibitor dramatically reduced 
downstream elements of inflammasome activation, IL-1α and IL-1β secretion, when bladder 
cells were infected with UTI89 (Nagamatsu et al. in review). Caspase 1/11 inhibition 
significantly reduced median bladder titers at four weeks after superinfection relative to the 
DMSO control group (Fig. 2B). We also saw a trend of caspase 1/11 inhibition in reducing the 
proportion of WT superinfected mice experiencing chronic cystitis to single infection levels (Fig. 
2B). DMSO also reduced the proportion of mice experiencing persistent bacteriuria and chronic 
cystitis, but to a lesser degree than caspase 1/11 inhibition (Fig. 2B vs. Fig. 1B-D), suggesting an 
anti-inflammatory role of DMSO alone. Intriguingly, DMSO was recently found to inhibit the 
NLRP3 inflammasome [56]. Taken together, these data implicate hemolysin and the NLRP3 
inflammasome in the priming response to enhanced chronic cystitis.   
We further investigated whether chemical exfoliation could enhance the proportion of 
mice experiencing chronic cystitis prior to a single infection. We utilized the cationic protein, 
protamine sulfate, which has previously been used to exfoliate the superficial facet cell layer of 
the urothelium [40, 57]. A 10 mg/mL dose delivered intravesically in 50 µL PBS was shown to 
exfoliate 65% of the facet cell layer 12 hours after treatment while an additional booster dose of 
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50 mg/mL led to 95% exfoliation [40]. We utilized these concentrations to initiate, but likely not 
complete, the process of exfoliation one hour prior to infection with UTI89. We did not observe 
a significant increase in the proportion of mice experiencing chronic cystitis over PBS 
pretreatment (Fig. 2C). Thus, these data suggest that at least partial IBC formation in conjunction 
with caspase 1/11 activation primes the bladder for enhanced chronic cystitis, but chemical 
initiation of exfoliation is not sufficient. Taken together, these data suggest that exfoliation per se 
might not play a significant role in impacting the likelihood of enhanced chronic cystitis but 
instead may reflect a downstream marker of the priming event. 
 
Superinfection leads to chronic cystitis in a resistant mouse strain 
 C57BL/6J mice typically rapidly resolve bacteriuria and are resistant to chronic cystitis 
upon single inoculation with UPEC [37, 38]. Five to ten percent of the time after inoculation 
with UTI89, C57BL/6J mice experience persistent bacteriuria, but this is generally due to kidney 
infection without concomitant high titer bladder infection [37, 41]. This degree of kidney 
infection is not infectious dose dependent and therefore likely due to ureteric reflux of the 
bacteria during experimental inoculation [37]. We investigated whether superinfecting C57BL/6J 
mice during acute infection would stimulate an immune response leading to chronic cystitis. We 
inoculated bladders with PBS or 107 CFU of UTI89 followed by superinfection with UTI89 1, 6, 
24, 48 hours or one week after initial infection and collected urine at days 1, 7, 14, and 21 dpi 
followed by enumeration of bladder and kidney titers at 28 dpi (Fig. 3). A 24 hpi superinfection 
resulted in 35% of mice sustaining persistent bacteriuria with bladder titers > 104 CFU at four 
weeks compared to 0% in the singly infected group (Fig. 3A). Kidney titers were also increased 
in the mice with persistent bacteriuria, but we did not observe a significant increase in the 
155 
proportion of mice with kidney infection greater than 104 CFU (Fig. 3B). These data suggest that 
at 24 hours after infection the bladders of C57BL/6J mice were primed to develop chronic 
cystitis upon superinfection. We investigated whether an ascending kidney infection plays a role 
in predisposing these mice to chronic cystitis by inoculating PBS into the bladder, either 24 
hours before or after infection with UTI89, to stimulate a bladder and ureter stretch response or 
potentially increase reflux of bacteria into the kidneys, respectively. We determined the 
percentage of mice with persistent bacteriuria and those with bladder and kidney titers greater 
than 104 CFU at sacrifice (Table 1). We found in all conditions that persistent bacteriuria was a 
100% predictor of kidney titers >104 CFU at four wpi. Persistent bacteriuria also predicted 
bladder titers greater than 104 CFU at four wpi in C57BL/6J mice superinfected 24 hpi with 
UTI89. For the group of mice inoculated with PBS before the initial UTI89 infection, persistent 
bacteriuria did not correlate with high bladder titers suggesting these bacteria were only 
replicating in the kidneys. Serially infecting with two inocula of UTI89 trended towards 
increased persistent bacteriuria and chronic cystitis compared to the group inoculated with 
UTI89 followed by PBS at 24 hpi (P = 0.066; Table 1 and Fig. 4A). Kidney titers of UTI89 
superinfected mice were significantly higher than when PBS was used to prime or superinfect 
perhaps suggesting that repeat infection may also increase susceptibility to pyelonephritis (Fig. 
4B). Thus, a 24 hpi superinfection of WT UTI89 led to increased rates of persistent bacteriuria 
and chronic cystitis; however, bladder/ureter stretch or kidney ascension at 24 hpi may contribute 
to this increase. 
C3H/HeN mice that progress to chronic cystitis upon single inoculation can be predicted 
by elevated serum levels of IL-5, IL-6, KC, and G-CSF at 24 hpi [37]. We hypothesized that 
similar elevations would predict sensitization to chronic cystitis in C57BL6/J mice if they were 
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subsequently superinfected. Thus, we determined levels of 23 serum cytokines from C57BL/6J 
mice 24 hrs after initial inoculation with PBS or UTI89 prior to superinfection. We then 
superinfected a subset of the mice initially infected with UTI89 (superinfection in Figure 5) 
leaving the other mice untouched (UTI89 group). All mice were evaluated with urine titers over 
28d and sacrificed to enumerate bladder titers. We stratified the superinfected mice based on 
outcome four weeks later as determined by persistent bacteriuria and chronic cystitis. We found 
elevations of serum KC (Fig. 5A), IL-6 (Fig. 5B), and G-CSF (Fig. 5C) in mice that progressed 
to chronic cystitis relative to those that resolved infection or were mock-infected with PBS. 
Therefore, higher levels of these cytokines correlate with chronic cystitis that develops later if 
mice are superinfected. At the time we obtained serum, the single infection and superinfection 
groups were identical, and no statistical differences existed among them. These data demonstrate 
that a subset of C57BL/6J mice respond to an initial infection in a way that results in higher 
specific serum cytokine levels and primes them to develop chronic cystitis if an additional insult 
is delivered 24 hpi.    
 
Response to infection differs between C3H/HeN and C57BL/6J 
 During chronic cystitis of singly-infected C3H/HeN mice, the bladder epithelium is 
hyperplastic and normal terminal differentiation of the superficial facet cell layer, including the 
expression of surface uroplakins, does not occur [37]. In this environment, the bacteria are able 
to persist extracellularly by an unknown mechanism. To assess this, we conducted scanning 
electron microscopy analysis on bladder tissue harvested at four wpi and found that bacteria 
replicate in the presence of ongoing epithelial exfoliation and neutrophil influx in chronic cystitis 
of both C3H/HeN and C57BL/6J mice (Fig. S1A-D). This analysis supports previous 
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experiments that have shown that during chronic cystitis the majority of bacteria are 
extracellular, replicating in the urine or adherent to underlying transitional epithelial cells [24, 
37]. The mechanism by which bacteria adhere in the absence of uroplakins has not been 
demonstrated in vivo, but in vitro studies have shown that FimH binds integrins and other host 
proteins such as TLR4 [30, 58, 59]. Alternatively additional adhesive factors such as other CUP 
pili may play a role. Interestingly, during chronic cystitis, neutrophils, which we observed to be 
actively engulfing bacteria, are insufficient for clearing infection; however, the reason for this is 
unclear. Mature superficial facet cells could not be discerned at this time point, but were present 
in mock-infected mice (Fig. S1E). Patients with persistent bacteriuria or rUTI have been reported 
to have similar histopathology [42]. In order to identify the bladder micro-environment in which 
UPEC replicate during chronic cystitis, we conducted microarray analysis on RNA extracted 
from bladders four wpi. C3H/HeN mice were singly-infected and C57BL/6J mice were 
superinfected to develop chronic cystitis. Mice from each strain inoculated with PBS were used 
as controls. Depicted in Figure 6 are the expression profiles relative to the global average with 
green indicating increased expression and red denoting decreased. C3H/HeN mice experiencing 
chronic cystitis had a dramatically different expression profile from resolved and mock-infected 
mice (Fig. 6A). Uroplakins were among the most downregulated genes during chronic cystitis in 
both mouse models, consistent with the lack of terminally differentiated superficial facet cells 
(Fig. S1). Eleven of the 20 (55%) most upregulated genes during chronic cystitis were the same 
in both mouse strains (Table S1). The functional categorization revealed that most of the up-
regulated genes function in inflammatory response, cytokine release, and ion binding [60-62]. Of 
interest among these genes in both of these mouse models is the inflammasome-related cytokines 
IL-1. We have shown that UPEC activate the caspase 4 murine homologue, caspase 11, during 
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acute infection in a hemolysin-dependent fashion (Nagamatsu et. al. in review). Despite these 
similarities, interesting differences existed in the ongoing inflammatory response in mice 
experiencing chronic cystitis (Table S1). In C57BL/6J mice, the inflammatory response is 
immunoglobulin- and cytokine-mediated whereas in C3H/HeN mice, we noted a remarkable 
absence of upregulated immunoglobulin genes. The increased expression of antimicrobial 
peptides such as RegIIIγ and the calgranulins (s100a8 and s100a9) is interesting because this 
increased expression is not sufficient to eliminate bacterial replication during chronic cystitis. 
Interestingly, C3H/HeN mice that were mock infected exhibited a very similar profile to mice 
that resolve infection (Fig. 6A). Contrary to C3H/HeN mice, C57BL/6J mice that resolved 
infection differed significantly from either chronic cystitis or mock infected mice, suggesting an 
element of altered physiology and immunological memory of the infection (Fig. 6B). This 
information supports research that serially infecting mice that resolve infection makes them less 
susceptible to recurrent infection [37, 63]. What is interesting here is that the mechanisms by 
which this occurs may differ between mouse strains, and possibly by extension, women. 
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Discussion  
 We have developed models of bacterial superinfection of the urinary tract, which may 
provide insight into the connection between recent and frequent sexual intercourse and the 
susceptibility to the development of chronic UTI [5, 22]. Our results demonstrate that 
superinfection resulted in increased susceptibility to chronic cystitis in both susceptible and 
resistant mouse genetic backgrounds, but the time window for priming differed between strains. 
We have previously shown that chronic cystitis predisposes to severe rUTI upon a subsequent 
infection weeks to months after clearance of the first infection with antibiotics [37]. Clinically, 
millions of women take post-coital and prophylactic antibiotics so as not to develop rUTI [64]. 
Therefore, if clinically applicable, our results detailed here may partially explain why frequent 
sexual intercourse is such a strong risk factor for UTI. The necessity of prophylactic antibiotics 
could be obviated if the risk factors and bacterial traits identified here can be altered in the 
clinical population of women suffering chronic rUTIs. 
 Frequent sexual intercourse is among the most important risk factors for rUTI in young 
women [22]. Peri-urethral carriage of the causal strain and sexual intercourse immediately 
precede the development of a rUTI [5]. Sexual intercourse likely introduces mixed populations 
of bacteria into the urinary tract, with E. coli being the most common [18]. In this environment, 
UPEC invade bladder tissue and replicate, forming IBCs and bacterial filaments, which have 
been observed in human urine in 40% of patients suffering acute UTI, 24-48 hours after reported 
sexual intercourse [21]. These data may provide mechanistic insight as to the frequent clinical 
observation that recent and frequent sexual intercourse over a brief period of time leads to 
increased rates of rUTI [23]. Furthermore, elevated levels of serum CSF1, CXCL-1, and CXCL-
8 in women with acute UTI were associated with a higher rate of rUTI [45]. Using C3H/HeN and 
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C57BL/6J mice, we have shown that superinfection during the period of acute infection 
dramatically increases the proportion of mice that experience chronic cystitis with inoculations 
of 107 UPEC (Fig. 1A and 3A). The bacterial characteristics responsible for frequent recurrences 
are beginning to be assessed [65]. Hemolysin is expressed by 50% of UPEC isolates, but is more 
likely to be associated with symptomatic UTI [66]. It is possible that hemolysin-mediated 
exfoliation and caspase 1/11 activation leads to UTI-associated symptoms. In our studies, we 
found that an increase in priming for chronic cystitis correlated with the bacterial ability to 
invade and replicate within the bladder tissue (Fig. 1B-C), and through hemolysin to activate 
caspase 1/11 leading to IL-1 secretion and bacterial replication (Fig. 1D and 2B). Activation of 
caspase 1/11 has been shown to contribute to epithelial cell death in vitro and exfoliation in vivo 
in C3H/HeN mice, suggesting that caspase-mediated exfoliation may expose the underlying 
epithelium upon which UPEC replicates during chronic cystitis (Nagamatsu et. al. in review). 
Inhibition of caspase 1/11 protected superinfected mice from chronic cystitis (Fig. 2), suggesting 
a role for cytokines downstream of caspase activation including IL-1α and IL-1β, identified in 
our microarray of four-week bladders (Fig. 6; Table S1). A microarray analysis revealed that in 
C3H/HeN and C57BL/6J mice, 11/20 of the most upregulated genes during chronic cystitis were 
the same. Differences between the responses to infection in these mouse strains may result from 
the dramatic increase in kidney infection or QIR presence in C57BL/6J relative to C3H/HeN 
mice [37, 40]. Further, this data supports the hypothesis that a muted inflammatory response to 
UPEC infection is more likely to lead to resolution [26]. Also, our studies suggest that serum 
biomarkers such as IL-6, KC, and G-CSF may predict a predisposition to rUTI (Fig. 5) [37]. 
Recently, it was demonstrated that cytokines involved in immune cell chemotaxis and maturation 
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(the human homolog of KC included) during acute UTI enhanced the likelihood of developing 
rUTI [45].  
We have created mouse models that have identified both bacterial and host immune 
factors that may predispose women to rUTI. Inhibiting caspase-mediated inflammation or 
downstream effectors may serve to prevent a UTI from becoming a chronic or recurrent UTI. 
Further work to identify bacterial and host factors that influence the balance between resolution 
and chronic infection is required to lead to better treatments clinically. The ability of UPEC to 
invade bladder tissue allows it to transcend stringent bottlenecks during infection [24, 25, 27]. 
The ability to replicate intracellularly also impacts the ability of a second invading strain to 
proliferate in the bladder environment (Fig. 1B-C). The molecular basis of bacterial colonization 
of the bladder during chronic cystitis is an area of active investigation. Previously, it has been 
shown that mannosides are effective in treating chronic cystitis arguing that FimH-mediated 
binding plays an important role [67]. It has recently been demonstrated that FimH variation 
outside of the binding pocket affects protein conformation and pathogenicity of UPEC [48]. This 
variation may impact bacterial adherence and replication during chronic cystitis. Furthermore, 
because invasion and intracellular replication appear to influence the likelihood to develop 
chronic cystitis, treatments with soluble compounds such as mannosides that block the ability of 
UPEC to invade the tissue or compounds that might alter FimH conformation hold promise as 
effective means to prevent or treat rUTI [67-70]. These analyses may allow us to identify high-
risk patients for more aggressive therapy and/or anti-virulence compounds to limit this troubling 
disease.  
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Materials and Methods 
Bacterial strains  
All WT bacterial strains utilized were derivatives of UTI89, including tagged, isogenic UTI89 
isolates, kanamycin resistant UTI89 attHK022::COM-GFP, kanamycin resistant UTI89 with re-
integrated UTI89 FimH, spectinomycin resistant UTI89 attλ::PSSH10-1, and chloramphenicol 
resistant UTI89 [24, 47, 71]. FimH mutant strains, ΔompA, Δkps, ΔhlyA, ΔcpxR were all 
previously published [47, 51, 52](Nagamatsu et al. in review).  
 
Mouse infections  
Bacteria for infection were prepared as previously described [72]. Six to seven week old 
female C3H/HeN (Harlan) or C57BL/6J (Jackson) were transurethrally infected with a 50 µL 
suspension containing 5 x 106 – 2 x 107 CFU of UTI89 or relevant mutant in PBS under 3% 
isofluorane. Protamine Sulfate (Sigma) was dissolved in PBS and caspase 1/11 inhibitor Ac-
YVAD-CMK (BACHEM) was dissolved in DMSO and transurethrally inoculated into the 
bladder. At indicated timepoints after infection, mice were anesthetized and infected again. 
Venous blood was obtained at 24 hpi, just prior to re-infection, by submandibular puncture and 
centrifuged at max speed at 4 oC in Microtainer serum separation tubes (BD) and stored at -20 oC 
until use. Cytokine expression was measured using the Bio-Plex multiplex cytokine Group I bead 
kit array (Bio-Rad), which measures 23 cytokines. Urine was obtained by gentle suprapubic 
pressure and serially diluted and plated on appropriate antibiotic plates. Mice were sacrificed by 
cervical dislocation under isofluorane anesthesia, and their organs were aseptically removed. 
Chronic cystitis was determined if animals had urine titers > 104 CFU/mL at 1, 7, 14, 21 dpi and 
163 
bladder titers > 104 CFU at sacrifice at 28 dpi [37]. Animals that resolved infection and had a 
recurrence or had resolved the infection with reservoir titers >104 CFU were marked in red and 
considered to have resolved the chronic infection. Organ titers shown are the total bacterial 
burden. 
Ethics statement 
 The Washington University Animal Studies Committee approved all mouse infections 
and procedures as part of protocol number 20120216, which was approved 01/11/2013 and 
expires 01/11/2016. Overall care of the animals was consistent with The guide for the Care and 
Use of Laboratory Animals from the National Research Council and the USDA Animal Care 
Resource Guide. Euthanasia procedures are consistent with the “AVMA guidelines for the 
Euthanasia of Animals 2013 edition.” 
 
Microarray experiments 
C3H/HeN or C57BL/6J mice were infected as discussed above. After 28 days, animals 
that had developed chronic cystitis, resolved the infection, or aged matched PBS controls were 
sacrificed for RNA isolation. Upon sacrifice, 5 bladders from each condition were immediately 
pooled and homogenized in Trizol for RNA isolation according to the manufacture’s suggested 
protocol. DNase treatment was performed to remove any contaminating DNA before submission 
to the Genome Technology Access Center for sample processing and hybridization on 
Affymetrix Mouse Gene 1.0 chips in triplicate. Data was analyzed using the Partek Genomics 
Suite. Gene lists were compiled using fdr-ANOVA analysis with a significance cut off of 
p<0.001. Experiments were repeated twice with a representative analysis shown. Microarray data 
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are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession 
number E-MTAB-2930.   
 
Scanning electron microscopy 
 Mice were infected as described above. Bladders were aseptically harvested, bisected, 
and splayed. Bladders were fixed in 2.0% glutaraldehyde in 0.1M sodium phosphate buffer 
overnight. Bladders were then washed three times with 0.1M sodium phosphate buffer and de-
ionized water before being fixed in 1.0% osmium tetroxide. Bladders were washed and then 
critical point drying was performed with absolute ethanol and liquid carbon dioxide. Sputter 
coating was performed with gold-palladium using a Tousimis Samsputter-2a. Images were 
obtained on a Hitachi S-2600H operated at 20kV accelerating voltage. 
 
Statistical analysis  
Datapoints below the limit of detection (LOD) were set to the LOD for graphical 
representation and statistical analysis. For cytokine data, values out of the range of the 
instrument were not included for analysis. Fisher’s exact test was utilized to determine 
differences between groups for rates of chronic cystitis. One-way ANOVA was utilized to 
determine whether any cytokine differences were apparent and pairwise assessment of median 
values was determined by Mann-Whitney test. Unless otherwise indicated, p<0.05 was 
considered significant. Analyses were performed in Graphpad Prism 5.0.   
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Figures and Tables 
  
Figure 1. Superinfections of C3H/HeN mice.  
A) Mice were infected with 107 CFU UTI89, 2 x 107 CFU UTI89, or PBS and re-infected with 
UTI89 at the indicated time points. One week total bladder titers are shown. Percentage of mice 
likely to develop chronic cystitis is displayed at the top of the column based on a CFU cutoff of 
106. Asterisks indicate p<0.05 from the PBS control and singly infected mice. B-D) Mice were 
infected with the indicated strain or PBS and re-infected one hour later. Urine titers were 
determined over time and four-week bladder titers are displayed. The fraction of mice with 
chronic cystitis is displayed at the top of each column. Red data points indicate resolved 
infection. Horizontal bars indicate median values. The dashed line at 20 CFU represents the 
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LOD, and the dashed line at 106 (A) or 104 CFU (B-D) represents the chronic cystitis cutoff for 
urine and bladder titers. Panel A reflects 2-4 experiments with 5-9 mice per group. Panel B is 2-7 
experiments with 4-5 mice per group. Panel C-D are 3 experiments with 4-5 mice per group. 
Statistical comparisons were determined using Fisher’s exact test based on the fraction of mice 
experiencing chronic cystitis.  
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Figure 2. Role of caspase 1/11 and exfoliation in C3H/HeN superinfections.  
A) Inoculation protocol shown for caspase inhibition studies of panel B. B) Four-week total 
bladder titer based on inhibitor or vehicle. C) Mice were inoculated with PBS, UTI89 or the 
indicated dose of protamine sulfate in 50 µL PBS and inoculated one hour later with UTI89. 
Urine was collected weekly and overall bladder titers are shown at four weeks. Panel B 
represents 5 experiments with n = 5-10 mice per group. Panel C represents 2 experiments with n 
= 5-10 mice per group. B-C) Observations in red indicate resolved infection. Percent of mice 
with persistent bacteriuria and chronic cystitis is shown at the top of each column. For Panel B 
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and C, a Fisher’s Exact Test was used to determine significance between proportions of mice 
experiencing chronic cystitis. Mann-Whitney U Test was used to compare median CFU values in 
Panel B. 
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Figure 3. C57BL/6J mice are susceptible to chronic cystitis when superinfected 24 hpi.  
A-B) Mice were transurethrally infected with PBS or UTI89 and re-infected at the indicated 
timepoints with UTI89. Urine was tracked weekly and four-week total bladder (A) and kidney 
pair (B) titer is displayed. N = 2-4 experiments with 4-5 mice per group. Statistical differences 
determined by Fisher’s Exact test.  
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Figure 4. UTI89 Superinfection of C57BL/6J mice increases bladder and kidney infection. 
A-B) mice were infected with PBS or UTI89 Kanr and re-infected 24 hrs later with PBS or 
UTI89 Spectr. Urine was tracked over four weeks and total bladder (A) and kidney pair titer (B) 
is displayed. Number above columns indicates number of mice with persistent bacteriuria with 
bladder (A) or kidney (B) titer > 104 CFU. Data represents 3-8 experiments with n = 4 – 29 mice 
per group. Panels also include data reproduced from Figure 3.Statistical differences determined 
by Fisher’s Exact test. 
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Figure 5. Serum cytokine signature of C57BL/6J mice with persistent bacteriuria.  
Serum was obtained 24 hrs after initial inoculation prior to superinfection. Levels of 23 
cytokines were determined and cytokines showing significant differences between resolved and 
chronic superinfected mice are shown. Levels of KC (A), IL-6 (B), and G-CSF (C) shown in 
pg/mL. Data represent 4- 6 experiments with n = 4 – 29 mice per group. Statistical differences 
determined by One-Way ANOVA overall and Mann-Whitney U test for pairwise comparisons.  
 
 
 
177 
 
Figure 6. Microarray gene changes for C3H/HeN and C57BL/6J bladders. 
A) C3H/HeN heatmap analysis for mice that resolved infection, experienced chronic cystitis, or 
were mock infected with PBS. B) C57BL/6J heatmap analysis for mice mice that resolved 
infection, experienced chronic cystitis, or were mock infected with PBS. Depicted is a 
representative analysis of two biological and three technical replicates. 
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Table 1. Characteristics of C57BL/6J superinfections 
Persistent 
Bacteriuriab 
Resolved 
Bacteriuria 
Persistent 
Bacteriuria 
Resolved 
Bacteriuria 
Conditiona 
Incidence 
% (n) 
Bladder 
Titersc,d PPVe  
Bladder 
Titers NPVe 
Kidney 
Titers PPVe 
Kidney 
Titers NPVe  
UTI89! 
UTI89 
30 
(28/94)  
4.4x106 92 
(22/24) 
5.5x102 100 
(50/50) 
3.6x107 100 
(28/28) 
1.2x103 73 
(49/67) 
UTI89! 
PBS 
16  
(6/37) 
2.5x106 83 
(5/6) 
3.2x102 100 
(31/31) 
8.6x107 100 
(6/6) 
6.0x101 90 
(28/31) 
PBS! 
UTI89 
9  
(3/32) 
1.9x103 0  
(0/3) 
3.4x102 100 
(29/29) 
4.0x107 100 
(3/3) 
2.0x101 100 
(29/29) 
a. All mice infected 24 hours after initial infection 
b. Defined as >104 CFU/mL bacteria in clean catch urine throughout four-week infection 
c. Median values listed 
d. Bladders of 20 mice were used for imaging purposes so no titers were available. 
e. PPV is the positive predictive value of persistent bacteriuria predicting bladder/kidney titer 
greater than 104 CFU. NPV is the negative predictive value of resolved bacteriuria predicting 
bladder/kidney titer less than 104 CFU. 
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Figure S1. Bacteria replicate on the bladder surface during chronic cystitis.  
Bladders of C3H/HeN and C57BL6 mice were splayed four wpi and fixed in glutaraldehyde. A-
B) Chronic C3H/HeN bladders. C-D) Chronic C57BL/6J bladders. E) Mock infected C57BL/6J 
bladder shown for comparison.  
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Table S1. Genes with highest fold change of chronic cystitis versus resolved. 
 
 
 
 
 
       
C57BL6 C3H/HeN 
Gene name 
Fold 
change 
(chronic v 
resolved) 
Functional 
Annotation 
Gene name 
Fold 
change 
(chronic v 
resolved) 
Functional 
Annotation 
Ubd$ 119.405$ Proteosome BC100530 144.401 Unknown 
Saa3$ 112.203$ Inflammatory 
Response 
S100a8 88.7327 Cytokine/Ion 
Binding 
S100a8$ 85.4193$ Cytokine/ Ion 
Binding 
Mmp7 87.0008 Ion Binding 
Mmp7$ 77.6183$ Ion Binding Ubd 77.6292 Proteosome 
RegIIIγ $ 66.2146$ Inflammatory 
Response 
S100a9 74.4965 Cytokine/ Ion 
Binding 
S100a9$ 44.9876$ Cytokine/ Ion 
Binding 
RegIIIγ  62.1077 Inflammatory 
Response 
Igk$V19$14) 31.1745) Immunoglobulin Cxcl2 39.3707 Cytokine 
Igk$V28) 27.7003) Immunoglobulin Il1b 38.9361 Cytokine 
Fam3b$ 25.7301$ Cytokine Sprr2f 38.7662 Tissue 
Remodeling 
Plekhs1) 24.3332) Tissue 
Remodeling 
Saa3 36.8235 Inflammatory 
Response 
Duox2) 23.492) Ion Binding Cxcl5 34.2451 Cytokine 
Gm5571) 22.2598) Immunoglobulin Il1a 33.0689 Cytokine 
Sprr2f$ 22.0386$ Tissue 
Remodeling 
Gabrp 31.6717 Ion Binding 
AA467197) 21.9697)  Sprr2d 31.4934 Tissue 
Remodeling 
Cxcl9) 21.46) Cytokine Fam3b 29.3965 Cytokine 
Cxcl2$ 17.698$ Cytokine Cxcr2 27.6748 Cytokine 
Pigr) 17.1008) Immunoglobulin Tmprss11g 26.263 Tissue 
Remodeling 
Tmprss11g$ 15.7865$ Tissue 
Remodeling 
Lcn2 25.9349 Ion Binding 
Nos2) 15.644) Inflammatory 
Response 
Il1f9 24.0818 Cytokine 
Il1a$ 15.0219$ Cytokine Sprr2g 23.4676 Tissue 
Remodeling 
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The pathogenesis of UPEC UTI is complex because UPEC invades tissue and colonizes 
multiple niches during infection, each niche presenting different advantages and challenges to 
persistence. Many of these niches allow UPEC to resist immune defense and antibiotic treatment 
[1-3]. Furthermore, the high rate of same strain recurrence and the rising incidence of infections 
with antiobiotic resistant pathogens necessitates a thorough examination into the pathogenesis of 
this complex disease [4-7]. It is imperative to investigate novel therapeutics targeting unique 
elements of the UPEC pathogenic cascade to specifically target the disease and avoid unwanted 
side effects [8-10]. Prior to this work, the role of the intracellular bladder niche during acute 
infection was believed to be important; however, the degree to which intracellular replication 
impacted infection outcome was unknown. Additionally, a host-pathogen checkpoint at 24 hpi 
was predictive of infection outcome, but the specific mechanisms feeding into this checkpoint 
had not yet been characterized [11]. The work presented in this thesis identifies key elements of 
the UPEC pathogenic cascade as well as implicates human behavioral factors that predispose to 
chronic and recurrent urinary tract infections. I have discovered and detailed the stringent 
population bottleneck that accompanies acute infection [12]. Additionally, I elucidated the 
molecular mechanism whereby pathoadaptive changes in the adhesive protein FimH impact 
mannose-binding, conformation, and virulence. Moreover, this work identified a balance 
between mannose-binding and dynamic flexibility, which leads to maximal success within the 
urinary tract. This trait may be generalizable to other organisms that adhere to different surfaces. 
Finally, I developed a model of frequent bacterial inoculation and determined a possible 
mechanism whereby women are susceptible to chronic, recurrent UTI after frequent sexual 
intercourse. Targeting these important pathogenic elements therapeutically could dramatically 
reduce the morbidity and economic cost of this common disease. 
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 This final chapter consists of three parts: Discussion (A), Future Directions (B), and 
Concluding Remarks (C). The Discussion (A) section will expand on the data presented herein 
and offer its context within the field regarding the pathogenesis of UTI. Specifically, I will 
discuss the 1) colonization of niches and reservoirs, 2) role of invasion and IBC formation during 
UTI, 3) UTI pathogenesis and symptoms, 4) factors responsible for colonization in a chronically 
inflamed bladder, 5) novel treatment modalities, and 6) bacterial population bottlenecks and 
virulence factors. In the Future Directions (B), I will outline the experimental design to test 1) 
virulence defects of high affinity pathoadaptive FimH alleles, 2) Identification of the FimH 
receptor during chronic cystitis, 3) mannoside efficacy against alternative FimH alleles in 
multiple niches, and 4) the role of IL-1 in priming the bladder during superinfection. Finally, I 
will offer my perspectives on the future of this disease in the Concluding Remarks (C). 
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A. Discussion 
Colonization of niches and reservoirs 
During UTI, UPEC is capable of colonizing multiple intracellular and extracellular niches 
in multiple organs. The pathogenesis is thought to begin with introduction of GI flora into 
periurethral or vaginal niches. The presence of UPEC in these areas increases prior to a UTI [13]. 
Some mechanical force such as sexual intercourse is thought to introduce bacteria into the 
urinary bladder [14, 15]. The bladder environment may not be sterile, as previously suspected 
[16]. UPEC would have to displace or interact with colonizers in order to establish productive 
infection of these niches. Furthermore, it is unlikely that an inoculum is monomicrobial. 
Mounting evidence suggests that the clinical practice of ignoring non-traditional uropathogens as 
contaminants may not accurately reflect the disease state [17, 18]. In fact, murine models of 
these polymicrobial infections suggest that the presence of other organisms may enhance UPEC 
pathogenesis [19]. When Group B Streptococcus and UPEC are co-inoculated, UPEC invade to a 
higher degree and form more IBCs than when inoculated singly [19]. Thus, the presence of other 
bacteria may enhance intracellular niche occupation, which would be predicted to enhance 
pathogenesis (Chapter 2) [12, 19]. Recent data suggests that other organisms may also be able 
to establish intracellular niche colonization [18, 20]. The ability to access this intracellular niche 
protected from the immune response and antibiotics may be a common component of the 
pathogenic cascade of multiple uropathogens. 
 Many recurrent UTI are caused by the same strain as the initial infection [4], suggesting 
that antibiotics are not effective at sterilizing niches colonized by UPEC. It was recently 
discovered that at the time of UTI, the dominant E. coli strain in the bladder was also the 
dominant E. coli species in the GI tract [21]. Antibiotic therapy may not be completely effective 
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in sterilizing this gut niche or Quiescent Intracellular Reservoirs (QIRs) within the bladder 
epithelium [22, 23]. Furthermore, it is possible that UPEC colonizes multiple niches within the 
GI tract as has previously been observed for other organisms [24, 25]. UPEC pili and other 
virulence factors may contribute to colonization of multiple niches within the GI tract in addition 
to the bladder [26]. Little is known about kidney colonization in humans because mice do not 
express the same receptor to which UPEC P pili bind in humans [27-29]. However, it has been 
suggested that multiple pilus systems contribute to kidney colonization in addition to P pili [30]. 
Type 1 and P pili may act in concert in the kidneys to facilitate attachment and biofilm formation 
(Figure 1) [31]. Colonization of these kidney niches may contribute to recurrent pyelonephritis 
[4, 32]. The ability of UPEC to ascend the ureters and colonize kidneys in an asymptomatic state 
may also lead to recurrent cystitis or pyelonephritis (Chapter 2). Data from multiple mouse 
models suggests that bacteria that colonize the kidney are the result of multiple cycles of 
ascension, colonization, and descent [12, 33]. UPEC infection is thus a highly dynamic process 
whereby multiple niches and reservoirs are colonized. The appropriate virulence factors are 
likely both niche-specific as well as general. The ability to regulate these genes to govern 
colonization and transition between these niches is essential for persistence [34]. 
 
Role of Invasion and IBC Formation During UTI 
UPEC bind to and invade superficial facet cells of the bladder epithelium immediately 
upon entry into the murine urinary tract [2, 35, 36]. Rapid, intracellular bacterial replication 
within the cytoplasm results in biofilm-like communities known as intracellular bacterial 
communities (IBCs) that protrude into the lumen of the mouse bladder [37, 38]. The first round 
of IBC formation is well synchronized within an individual mouse and across mice for the first 
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six hpi [12, 36]. Each IBC contains 104 – 105 CFU at 6 hpi derived from a single, invasive 
bacterium (Chapter 2) [12]. Thereafter, the infection is highly variable with regard to the timing 
of pathogenic events and the outcome [36]. That is, the variance of bladder bacterial titers at 6 
hpi is very small, but at later timepoints, a bimodal distribution of bacterial titer begins to 
develop [39]. This bimodal distribution reflects mice that progress to chronic cystitis with high 
titers in the bladder, and those that resolve infection with low titers in QIRs. Thus far, the 
importance of the invasion and IBC cycle has only been assessed through mutations affecting 
this process, among other elements of pathogenesis. In this thesis, I provided evidence 
demonstrating the importance of this cascade during infection with WT UPEC strains. 
 We developed a library of 40 strains of UTI89 each with a unique DNA sequence that 
could be detected by eight multiplex PCR reactions (Chapter 2) [12]. During the first six hours 
of infection, bacterial CFU increased while the fraction of unique tags decreased. This increase 
in CFU corresponds to bacterial replication within IBCs, and the decrease in tag fraction results 
from innate defenses of neutrophil influx and superficial facet cell exfoliation [2, 12]. In 
extracted bladders, we found that higher numbers of IBCs corresponded to a higher fraction of 
unique tags isolated. An average C3H/HeN bladder has 50 IBCs from an inoculum of 107 CFU 
[12]. A higher fraction of tags was also present at two weeks post infection in mice experiencing 
chronic cystitis than mice that resolved infection [12]. Taken together, these data regarding the 
population bottleneck present several hypotheses regarding the transition between acute and 
chronic infection. These three hypothesis explain how UPEC transcend the stringent acute 
population bottleneck to cause chronic cystitis. The following hypotheses address how bacteria 
are able to cause chronic cystitis by transiting the acute population bottleneck: 1) IBC formation 
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and subsequent release allow clones to perpetuate infection, 2) increased luminal bacteria or 
increased flux out of IBCs, or 3) kidney colonization.    
The first hypothesis assumes that the most stringent bottleneck occurs simultaneously 
with IBC formation, and that UPEC emerging from an IBC would produce a founder effect on 
the UPEC population. I have seen a direct relationship between IBC number and the proportion 
of mice experiencing chronic cystitis based on inoculum concentrations and bacterial strain 
(Chapters 2-3). Bacteria that flux out of the IBC to colonize the bladder during chronic cystitis 
persist luminally, adherent to exposed underlying epithelial cells (Chapter 4) [40]. UPEC resist 
the inflammatory response of this chronic condition and replicate indefinitely throughout the 
lifetime of the animal [40]. As a stable, extracellular infection it would seem unlikely for a 
continued decrease of the roughly 50% of remaining unique clones. This observation is 
consistent with other systems in which stable, luminal infections by WT organisms are not 
significantly diminished [41]. This hypothesis would predict that a larger number of IBCs 
precedes chronic cystitis while fewer precede resolution of the infection [11, 12, 34]. This 
hypothesis is consistent with the observation that an increased inoculum of either UTI89 or 
CFT073 leads to an increase in IBC number and an increase in the proportion of mice that 
experience chronic cystitis (Chapter 3). Furthermore, FimH mutants that form fewer IBCs, but 
bind the tissue equally well, are less likely to cause chronic cystitis. Based on these data, this is 
my favored hypothesis, but I will now describe possible alternative hypotheses.     
An alternative hypothesis is that 1st generation IBC number does not significantly differ 
based on eventual infection outcome, but increased 2nd generation IBCs or bacterial flux precede 
chronic cystitis. Serum elevations of IL-5, IL-6, KC, and G-CSF at 24 hpi predict the 
development of chronic cystitis later [40]. Because the immune response to infection differs 
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between longterm outcomes, it is likely that some difference in the pathogenic cascade or niche 
occupation leads to this variance in immune response. Therefore, for this hypothesis, we will 
assume that mice that progress to chronic cystitis and mice that resolve infection have equal 
IBCs at 6 hpi. The difference between these conditions would result from either an increase in 
bacterial flux from the IBC to colonize the bladder, an increase in 2nd generation IBCs, or an 
increase in luminal bacteria throughout acute infection. These possibilities are not mutually 
exclusive. However, each of these would imply that the immune response would react to the 
increase in luminal bacteria. At 24 hpi, mice that progress to chronic cystitis have elevated urine 
titers and an increased inflammatory score relative to their littermates who resolve infection [40]. 
The developmental history of these bacteria is unknown, but it is unlikely that these bacteria 
were luminal throughout infection for several reasons. First, neutrophil and macrophage influx 
into the bladder would preferentially target these bacteria, eliminating them [36]. Additionally, 
the ability to attach to the bladder is not sufficient for longterm persistence. UTI89 
FimH::A27V/V163A binds bladder tissue and invades superficial facet cells, but is not able to 
form IBCs nor cause chronic cystitis (Chapter 3) [42]. Interestingly, this mutant has enhanced 
mannose-binding ability, suggesting an increased attachment to bladder tissue (Chapter 3) [42]. 
Despite this increased binding, this strain is rapidly cleared from the urinary tract [42]. 
Additionally, a FimH mutant regulated by tetracycline expresses FimH in the lumen of the 
bladder, but once it invades the tissue, FimH expression is turned off [43]. Despite equal levels 
of luminal and invasive bacteria at 1 hpi, this mutant was attenuated as soon as 6 hpi. Taken 
together, these data suggest that IBC formation is essential for pathogenesis, and that bacteria 
that remain luminal throughout infection are unlikely to be the founder population later. While it 
is formally possible that increased bacterial flux out of initial IBCs or increased IBC formation 
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during the 2nd round predicts chronic cystitis, it is unlikely as these events occur between 16 and 
24 hpi, when the predictive immune response has already been initiated [11, 40]. Therefore, 
based on these data, I do not favor this alternative hypothesis.  
A third hypothesis is that bacterial ascension/replication in the kidneys results in the 
systemic immune response predictive of infection outcome. The C3H/HeN model of UTI is 
susceptible to a high rate of vesicoureteral reflux (VUR) and immediate post-inoculation kidney 
colonization [39, 44]. Treatment of mice with dexamethasone to dampen the inflammatory 
response significantly decreased the proportion of mice experiencing chronic cystitis without 
altering urine, bladder, or kidney titers at 24 hpi [40]. This result suggests that the host mediated 
inflammatory signal was blocked without dramatically affecting the pathogenic cascade. 
Furthermore, elevation of cytokines at 24 hpi did not correlate with kidney titers, but did 
correlate with urine titers suggesting a higher bladder contribution to this immune response. 
Increasing the inoculum to 108 CFU dramatically increased the proportion of mice that 
experienced chronic cystitis, but did not significantly increase kidney titers [40] (Chapter 3). 
While it is possible that kidneys can be colonized in a niche specific way in this model, as has 
been suggested (Figure 1) [30, 31], the data do not support kidney colonization differences as 
predictors of chronic cystitis in C3H/HeN mice. Therefore, taken together, our data best fits the 
hypothesis that an increase in UPEC intracellular niche presence leads to the systemic immune 
response predictive of chronic cystitis. Bacteria that colonize IBCs and flux out are therefore the 
most likely to colonize the bladder after the IBC cycle has concluded. 
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UTI pathogenesis and symptoms 
Much of the work in this thesis attempts to explain UTI pathogenesis based on virulence 
factors and bacterial niche occupation in the urinary tract. Understanding the pathogenesis of a 
disease can also explain elements of symptomatology. Recent work is beginning to shed light on 
how UPEC and other inflammatory responses lead to UTI symptoms [45-47]. Interestingly, 
many of these studies have shown that bacterial presence is not essential, as LPS introduction 
into the bladder can lead to pain [45]. However, many of these symptoms are likely the result of 
inflammation and bacterial replication in preventing adequate bladder stretch or activating and 
repressing neuronal communication [48]. I believe bacterial replication in the urinary tract in the 
context of virulence factors and niche occupation may influence immediate and recurrent 
symptoms. 
Although E. coli LPS has been shown to lead to a bladder pain response [45], the degree 
to which it affects the host is likely multifactorial. The particular LPS O-antigen structure and 
LPS shed frequency affect this bladder response [45]. Furthermore, the composition of the 
bacterial inoculum can likely influence the bladder response. As mentioned above, it is unlikely 
that a typical UTI-causing inoculum is monomicrobial [14, 15]. It is possible that other 
organisms, such as the gram positive, Streptococcus agalactiae, that are often co-inoculated, can 
dampen the pain response in addition to the inflammatory response [19, 20]. Additionally, the 
degree to which UPEC invades the epithelium will likely regulate the ability of the bladder to 
stretch during filling and voiding [47]. The confluence of bacterial virulence factors including 
the specific allele of FimH governs the pathogenesis of this organism. These virulence factors 
and the attributes they confer likely also impact how the host responds to the infection, resulting 
in symptoms. Ongoing bacterial replication during chronic cystitis would likely lead to persistent 
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and common UTI symptoms of dysuria, urgency, and frequency. If the infection resolves and 
QIRs form in the tissue [22], ongoing host responses may lead to symptoms in the absence of 
bacteriuria [4, 49]. Clinical investigations into these issues may begin to shed light on confusing 
diseases such as interstitial cystitis [48, 50]. 
 
Factors responsible for colonization in a chronically inflamed bladder 
During the transition from acute to chronic infection, bladder physiology changes 
depending on outcome (Chapter 4) [11, 40]. In mice that resolve infection, the superficial facet 
cell layer regenerates with basal stem cell proliferation [51, 52]. Alternatively, during chronic 
cystitis, the entire superficial facet cell layer is denuded, no mature uroplakins are found on the 
bladder surface, and uroplakin genes are among the most downregulated murine genes in this 
state (Chapter 4). Several mutants in bacterial genes exhibit subtle defects during acute 
pathogenesis, but are dramatically outcompeted once chronic cystitis develops (Chapter 3) [11]. 
Therefore, different virulence factors may be required for bacteria to maintain bladder presence 
in this chronic inflammatory environment. During chronic cystitis, invasion does not occur to an 
appreciable degree [40]. Despite this observation, roughly 20% of the bacteria are present in a 
gentamicin-protected niche, which may exist at tight junctions (Chapter 4). What UPEC are 
binding in this niche and in the entire bladder during this period remains to be characterized 
because of the absence of mannosylated uroplakins.  
Several alleles of the FimH adhesin are under positive selection among UPEC compared 
to fecal E. coli [42] FimH alleles such as FimH::S62/A163 have a slight competitive defect 
during the first 6 hpi (Chapter 3), which is dramatically accelerated thereafter. I have shown that 
FimH is able to adopt at least two different conformations, which alter mannose-binding affinity. 
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It is unclear as yet whether FimH is able to dynamically interconvert between these 
conformations or whether binding affinity differs in the elongated, mannose-bound, state 
between FimH alleles. FimH alleles with the highest mannose-binding affinity are attenuated in 
vivo, as are strains with the lowest affinity (Chapter 3). Furthermore, a gradient exists whereby 
subtle differences in mannose binding between FimH::A62/V163 and FimH::S62/A163 lead to 
large differences in pathogenesis. Thus, FimH::A62/V163 may bind even tighter to a different 
epitope that is exposed during chronic cystitis. UTI89 FimH has been shown to bind to α3 and 
β1 integrins in a cell culture system resembling undifferentiated, transitional bladder epithelial 
cells such as those exposed during chronic cystitis [53]. Additionally, strains possessing 
FimH::A62 were shown to have enhanced binding to type I and type IV collagen in vitro [54]. 
Type IV collagen is present in the basement membrane, which is unlikely to be exposed during 
chronic cystitis, but an epitope with a similar terminal sugar may be present. UTI89 FimH is 
more likely to adopt the compressed conformation (Chapter 3). In this state, shifts in loop 
positions cause a partial occlusion of the mannose-binding pocket, but an adjacent, deep groove 
may accommodate a different epitope.  
Other non-FimH colonization factors may also be important during chronic cystitis, 
including other CUP pili [34]. As mentioned above, due to superficial facet cell exfoliation and 
ongoing neutrophil influx and inflammation, additional binding epitopes and nutrients may be 
exposed. UPEC has the ability to downregulate neutrophil influx and function [55], perhaps 
implicating immune-downregulatory factors during chronic infection. Similarly, nutritional 
acquisition or other virulence factors may confer benefit in this context. UTI89 outcompetes 
CFT073 expressing UTI89 FimH, but only after 7 dpi (Chapter 3). Therefore, UTI89 expresses 
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other factors allowing for longterm survival including transcendence of possible extracellular 
bottlenecks that CFT073 is incapable of transiting [11]. 
 
Novel treatment modalities 
 The rising rates of antibiotic resistant uropathogens and their worldwide spread 
necessitates the need for developing alternative therapies for UTI. Anti-virulence compounds 
represent one promising target for enhanced target specificity without increased side effects and 
off target effects of antibiotics [8]. Mannosides are mannose analogs that bind with high 
specificity to the FimH binding pocket of UPEC, preventing attachment to the bladder 
epithelium [56-58]. These molecules have enhanced affinity over the natural substrate, are 
readily available in mouse urine after one oral dose, and are effective against multi-drug resistant 
strains [57, 59]. The mannose-binding pocket of FimH is invariant among UPEC, likely because 
of its essential role in uropathogenesis [42]. Thus, complete resistance to mannosides would be 
unlikely because it would dramatically reduce affinity for the natural substrate. Furthermore, 
based on recent data demonstrating the presence of uropathogens in the GI tract during the time 
of infection, mannosides may help to eliminate a gut reservoir of bacteria [21]. The data 
presented in this thesis provides a strong rationale for the use of these compounds. 
 UPEC transit the stringent bottleneck during acute infection by invading bladder tissue 
and forming IBCs (Chapter 2). Blocking this crucial step would help eliminate infection. 
Furthermore, animals are more likely to develop chronic cystitis and recurrent, chronic cystitis, 
when infected with two invasive UPEC strains (Chapter 4). Inhibiting a fraction of the invasive 
organisms would also likely lead to clearance or a less severe infection. Alternatively, if the drug 
is admistered after the initiation of chronic cystitis, it effectively reduces bacterial burden 
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10,000-fold after three doses [57]. The FimH allele varies among UPEC, but mannosides have 
been shown effective for at least three different alleles encompassing over 70% of natural 
sequence variation [42, 57, 59, 60].  
I can envision several potential problems with mannoside treatment. First, if the drug is 
administered during acute infection, but after the bacteria have established IBCs, it would not be 
effective [57]. Because of the possibilities of QIR formation leading to recurrences or the 
development of chronic cystitis, the invasion process may already establish negative downstream 
sequelae. Second, downregulation of type 1 pili because of mannoside administration might lead 
to the expression of other pilus systems, increasing the risk for pyelonephritis [12, 33, 61]. 
Nevertheless, these molecules can be utilized instead of antibiotics or in synergistic combination 
[57]. In addition to inhibiting type 1 pili by blocking its interaction with the mannosylated 
receptors in vivo, compounds known as pilicides can block the synthesis of multiple types of 
extracellular fibers [62, 63]. Pilicides could obviate some of the negative side effects including 
possible ascension and pyelonephritis. These molecules may have more side effects because of 
the near ubiquitous presence of CUP pili among enterobacteriaceae, including gut commensals 
[64, 65]. Further evaluation of mannosides and pilicides is necessary, but these treatments hold 
promise as alternative or complementary therapies for UTI. The work described in this thesis 
describes the key elements of UPEC pathogenesis, providing rationale for aggressive and novel 
treatments aimed at limiting this disease. 
 
Bacterial population bottlenecks and virulence factors 
UPEC must overcome several bottlenecks and barriers to establish colonization of the 
urinary tract [12, 33]. The bottlenecks that organisms transit to cause disease are numerous and 
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likely similar between mucosal infections [11, 66-70]. These host and environmental filters 
attempt to reduce the numbers of pathogenic organisms that reach protected sites. For UPEC, the 
increased immune response corresponds with the ability to access deeper tissues [11, 40]. 
Organisms of the genus Vibrio have several virulence factors allowing them to carve out niches 
within the host. Vibrios express Type VI secretion systems allowing them to target other species 
to eliminate niche competition [71]. Once certain Vibrio species have attached to the appropriate 
niche, they can also invade the epithelium, likely presenting another bottleneck to pathogenesis 
[72]. Within these genes, positive selection has likely occurred favoring certain allelic variants. 
Thus, many of the findings presented for UPEC in this thesis can and should apply to the 
consideration of other infectious diseases. 
One very important consideration that should be taken from this thesis is that presence or 
absence of a virulence factor is not sufficient to mediate disease phenotype. Furthermore, allelic 
variation among virulence factors may serve to modulate that particular event in the host-
pathogen interface. For example, positively selected residues in the FimH adhesin modulate the 
ability of UPEC to attach to bladder tissue, invade, form IBCs, and bind mannose (Chapter 3). 
A spectrum of disease severity exists partially regulated by the specific FimH variant an E. coli 
expresses. Similar investigations into other mucosal pathogens would likely yield similar 
findings [72]. Therefore, I propose that it is not what specific virulence factors an organism 
expresses, but rather which allele of each virulence factor that it expresses that confers specific 
niche pathogenicity.    
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B. Future Directions 
Virulence defects of high affinity pathoadaptive FimH alleles 
 UTI89 expressing FimH::A27V/V163A and FimH::V163A are attenuated during chronic 
infection, and UTI89 FimH::A27V/V163A invades the urothelium but does not form IBCs 
(Chapter 3) [42]. Purified Fim tips containing these mutations have high mannose affinity and 
presumably only exist in the elongated conformation. The experiments outlined below will 
determine the reason for the inability of these strains to form IBCs and whether these high-
affinity strains can colonize the bladder after the onset of chronic cystitis. 
 
Is high mannose affinity inhibiting IBC formation a general phenomenon? 
 I hypothesize that the high affinity state is mutually exclusive with the ability to form 
IBCs in vivo. UTI89 FimH::A27V/V163A does not form IBCs at 6 hpi and is rapidly cleared by 
24 hpi [42]. UTI89 FimH::V163A was not dramatically different from UTI89 at 24 hpi in single 
infection; however, this result was accompanied by a large titer variance and was not explored at 
other timepoints [42]. Both FimH mutants exhibit high mannose affinity and an increased ability 
to form biofilm ex vivo (Chapter 3) [42]. Both strains were also defective in co-infection with 
WT UTI89 during chronic cystitis. In order to test my hypothesis, I would inoculate C3H/HeN 
mice with UTI89 or UTI89FimH::V163A and determine IBC number at 6 hpi using whole 
mount LacZ staining [73]. I expect UTI89 FimH::V163A will not form IBCs.  
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Why are strains expressing high mannose affinity FimH incapable of forming IBCs? 
 I hypothesize that FimH cannot detach from its uroplakin receptor on the bladder cell 
surface if it is locked in the elongated, high-affinity conformation. To test this hypothesis mice 
could be infected UTI89 with FimH::A27V/V163A and FimH::V163A as well as strains 
artificially locked in the elongated or compressed conformation via cysteine bonds [74]. Invasive 
UPEC co-stained with uroplakin III and Rab27b, indicating UPEC internalization into fusiform 
vesicles with its receptor [75]. A TLR4-dependent process can expel bacteria within these 
vesicles into the lumen of the bladder [76]. Hours later, bacteria within IBCs are no longer 
coated with Rab27b, and appear to replicate in the cytoplasm of the epithelial cell [38]. How 
bacteria burst out of this vesicle and replicate within the cytoplasm is unknown. The following 
experiments will determine the role of FimH in this mechanism:  
A) I would determine whether UTI89 FimH::A27V/V163A cannot form IBCs because it is 
trapped within fusiform vesicles by utilizing a GFP expressing strain and staining bladders at 6 
hpi for uroplakin III, Rab27b, and host cell nuclei with DAPI. By examination using confocal 
microscopy, I would expect to find UTI89 FimH::A27V/V163A and other strains with highest 
mannose affinity to remain in vesicles, whereas UTI89 will be free within the cytoplasm.  
B) UPEC can be expelled from within the epithelial cell by elevations of cAMP and fusion of 
fusiform vesicles to the bladder surface [75]. I would inhibit this elevation of cAMP by 
introduction of compound H89, which has been previously shown to decrease UPEC expulsion 
[75]. I predict that administration of this molecule will lessen the defect of strains expressing 
high mannose affinity. It is also possible that the ability of these high affinity strains to escape 
the vacuole is reduced temporally, in which case H89 may restore IBC formation. Alternatively, 
these strains may be incapable of detaching from the uroplakin receptor, which would result in 
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increased bacterial titers without increasing IBC formation. This hypothesis can be tested using a 
uroplakin transgenic mouse and intravital multiphoton microscopy [77]. C57BL/6J mice 
expressing RFP from the uroplakin 1 locus (UpkIb) are commercially available through Jackson 
Laboratories. These mice can be infected with GFP-expressing UTI89 strains expressing various 
FimH alleles. As a pilot experiment, confocal microscopy can be conducted on bladders 
extracted at 1, 3, 6, and 12 hpi to determine bacteria-uroplakin colocalization. If this staining is 
successful, I would image, in real time in a live mouse, the engagement and detachment of the 
uroplakin receptor and the impact of FimH allele on this process. I predict that strains with high 
mannose affinity will be unable to detach from the receptor resulting in a high degree of bacteria-
uroplakin colocalization, whereas FimH that can adopt the compact conformation will separate 
from the receptor by 6 hpi to form IBCs.   
 
3) Can fitness defects of high affinity FimH alleles be rescued after the onset of chronic cystitis? 
 When co-inoculated with WT UTI89, UTI89 with FimH::V163A and 
FimH::A27V/V163A are attenuated in the urine and in the bladders at four weeks. UTI89 
FimH::A27V/V163A cannot form IBCs, likely explaining this virulence defect [42]. I have 
shown that both of these mutations increase mannose-binding affinity (Chapter 3). During 
chronic cystitis, uroplakins are not present, implicating another receptor for FimH (see 
Discussion). If binding affinity is the sole determinant of success for otherwise isogenic strains, I 
would predict that FimH::A27V/V163A would outcompete UTI89 in this environment.  
To test whether enhanced binding increases pathogenesis during chronic infection, I 
would infect mice with UTI89 Spectr and re-infect at four weeks with UTI89 
FimH::A27V/V163A or FimH::V163A; both kanamycin resistant. WT UTI89 Kanr will serve as 
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the control in a separate set of mice. In a pilot of a small number of mice, a WT re-infection was 
not able to colonize a mouse experiencing chronic cystitis. If this result replicates, it suggests 
that adaptation to the inflamed environment has occurred, excluding the incoming inoculum. In 
that event, I would treat mice with antibiotics to sterilize the urinary tract, and challenge them 
with FimH::A27V/V163A after the antibiotics have cleared. Preliminary data suggests that IBC 
formation does not occur at 6 hpi after a re-infection when mice are sensitized to develop chronic 
cystitis by the above protocol (Figure 2). I predict that in mice that have developed chronic 
cystitis, exfoliation is so rapid, that there is no invasive bacterial population. This hypothesis can 
be tested by conducting ex vivo gentamicin protection assays and confocal microscopy 1, 6, and 
24 hours after infection of sensitized mice with UTI89 expressing GFP. The degree of 
exfoliation can be assessed using scanning electron microscopy [2, 78]. Whole bladders from 
naïve mice can be examined as well as mice that resolved infection or developed chronic cystitis 
on the first infection. If sensitized mice exfoliate more completely and more rapidly than mice 
that resolved infection, I would predict that UTI89 FimH::A27V/V163A can cause chronic 
cystitis. If this strain is still attenuated and IBC formation is not essential in this condition, it 
would suggests that the compact state of FimH is favored during chronic cystitis.    
 If the introduced inoculum is capable of colonizing to an equal degree, I would predict 
that introduction of UTI89 FimH::A27V/V163A or UTI89 FimH::V163A would outcompete the 
WT strain because of its enhanced mannose binding. If it is not able to colonize, this also 
suggests that the compact state that FimH adopts in WT UTI89 is important for colonizing the 
chronic bladder. These experiments can also be conducted with strains locked in the elongated 
and compact states [74]. 
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Identification of the FimH receptor during chronic cystitis  
 As mentioned above and in the Discussion (A), the superficial epithelial layer is denuded 
during chronic cystitis, and mature uroplakins are not expressed [40]. I will outline a biased and 
unbiased approach to identify the receptor for FimH in a chronic bladder. 
Biased approach 
Several epitopes have been reported to bind FimH in vitro including α3 and β1 integrins, TLR4, 
and collagen [53, 54, 79]. I would infect mice with GFP-expressing UTI89 and stain bladders at 
4 weeks post infection with antibodies to α3 integrin, β1 integrin, TLR4, and collagen IV. I 
would determine the percentage of these receptors that co-localize with green bacteria and vice 
versa. In chronic mice, if one of these is the potential receptor, bacteria and the receptor will 
colocalize to a high degree. I would additionally extract bladders from chronically infected mice, 
wash them with α-methyl-D-mannopyranoside to detach bacteria, and incubate with fluorescein-
labeled UTI89 or FimH mutants, and stain with antibodies for the prospective receptors and 
DAPI. The ability to bind purified FimCH and FimCGH could then be analyzed using biolayer 
interferometry with OCTET. 
Unbiased approach  
I would use a similar biolayer interferometry setup with biotinylated FimCH and FimCGH 
bound to OCTET pins and add the following homogenized bladder preparations: uninfected, 
protamine sulfate-exfoliated urine and bladder tissue, and bladder tissue from mice experiencing 
chronic cystitis. If the biotinylation reaction prevents binding, I would immobilize FimCH and 
FimCGH on eliza plates, and conduct the following analyses. I would run these samples in 
separate wells to bind mouse bladder proteins to immobilized WT or binding-null FimCH or 
FimCGH. I would then wash the wells to remove unbound samples, add mannose to elute the 
202 
receptor, and run these samples on a gel to identify bands specific to chronic mouse bladders. 
The band corresponding to uroplakins in naïve mouse bladders should be present in uninfected as 
well as protamine-treated bladders and absent from chronic cystitis bladders. This internal 
control ensures the assay is functional. Mice that are pretreated with protamine sulfate and 
infected 1 hpi later do not develop chronic cystitis at a higher rate (Chapter 4), suggesting either 
that the receptor is not exposed without immune activation or that IBC formation is required 
prior to exfoliation. Comparing bladders of protamine-treated mice and mice experiencing 
chronic cystitis will help to identify the receptor as well as answer the previous question. Protein 
bands satisfying these conditions will be sent for mass spectrometry analysis to identify the 
receptor that FimH binds during chronic cystitis. 
Mannoside efficacy against multiple FimH alleles in multiple niches 
 Oral administration of mannosides has proven effective in dramatically reducing bacterial 
colonization of the mouse bladder [57, 59, 60]. The infecting strain in these experiments has 
been UTI89, EC958, and PBC1, all of which express different FimH alleles. In order to test 
whether mannosides are equally effective against common FimH alleles of UPEC strains, I 
would infect mice with UTI89 differing only by FimH allele. For strains less effective than 
UTI89 at causing chronic cystitis, an inoculum of 108 CFU can be introduced to initiate a greater 
proportion of chronic cystitis. I would administer a single oral dose of a high affinity mannoside 
and evaluate bladder and kidney bacterial burden 6 hrs after mannoside or PBS administration.  
An interesting experiment would be to colonize the GI tracts of mice with UTI89 
expressing FimH alleles after a four-day course of streptomycin [80]. Oral gavage of bacteria 
with or without mannoside will test whether FimH is necessary for gut colonization. Previous 
reports regarding the role of type 1 pili in gut colonization are conflicting [80, 81]. Inocula 
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containing multiple strains differing only by FimH can be introduced to answer the question of 
whether these differences impact gut fitness. These competitive experiments may help us 
understand why the most common alleles observed in the population are less fit in the urinary 
tract (Chapter 3). These gut colonization experiments will answer multiple questions. First, is 
FimH necessary for gut colonization? Second, if FimH is necessary, does the FimH allele impact 
GI colonization as has been shown previously for one allele in gnotobiotic mice [42]? Third, can 
mannoside effectively eliminate UPEC from this niche as well as from the bladder? This last 
question is important given the recent data showing gut and bladder colonization of UPEC in 
humans at the time of UTI [21]. Mannoside could be used bifunctionally to eliminate the 
immediate cause of UTI as well as reduce bladder and GI reservoirs that could serve as sources 
of recurrent UTI [22, 23].  
 
The role of IL-1 in priming the bladder for superinfection 
 The precise molecular mechanism underlying the proportional increase in the 
development of chronic cystitis for superinfected mice is unknown (Chapter 4). This increase 
does not occur when the initial inoculum has mutations in hlyA or cpxR, nor does it occur when 
the bladder is pretreated with a caspase1/11 inhibitor prior to infection. Taken together, these 
results suggest that activation of the inflammasome without an exaggerated response is essential 
to increase the proportion of mice suffering chronic cystitis.  
The inflammasome is a mutli-protein assembly complex resulting in the activation and 
release of caspase-1/11, IL-18, IL-1β, and Il-1α, dependent on whether caspase-11 is also 
activated [82]. Inflammasome activation depends on the type of stress, and can be named based 
on a particular scaffolding protein that aids in stimulus recognition. UPEC activates the non-
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canonical bladder inflammasome via NLRP3 in conjunction with caspase-11 elaboration by the 
sensing of hemolysin (Nagamatsu et al. in preparation). Strains overexpressing hemolysin 
(ΔCpxR) lead to increased activation, while strains lacking hemolysin do not activate the 
inflammasome. mRNA levels of caspase-1, caspase-11, nlrp3, and IL-1β are increased in the 
serum of infected mice in a dose-dependent manner. Although systemic levels of IL-1α and IL-
1β were not predictive of ensuing chronic cystitis [40] (Chapter 4), the local bladder 
environment may be enriched for these cytokines. Indeed, infected bladders had increased levels 
of IL-1β in a hemolysin-dependent manner (Nagamatsu et. al. In Preparation). UTI89ΔHlyA is 
not attenuated for the development of chronic cystitis, but does not prime the bladder for 
enhanced chronic cystitis in superinfected C3H/HeN mice. This result suggests that an 
alternative pathway may also lead to chronic cystitis, but that elevations in Hemolysin-mediated 
exfoliation and inflammasome activation increase this response.  
In order to test the role of the inflammasome during superinfection further, I would 
superinfect mice 1-6 hours after the initial infection and determine serum and bladder levels of 
IL-1α, IL-1β, IL-5, IL-6, KC, and G-CSF using ELISA or Bioplex at 24 hpi. Bladder levels of 
IL-1α and IL-1β will be correlated to serum levels of IL-5, IL-6, KC, and G-CSF to predict 
which mice had triggered the checkpoint to develop chronic cystitis [11, 40]. I would predict that 
superinfected mice have increased bladder IL-1α and/or IL-1β, and that this would correspond to 
mice with elevated serum IL-5, IL-6, KC, and G-CSF. If this result is seen, I would treat mice 
with Anakinra to block the IL-1 receptor, which I predict would block the enhancement of 
chronic cystitis in superinfected mice. If Anakinra prevents increased chronic cystitis, it could be 
used instead of, or in combination with, antibiotics for extreme cases of UTI. For additional 
proof of the role of the inflammasome in superinfected mice, I would backcross C3H/HeN mice 
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with caspase-1/11-/- C57BL/6 mice for > 10 generations to develop C3H/HeN mice that lack 
caspase 1/11. I would predict these mice do not develop chronic cystitis.  
C. Concluding Remarks 
 This dissertation expounds upon the growing complexity of UPEC UTI that is just now 
being appreciated. I detailed the complex population dynamics and niche distribution of UPEC 
throughout UTI, identifying a key bottleneck that bacteria need to transit in order to establish 
long-term colonization. This work additionally showed that the degree of IBC formation 
correlates with disease outcome. Further, positively selected FimH residues conferred enhanced 
fitness during acute and chronic UTI. These studies brought up a mannose-binding paradox, 
whereby affinity extremes were less fit than FimH exhibiting moderate affinity. This affinity 
relates to the ability of FimH to adopt at least two conformations, both of which are essential 
during bladder colonization. Finally, I established a model to mimic frequent sexual intercourse, 
showing that caspase 1/11 activation leads to enhanced chronic cystitis in a susceptible mouse 
strain. I also showed that this model lead to chronic cystitis in a strain resistant when infected 
singly. This thesis provides added rationale for treating the invasive stage of the UPEC 
pathogenic cascade aggressively before long-term, negative sequelae develop. Accordingly, the 
ability of UPEC to occupy specific niches in a time and space dependent manner is crucial for 
successful colonization. By targeting UPEC within these niches at the appropriate times during 
the complex pathogenic cascade, we can eradicate this troublesome disease.   
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Figure 1. Potential role of type 1 and P pili during pyelonephritis. 
P pili bind to receptors on the kidney epithelium when UPEC enters the kidney. Type 1 pili may 
serve to coalesce bacteria within biofilms in this environment [31]. Possible intracellular niches 
or antibiotic resistant niches may also exist.  
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Figure 2. IBC formation in sensitized mice. 
Mice were infected with 108 CFU UTI89 or PBS and urine was tracked for 28 days. Mice were 
then treated with trimethoprim-sulfamethoxazole for 7 days in drinking water. After 21 days free 
from antibiotics, mice were infected with 107 CFU UTI89 and bladders were extracted for whole 
mount LacZ analysis 6 hpi.  
 
